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ABSTRACT 
 
Sonic Hedgehog Signaling Pathway in Amyloid Precursor Protein 
Trafficking and Proteolysis 
 
Anna Gennadiy Vorobyeva 
Aleister J. Saunders 
 
 Alzheimer’s disease (AD) is the most common form of dementia for which there 
is no cure. AD is characterized by progressive neurotoxicity resulting in cell death and 
cognitive decline. Two hallmarks responsible for the aforementioned neuropathology are 
senile plaques and neurofibrillary tangles composed of Amyloid-β (Αβ) peptide and 
hyperphosphorylated tau protein, respectively. Aβ is produced from regulated proteolysis 
of Amyloid precursor protein (APP). Alterations to this process can results in increased 
Aβ deposition resulting in AD pathogenesis. Here we discovered that cyclopamine, a 
plant sterol, modulates APP metabolism by altering APP subcellular trafficking. 
Cyclopamine treatment alters retrograde trafficking of APP C-terminal fragments (CTFs) 
after endocytosis, thereby decreasing Aβ generation. This raises the possibility that 
cyclopamine may ameliorate AD-like pathologies in other AD animal models.  
 We addressed the possibility that cyclopamine’s target, Smoothened (Smo), can 
alter APP metabolism and discovered a likely novel regulatory role for Smo. Smo is a 
component of the Sonic hedgehog (Shh) signaling pathway, which requires the primary 
cilium for canonical mammalian Shh signaling. Pharmacological and genetic analysis 
lead us to believe several Shh signaling components modulate APP proteolysis via a 
	   xiii	  
previously uncharacterized noncanonical Shh mechanism. Collectively these findings 
lead us to investigate the possibility that APP colocalizes with Shh signaling components 
to the primary cilia and whether or not primary cilia respond to extracellular Aβ levels. 
We discovered APP colocalized with Smo to primary cilia and that primary cilia were 
significantly compromised upon Aβ treatment. Collectively, this thesis provides 
significant insight into APP proteolysis through regulating trafficking events. Modulating 
APP trafficking opens a novel avenue to address Aβ production. In addition, we 
discovered a novel target for AD therapeutics; the Shh signaling pathway. 	  
	  
	  
CHAPTER 1: INTRODUCTION 
 
EPIDEMIOLOGY OF ALZHEIMER’S DISEASE 
 In 1901 a German psychiatrist, Alios Alzheimer, began studying a 50 year-old 
woman, Auguste D. The patient’s husband noticed changes in his wife’s sleep pattern, 
increasing confusion, and deteriorating memory. In 1906 the patient died and Alios 
Alzheimer followed up his clinical studies by investigating her brain morphology and 
histology. Postmortem brain autopsy revealed histological changes; decreased brain 
volume due to cortical and hippocampal atrophy, and two types of brain lesions later 
identified as senile plaques and neurofibrillary tangles (NFTs) composed of neurotoxic 
Amyloid-β (Αβ) and hyperphosphorylated tau protein, respectively. In 1906, Alios 
Alzheimer presented these never before documented clinical and histological data to the 
scientific congress of psychiatrists in Germany. Shortly after, Auguste D.’s case was 
coined Alzheimer’s disease (AD)	    (Hippius and G. Neundorfer 2003, Weintraub et al., 
2012). 
 Alzheimer’s disease is a progressive neurodegenerative disease of the brain 
leading to neuronal atrophy, progressive cognitive decline and eventually death. AD is 
the most common form of dementia. Dementia is a comprehensive term used to describe 
all neurodegenerative diseases that affect the brain and lead to changes in mood, behavior 
and cognition. Besides AD, other types of dementias include: frontotemporal lobar 
degeneration (FTLD), dementia with Lewy bodies (DLB), Parkinson’s disease (PD) and 
vascular dementia. Unlike other dementias, AD symptoms include defects in episodic 
memory, semantic memory, visuospatial and executive aptitude for navigation and 
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problem solving, respectively (Weintraub et al., 2012). Severity in various cognitive tasks 
creates a profile that sets AD apart from other dementias. AD neuropathology is 
characterized by cortical and hippocampal atrophy and two brain lesions; neurofibrillary 
tangle and senile plaque burden (to be discussed in greater detail later). These 
neuropathologies are unique to AD because other forms of dementia may foster one of 
the two brain lesions, not both. Simultaneous detection of both lesions is only possible in 
postmortem brain tissue, further contributing to the difficulty for clinicians to provide a 
definitive diagnosis. Currently, noninvasive brain imaging techniques are being explored 
to address neurofibrillary tangle and/or senile plaque burden  (Johnson et al., 2012, Rinne 
et al., 2012). A recent study demonstrated that positron emission tomography (PET) 
imaging of senile plaque via specific uptake of [18F] flutemetamol (Vizamyl©) compound 
is a reliable noninvasive technique clinicians can use to image amyloid plaque load and 
be used for AD diagnosis (Rinne et al., 2012). Similar compounds are now being 
investigated for noninvasive PET imaging for neurofibrillary tangles  (Hashimoto et al., 
2014, Okamura et al., 2013, Tago et al., 2014). Since AD brain lesions are evidenced 
prior to cognitive impairment, early detection will allow clinicians to take appropriate 
steps to slow progression of the disease and extend adequate quality of life of the patient  
(Jack et al., 2013, Jack et al., 2010). On average AD patients live four to eight years 
during which approximately half of that time requires special and costly aid (Ganguli et 
al., 2005).  
 Statistical data for 2014 indicates that approximately 5.2 million Americans are 
living with AD. Of the 5.2 million reported cases, 5 million are individuals 65 and older 
while 200,000 cases are in younger individuals. One in nine persons, 65 and older, are 
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diagnosed with AD and nearly one third of 85-year-old individuals have AD (Gaugler et 
al., 2014). Because people are living well into their 80’s and 90’s, the aforementioned 
statistics are expected to drastically increase with each year. In other words, due to the 
baby boomers generation, by 2050 the number of 65 and older population living with 
Alzheimer’s is expected to climb to 13.8 million. The extended duration of the disease 
and disability associated with it has a direct impact on national Medicare and Medicaid 
budget and family’s out-of-pocket spending. Medicare and Medicaid will cover $150 
billion for Alzheimer’s and other dementia-related care in 2014. These $150 billion only 
covers 70 percent of the total care costs. The remainder becomes the responsibility of the 
patient and/or family, which could account to as much as $92,977 per person per year for 
nursing home care alone (Gaugler et al., 2014). These facts are an incentive for increased 
Alzheimer’s research funding in efforts to understand the disease and identify a suitable 
treatment before reaching 13.8 million individuals living with AD by 2050.  
 A century has passed since Alzheimer’s disease and its pathological hallmarks 
were characterized. Only through intensive research efforts in the last 30 years that senile 
plaques were isolated, core protein sequenced and the precursor protein was identified  
(Allsop et al., 1983, Glenner and C. W. Wong 1984, Kidd et al., 1985, Allsop et al., 
1988). Although researchers cannot explain the cause of this devastating disease, risk 
factors have been identified, the greatest of which is age.  
 
ALZHEIMER’S DISEASE GENETICS AND RISK FACTORS 
 Several risk factors, age being the biggest, are associated with increased 
possibility of developing Alzheimer’s disease. Precise etiology of AD is unknown, but is 
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likely due to combination of genetic and environmental factors. There are two forms of 
AD: Early Onset Alzheimer’s disease (EOAD) also referred to as familial Alzheimer’s 
disease (FAD), or Late Onset Alzheimer’s disease (LOAD) also referred to as sporadic 
AD (SAD). As the name implies, EAOD occurs in persons before age of 60. EAOD is 
known as the inherited version of AD and is autosomal dominant in nature  (Tanzi and L. 
Bertram 2005). To this end, mutations in three genes result in EAOD. These genes are: 
Amyloid precursor protein (APP, chromosome 21), Presenilin1 (PSEN1, chromosome 
14) and Presenilin2 (PSEN2, chromosome 1)  (Levy-Lahad et al., 1995, Sherrington et 
al., 1995). Presenilins are the catalytic components of the γ-secretase complex 
responsible for proteolysis of APP and Amyloid-β (Aβ) generation  (Haass and B. De 
Strooper 1999, Wolfe et al., 1999, De Strooper et al., 1999, Gandy and P. Greengard 
1994, Gandy et al., 1994). The aforementioned mutations lead an increase in the amount 
of neurotoxic Aβ42 versus the less neurotoxic Aβ40 . A plethora of APP and PSEN1/2 
mutations have been identified that ensure EOAD (a comprehensive list can be found at 
Alzheimer Disease and Frontotemporal Dementia Mutation Database; 
http://www.molgen.ua.ac.be/ADMutations). However APP and PSEN1/2 mutations only 
account for approximately 5% of total AD cases.  
 The predominant form of AD is the non-familial sporadic form which affects 
persons older than 65, hence LOAD. Although a causative genetic links is not yet 
established, LOAD is associated with genetic variants. Genetic variants do not cause 
LOAD, but do increase the likelihood of developing Alzheimer’s disease. Only one 
genetic factor is strongly ascribed to LOAD, the apolipoprotein E gene (APOE, 
chromosome 19) ε4 allele  (Saunders et al., 1993, Saunders et al., 1993, Saunders and A. 
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D. Roses 1993). ApoE is involved in Aβ clearance from the brain  (Shibata et al., 2000, 
Deane et al., 2008). There are three common APOE alleles: ε2, ε3, ε4. ApoE ε2 is 
neuroprotective, ε3 is neutral, and ε4 is less efficient at Aβ clearance thus promoting 
senile plaque deposition in an age-dependent manner (Corder et al., 1993). Unfortunately 
ApoE-ε4 accounts for less than 20% of all LOAD cases which leaves the remainder due 
to yet unknown causes (Slooter et al., 1998). An attempt at identifying novel candidate 
LOAD genetic variants has been through genome-wide association studies (GWAS). A 
single GWAS study can assess up to one million single nucleotide polymorphisms 
(SNPs) and analysis could determine association with disease likelihood or other AD-
related endpoints such as age of onset. Besides APOE, a number of other candidate genes 
have been identified including: CD33, CLU, CR1, PICALM, BIN1, ABCA7, CD2AP, 
EPHA1, MS4A6A/MS4A4E, ATXN1 and SORL1  (Tanzi 2012). These candidate genes do 
not account for the entirety of all LOAD cases. LOAD twin studies of individuals that do 
not bear mutations in the previously mentioned genes suggest a genetic link is yet to be 
identified  (Bergem et al., 1997, Steffens et al., 1997, Reynolds et al., 2006, Scheltens 
2007). 
 Other LOAD risk factors include cardiovascular, cerebrovascular disease, 
hypertension, diabetes and traumatic brain injury  (Emmerling et al., 2000, Launer et al., 
2000, Launer et al., 2001, Luchsinger et al., 2001, Iwata et al., 2002, Ikonomovic et al., 
2004, Korf et al., 2004, Alafuzoff et al., 2009, Sivanandam and M. K. Thakur 2012, Shah 
et al., 2012). Cerebrovascular disease is most correlated with development of AD. Studies 
show increased dementia on-set following first stroke in patients lacking pre-stroke 
cognitive impairment  (Pendlebury and P. M. Rothwell 2009, Pendlebury 2009, Jacquin 
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et al., 2014). Life style factors such as smoking, lack of exercise, high fat diet, and lesser 
level of education are also associated with development of Alzheimer’s disease.  
 A common mechanism underlying the aforementioned genetic and environmental 
risk factors is the increased neurotoxic Amyloid-β peptide (Aβ) accumulations (senile 
plaques) observed in postmortem AD brains  (Gandy et al., 1994, Perry et al., 1998, 
Smith et al., 1999, Chodosh et al., 2002, Morris et al., 2003, Valenzuela and P. Sachdev 
2006, Angevaren et al., 2008, Deane et al., 2008, Profenno et al., 2010).  
 
ALZHEIMER’S DISEASE NEUROPATHOLOGY 
 Neuropathology of Alzheimer’s disease is characterized by Aβ accumulation and 
neurofibrillary tangle burden, which lead to synaptic loss and neuronal cell death  (Tanzi 
and L. Bertram 2005, Serrano-Pozo et al., 2011). Synapses are specialized structures 
between neurons necessary for cellular communication, learning and memory  
(Gustafsson and H. Wigstrom 1992, Bliss and G. L. Collingridge 1993, Bliss et al., 
2013). A well-accepted concept is that synaptic loss occurs due to increased levels of 
extracellular neurotoxic Aβ that aggregates into senile plaques  (Ferrer and F. Gullotta 
1990, Moolman et al., 2004, Tsai et al., 2004, Spires et al., 2005, Jacobsen et al., 2006, 
Meyer-Luehmann et al., 2008). Studies report synaptic dystrophy occurs long before AD 
symptoms are apparent. The latter coincides with reports showing increased Aβ levels 
prior to symptom onset  (Jack et al., 2010). Therefore it is likely that structural changes 
are a consequence of the molecular mechanisms that underlie increased Aβ generation  
(Shankar and D. M. Walsh 2009, Shankar et al., 2008). Structurally, studies using 
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biopsies of human postmortem AD brain tissue report a 55 % decrease in synaptic density 
in the CA1 region of the hippocampus  (Scheff et al., 2007, Coleman and P. J. Yao 2003).  
 Second major hallmark of AD is the neurofibrillary tangles composed of 
hyperphosphorylated tau protein  (Kosik et al., 1984, Grundke-Iqbal et al., 1986, 
Grundke-Iqbal et al., 1986, Wood et al., 1986). Tau is a microtubule-associated protein 
required for maintenance and stability of neuronal microtubules  (Dehmelt and S. Halpain 
2005). This function is especially important for axonal retrograde and anterograde 
trafficking of synaptic cargo. Hyperphosphorylation of tau leads to dissociation from 
axonal microtubules, which results in microtubule disassembly and abolished cargo 
trafficking (Lee et al., 2001). Although tau filaments are thought to be neurotoxic, their 
presence does not precede nor lead to Aβ deposition  (LaFerla and S. Oddo 2005). 
However the opposite is true, Aβ deposition occurs prior to tau hyperphosphorylation. 
This observation is one of the central events of the amyloid hypothesis  (Selkoe 1991, 
Hardy and D. Allsop 1991, Hardy and D. J. Selkoe 2002). The amyloid hypothesis 
proposes that increased Aβ deposit reaches a critical threshold upon which Aβ 
oligomerizes. Aβ accumulation induces a cascade of events beginning with decreased 
long-term potentiation (LTP, molecular mechanism of learning and memory), synaptic 
loss, inflammation, tau hyperphosphorylation and finally neuronal death and dementia. 
Amyloid hypothesis is implicated in EAOD and LOAD since both are due to increased 
Aβ42 levels. Similarly, LOAD and EAOD reach a critical point when Aβ deposits and 
provokes the amyloid cascade. The underlying mechanism of this hypothesis is due to 
neurotoxic Aβ42, the proteolytic product of Amyloid precursor protein (APP). Therefore, 
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understanding molecular mechanisms that regulate APP proteolysis is critical for 
designing drug therapies to address amyloidosis.  
 
AMYLOID PRECURSOR PROTEIN 
 APP is a type I transmembrane protein with a large N-terminal ectodomain and a 
relatively smaller cytoplasmic C-terminal domain (Dyrks et al., 1988). The function of 
APP is unclear, however researchers hypothesize it may act as a ligand, a receptor or an 
adhesion protein (Kang et al., 1987). Studies show APP binds extracellular matrix 
proteins such as proteoglycans and laminin  (Narindrasorasak et al., 1992, Kibbey et al., 
1993, Soba et al., 2005). Additionally, fast axonal trafficking of APP to the synapse 
insinuates a role in synaptic activity  (Koo et al., 1990, Schubert et al., 1991, Sisodia et 
al., 1993). In support, a reported decrease in learning and memory aptitude of rats was 
observed upon treatment with an antibody against APP (Doyle et al., 1990). Knockout 
studies in mice are a clear indication of its important physiological role. While APP-/- 
mice resulted in minor defects, knockout of APP and its homologue APLP2 was lethal  
(Zheng et al., 1995, von Koch et al., 1997, Heber et al., 2000).  
 Alternative APP splicing leads to three isoforms, each differing in amino acid 
length: 695, 751 and 770 amino acids. Importantly, differences between the isoforms are 
only in the N-terminus, suggesting the C-terminus function is conserved between all APP 
isoforms. These APP isoforms are differentially expressed in a tissue specific manner; for 
example, APP695 is preferentially restricted to neurons. All of the APP isoforms contain 
the C-terminal YENPTY protein interaction domain within which lies the NPXY 
endocytosis signal. APP undergoes several post-translational modifications, which 
8
	  
include but are not limited to sulfation, phosphorylation, N- and O-Glycosylation  
(Weidemann et al., 1989, Lyckman et al., 1998). 
 APP is proteolytically processed by two pathways (Figure 1-1). Amyloidogenic 
cleavage of APP produces a 40, or the more neurotoxic 42, amino acid Aβ peptide (Aβ40 
and Aβ42, respectively). In normal conditions, Aβ42 levels are substantially less (about 10 
% of total) than Aβ40. Since Aβ42 is more prone to oligomerization, it is likely that in AD 
the balance is shifted towards Aβ42 production (Tamaoka et al., 1994). First, APP is 
cleaved by an aspartyl β-secretase (BACE1) at the peptide bond between Met597 and 
Asp598 at the N-terminus of the Aβ sequence  (Hussain et al., 1999, Sinha et al., 1999, 
Vassar et al., 1999, Vassar 2002). β-secretase liberates an extracellular soluble APP 
fragment (sAPPβ) and a 99 amino acid membrane-tethered C-terminal APP domain 
(C99). β-Secretase cleavage occurs in more acidic environment of early endosomes 
(Vassar et al., 1999). C99 is further cleaved by γ-secretase complex between Val637 and 
Ile638 liberating Aβ40 or between Val637 and Ala639 liberating Aβ42 and a free cytosolic 
APP intracellular domain (AICD). It is important to note that three consecutive cleavages 
by γ-secretase occur before fragment liberation occurs. First γ-secretase cleaves C99 at 
the ε-site (Leu646-Val647), followed by ζ-site (Val643-Ille644) and finally γ-site  (Yu et 
al., 2001, Zhao et al., 2004, Weidemann et al., 2002).  
 An alternative APP cleavage pathway is the non-amyloidogenic cleavage 
pathway. It is initiated by the zinc metalloproteinases (ADAM10, ADAM17, ADAM9, 
TACE) collectively termed α-secretases. These proteases cleave APP within the Aβ 
sequence thereby precluding its generation. α-Secretase cleaves APP between Lys613 
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and Leu614 liberating an N-terminal soluble fragment (sAPPα) and an 83 amino acid C-
terminal membrane-tethered domain (C83)  (Esch et al., 1990, Sisodia et al., 1990, 
Roberts et al., 1994, Lammich et al., 1999). α-Secretase cleaves APP at the plasma 
membrane (Parvathy et al., 1999). Similar to the amyloidogenic pathway, γ-secretase 
cleaves C83 liberating two soluble fragments, p3 and AICD.  
 γ-Secretase is an enzyme complex composed of four proteins: nicastrin, Aph1 
(anterior pharynx defective 1), Pen2 (presenilin enhancer 2) and PSEN1 or 2 (presenilin 
1/2). γ-Secretase is assembled in the endoplasmic reticulum. For full activation, PSEN1/2 
must undergo autoproteolysis to give rise to the catalytically active PSEN-CTF (18 kDa) 
and PSEN-NTF (30 kDa)  (Haass and B. De Strooper 1999, Wolfe 2013, Wolfe 2013). 
Subcellular location of γ-secretase proteolysis is a topic of controversy; some reports 
suggest cleavage occurs in endosomes where the pH is more optimal for γ-secretase 
activity while other reports suggest the majority of active complex is localized to the 
trans-Golgi network (TGN)  (Choy et al., 2012, Wolfe 2013). This discrepancy may in 
part be due to cell-type specific differences.  
 Only glycosylated (mature) APP is transported to the plasma membrane via 
secretory pathway. At the plasma membrane, majority of APP is cleaved by α-secretase 
liberating the sAPPα fragment and inducing membrane invagination and clathrin-
mediated endocytosis of membrane-tethered C83 fragment. Alternatively, similar to other 
type I transmembrane proteins, full-length APP can be quickly endocytosed into early 
endosomes where it is either recycled back to the plasma membrane or cleaved by β-
secretase.  In early endosomes, APP C-terminal fragments are sorted and trafficked to the 
TGN via the retrograde trafficking pathway. γ-Secretase cleavage of C83/C99 follows 
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arrival at the TGN. Full-length APP is not a substrate for γ-secretase; only C83 and C99 
are suitable for cleavage  (Struhl and A. Adachi 2000, Goo and W. J. Park 2004). This 
could imply a level of specificity and organization since mature APP leaves the TGN and 
may be in proximity to a functional γ-secretase complex. An alternative post-endocytic 
trafficking route is the lysosomal degradation pathway. From early endosomes, C83 and 
C99 are trafficked to late endosomes and further recruit ESCRT complex proteins 
required for multivesicular body (MVB) formation. Eventually, MVBs fuse with 
lysosomes and mature to degrade its contents (Figure 1-2)  (Gruenberg and H. Stenmark 
2004, Raiborg and H. Stenmark 2009, Choy et al., 2012). Precise regulation of APP 
trafficking is critical for proper distribution and production of APP proteolytic products.  
 Studies indicate sAPP is neuroprotective and may be involved in neurogenesis in 
the adult brain (Caille et al., 2004). When animals were infused with sAPP for two 
weeks, an 18 % increase in synaptic density was observed. These animals demonstrated 
enhanced learning and memory aptitude (Roch et al., 1994). Learning and memory relies 
on strong synapses and mature dendritic spine arbors, therefore it is possible sAPP 
enhances learning and memory though enhanced spine arborization. This was confirmed 
by a detailed dendritic spine comparison between APP-/- and APP-/- overexpressing sAPP 
animals (Weyer et al., 2014). Moreover, treatment of neurons with sAPP in vitro 
confirmed its role in neuroprotection. When rat cortical neurons were treated with sAPP, 
they survived longer than the untreated cultures (Araki et al., 1991). Similarly, protective 
effects were demonstrated by treating glucose-deprived cortical cultures with sAPP 
(Mattson et al., 1993). In parallel, Goodman and colleagues exposed cortical cultures to 
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excessive Aβ concentrations and observed 60 % cytotoxicity. However, cells treated with 
both Aβ and sAPP showed 25 % cytotoxicity  (Goodman and M. P. Mattson 1994).  
 While sAPP is neuroprotective, AICD is suggested to be neurotoxic and is 
thought to function as a transcription factor. Generation of AICD by the proteolytic 
cleavage of C83/C99 by γ-secretase closely resembles that of another type I 
transmembrane protein called Notch. Notch-mediated signaling relies on NICD 
generation through γ-secretase proteolysis  (Kopan et al., 1996, Brou et al., 2000, Fortini 
2002). Upon release, NICD translocates to the nucleus and mediates transcriptional 
activation of downstream genes  (Selkoe and R. Kopan 2003). Striking similarities 
between APP and Notch processing prompted the investigation of a possible role of 
AICD in transcriptional regulation. In 2001, Cao and Sudhoff demonstrated that Fe65, an 
adaptor protein, associates with the histone acetyltransferase Tip60 and that both 
associate with AICD to form a trimeric complex  (Cao and T. C. Sudhof 2001). Earlier 
studies demonstrated Tip60 has DNA binding activity and may therefore mediate 
transcriptional regulation with AICD (Ikura et al., 2000). Later experiments demonstrated 
increased GSK3β, APP, BACE and TIP60 mRNA levels in response to AICD 
overexpression (von Rotz et al., 2004). Therefore it is likely that AICD functions as a 
transcription factor and may increase the APP load and exacerbate amyloidogenic 
processing and Aβ generation. Overexpression of AICD also leads to apoptosis via 
increased p53 activation and this effect was abolished in p53 deficient cells (Ozaki et al., 
2006).  p53 regulates the pro-apoptotic caspase response and together with GSK3β these 
factors promote regulated apoptosis  (Watcharasit et al., 2002, Alves da Costa et al., 
2006). In addition, previous studies show GSK3β phosphorylates tau and upon 
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exacerbated activity may be the mechanism for NFT formation (Lovestone et al., 1994). 
This positive feedback of AICD could exacerbate AD neuropathology.  
 Along with AICD, Aβ is also produced by γ-secretase cleavage. Aβ is neurotoxic 
at elevated concentrations, however it is present in picomolar concentrations in brains of 
healthy individuals and has an important biological role  (Seubert et al., 1992, Pearson 
and C. Peers 2006). Literature implies Aβ is a positive regulator of learning and memory 
and synaptic plasticity at picomolar range (< 0.2 nM).  In fact it is required for LTP, the 
molecular mechanism for learning and memory (Puzzo et al., 2008). More evidence 
comes from APP-/- and BACE-/- mice that display aberrant LTP and synaptic plasticity  
(Dawson et al., 1999, Saura et al., 2004, Laird et al., 2005). Studies indicate that Aβ is 
released upon synaptic activity and promotes LTP (Kamenetz et al., 2003). Analogously, 
activating NMDA receptors also increases surface APP endocytosis and Aβ production  
(Lesne et al., 2005, Kamenetz et al., 2003). Interestingly, studies also demonstrate that 
suitable concentrations of Aβ can depress synaptic activity and decrease exitotoxicity by 
decreasing glutamate release (Kamenetz et al., 2003). Together these findings and the 
amyloid hypothesis has motivated researchers to address Aβ generation without affecting 
peptides’ aforementioned biological function. 
 
ALZHEIMER’S DISEASE THERAPY 
 Current therapies are designed to address symptoms and extend patients’ quality 
of life. Aside from pharmacological therapeutics, some unconventional therapies are also 
suggested. Several of these include: music, drum, art, light and pet therapy. These 
therapies ameliorate behavioral symptoms such as, aggression, impatience, empathy and 
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decreased attention. For example, music therapy can calm AD patients when in distress, 
while art therapy helps with self-expression when verbal skills are significantly 
compromised in late stages of the disease. The aforementioned therapies are not meant to 
cure or slow the progression of the disease, but may aid in increasing quality of life.  
 Currently, clinicians prescribe donepezil, rivastigmine or galantamine to patients 
diagnosed with early stages of Alzheimer’s disease. Donepezil, rivastigmine and 
galantamine are all acetylcholinesterase inhibitors  (Balin and A. P. Hudson 2014). The 
hippocampus and cortex receive considerable cholinergic inputs from the basal forebrain  
(Yakel 2012, Yakel 2013, Yakel 2014). These tissues all undergo extensive tissue 
atrophy during the course of the disease (Perry et al., 1978). In 1970’s reports from 
postmortem AD brain tissue analysis showed significant decrease in acetylcholine (ACh), 
acetylcholinesterase (AChE) and an overall cholinergic decline  (Bowen et al., 1976, 
Davies and A. J. Maloney 1976, Perry et al., 1977, Whitehouse et al., 1982, Rylett et al., 
1983, Nilsson et al., 1986). Together, these findings prompted the rise of the cholinergic 
hypothesis of Alzheimer’s disease (Bartus et al., 1982).  
 Acetylcholine is an excitatory neurotransmitter implicated in synaptic plasticity 
and learning and memory  (HUGHES and F. ROBINSON 1951, Drachman and J. Leavitt 
1974). ACh is released into the synaptic cleft and binds the nicotinic acetylcholine 
receptor (nAChR) and/or the muscarinic acetylcholine receptor (mAChR) on the 
postsynaptic membrane. Both receptors lead to neuronal depolarization and excitability. 
AChE is also located at the postsynaptic membrane and has high affinity for ACh. Upon 
binding to AChE, acetylcholine is degraded and thereby decreases degree of excitability. 
Knowing this, clinicians began to treat patients with acetylcholinesterase inhibitors in 
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efforts to increase presence of ACh in synaptic cleft and excitability (Nochi et al., 1995). 
Clinical studies showed these inhibitors lead to positive effects. Up to 80 % of patients 
experienced improvements in their daily tasks, enhanced memory recall and progression 
of cognitive decline was slowed by approximately one year  (Friedhoff and S. L. Rogers 
1997, Rogers et al., 1998). AChE inhibitors slow progression of the disease and increase 
patients’ quality of life, but do not address the underlying cause of AD.  
 The amyloid hypothesis points to increased Aβ load at the root of AD 
patogenesis. Because of this, researchers are developing various ways to decrease Aβ 
load. One mechanism to decrease Aβ levels is to increase clearance from the brain. 
Immunization with Aβ peptide was hypothesized to induce the endogenous immune 
response and encourage Aβ clearance. Another way to induce Aβ clearance is to develop 
an antibody vaccine against human Aβ in hopes this too would prompt an immune 
response. Unfortunately neither the immunization nor vaccination method resolved AD 
pathology  (Orgogozo et al., 2003, Anand et al., 2014). 
 Interestingly frequent users of NSAIDs, Non-Steroidal Anti-Inflammatory Drugs 
such as ibuprofen, reportedly have decreased LOAD incidence rate. Further studies 
indicated that, although not all NSAIDs, ibuprofen induced changes in Aβ structure and 
decreased synaptotoxicity (Meraz-Rios et al., 2013). Since inflammation is also part of 
AD neuropathology, it is reasonable to speculate that decreased inflammation is the 
underlying mechanism of ibuprofen’s effects on AD pathology. It would be interesting to 
determine the mechanism and also identify why this effect is specific to ibuprofen and 
not all NSAIDs. 
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 In addition, the amyloid hypothesis prompted researchers to target the secretases 
involved in Aβ generation, namely β- and γ-secretase. A number of γ-secretase transition 
state inhibitors are currently available. However, these drugs are only used for research 
purposes and are not suitable for human therapy. γ-Secretase cleaves numerous substrates 
besides APP. This presents a challenge for decreasing Aβ production specifically through 
inhibiting γ-secretase activity. One pharmacological agent was tested in clinical trials, 
Semagacestat (LY450139); a direct γ-secretase modulator, showed efficacy but failed due 
to severe gastrointestinal and skin cancer side effects. Similar to other γ-secretase 
inhibitors, Semagacestat’s side effects are relevant to previously documented Notch 
signaling defects  (Fleisher et al., 2008, Imbimbo and G. A. Giardina 2011, Henley et al., 
2014). It is for this reason of specificity that great precision must be taken while 
developing secretase inhibitors. Taken together, identification of novel gene targets that 
regulate APP metabolism is necessary. Identification of genes that regulate APP 
metabolism will lead to a better understanding of the disease and open novel avenues for 
therapeutic design. In 2007, using an AICD-based functional screen we identified 
putative genes involved in regulation of APP proteolysis (Zhang et al., 2007). This screen 
was designed to monitor γ-secretase mediated cleavage of APP in cells. Using this screen 
we identified components of the Sonic hedgehog (Shh) signaling pathway as a putative 
regulators of APP metabolism. 
 
CANONICAL HEDGEHOG SIGNALING PATHWAY 
 Morphogenic Hedgehog signaling (Hh) plays a major role in embryonic 
development, body patterning and neurogenesis  (Varjosalo and J. Taipale 2008). During 
16
	  
the 80’s Nusslein-Volhard and Wieschaus performed genetic studies using Drosophila 
revealed a “spiked” phenotype for which the gene was identified and called Hedgehog 
(Hh) (Nusslein-Volhard and E. Wieschaus 1980). Soon after Drosophila Hh was cloned 
and its mammalian homolog was identified  (Lee et al., 1992, Tashiro et al., 1993, 
Echelard et al., 1993, Marigo et al., 1995). There are three mammalian Hedgehog family 
members: Sonic (Shh), Indian (Idh) and Desert (Dhh) (Ingham and A. P. McMahon 
2001). Dhh shares the most homology with Drosophila Hh. Dhh expression is mainly 
restricted to gonads while Shh is most potent and is implicated in development, 
neurogenesis and maintenance of the central nervous system  (Riddle et al., 1993, 
Johnson et al., 1994, Bitgood et al., 1996, Marigo et al., 1996). Ablating Shh signaling 
during development leads to failed organogenesis and is typically incompatible with life. 
Mutations in SHH gene or other downstream signaling components results in a range of 
phenotypes; the most common is cyclopia (Chiang et al., 1996). Besides developmental 
stages, recent literature shows Shh signaling in the adult brain  (Charytoniuk et al., 2002, 
Alvarez-Buylla and R. A. Ihrie 2014). Shh was detected in the projecting axons and 
hippocampal postmitotic neurons  (Huang and S. Kunes 1996, Traiffort et al., 2001, 
Charytoniuk et al., 2002, Lai et al., 2003, Machold et al., 2003, Petralia et al., 2011). In 
particular enrichment was observed in dendrites, spines, and post-synaptic terminals 
suggesting Shh may play a role in synaptic activity  (Masdeu et al., 2007, Petralia et al., 
2011, Petralia et al., 2011, Petralia et al., 2012). Shh peptide was also detected in layers 
4/5 and 2 cortical neurons, motor neurons, cerebellar Purkinje cells and basal forebrain 
structure  (Charytoniuk et al., 2002, Reilly et al., 2002, Garcia et al., 2010). Adult 
hippocampus receives substantial projections from the basal forebrain, a major 
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cholinergic CNS system. Together these finding implicate functional Shh signlaing 
circuit in the basal forebrain to the adult hippocampal structure. Interestingly, besides 
hippocampal atrophy, defects in the cholinergic system are also observed in AD. 
Consequently, one may speculate that neurodegeneration of basal forebrain cholinergic 
neurons observed in AD could subsequently lead to abolished Shh signaling to the 
hippocampal structure resulting in increased atrophy and impaired neurogenesis.  
 The 45 kDa Shh protein is posttranslationally modified beginning with 
autoproteolysis into N- (~19 kDa) and C-terminal (~25 kDa) fragments. N-terminal Shh 
is further modified with a cholesterol and palmityol moieties at the C- and N-terminus, 
respectively making it a hydrophobic peptide  (Porter et al., 1995, Porter et al., 1996, 
Porter et al., 1996, Pepinsky et al., 1998). These modifications are thought to aid in 
plasma membrane insertion, secretion and long distance signaling. In order to leave the 
secreting cell, Shh requires a 12-pass transmembrane Dispatched (Disp) protein located at 
the plasma membrane  (Burke et al., 1999, Kawakami et al., 2002). Interestingly, the 
same metalloproteases (α-secretase, ADAMs) involved in APP non-amyloidogenic 
processing also cleave Shh’s lipid moieties for extracellular release  (Dierker et al., 2009, 
Ohlig et al., 2011). 
 Shh binds a 12-pass transmembrane receptor Patched (Ptch1/2). Ptch1 contains 
two extracellular loops thought to be sterol-sensing domains (Johnson et al., 2002). Upon 
Shh binding to Ptch1, the complex is endocytosed for lysosomal degradation  (Chen and 
G. Struhl 1996, Incardona et al., 2000, Gallet and P. P. Therond 2005). This in turn 
alleviates inhibitory effects on the downstream 7-pass transmembrane protein 
Smoothened (Smo) and allows for downstream signal transduction (Smo; will be 
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discussed in greater detail in later sections). Briefly, Smo is a 7-pass transmembrane G 
protein-coupled receptor whose ligand is yet to be determined (Wang et al., 2013). In 
addition to Shh signal transduction, Smo is though to bear an oxysterol (oxidized form of 
cholesterol) binding domain that is distinct from binding sites of small molecule 
modulators  (Sharpe and F. J. de Sauvage 2012). In presence of Shh, activation of Smo 
requires its translocation from intracellular vesicles to the plasma membrane. Following, 
G protein-coupled receptor kinase 2 (GRK2) and casein kinase 1 (CK1) phosphorylate 
Smo at the C-terminal tail. Phosphorylation of Smo prevents ubiquitination and 
subsequent endocytosis and lysosomal degradation  (Jia et al., 2004, Zhang et al., 2004, 
Li et al., 2012, Xia et al., 2012). GRK2 phosphorylation, specifically, recruits β-Arrestin 
1/2 to prompt downstream Shh signaling  (Chen et al., 2004, Meloni et al., 2006).  
According to literature, Ptch1 maintains Smo in intracellular vesicles by an 
unknown mechanism. Upon activation, Ptch1 is internalized allowing Smo to translocate 
to the plasma membrane and become phosphorylated for β-Arrestin recruitment. β-
Arrestins are typically recruited to active GPCRs and induce desensitization via receptor-
mediated endocytosis. Therefore it is likely that upon β-Arrestin recruitment, Smo is also 
internalized for further signaling. Interestingly in Shh signaling cells, Ptch1 to Smo ratio 
is 1:45 and it seems unlikely that one molecule of Ptch1 is capable of inhibiting all Smo 
molecules  (Denef et al., 2000, Ingham et al., 2000, Taipale et al., 2002). In addition, 
even upon inhibition of Smo with an antagonist (cyclopamine) the protein is still able to 
translocate to the plasma membrane without further Shh activation. These findings give 
reason to speculate that there may be two separate pools of Smo and a possible unknown 
function of this GPCR.  
19
	  
 Upon Shh binding Ptch1, Smo interacts with the Hh cytosolic complex composed 
of Kif7, serine/threonine kinase Fused (Fu) and adaptor protein Suppressor of Fused 
(SuFu) which sequester the Gli zinc-finger binding transcription factors with slightly 
overlapping functions (Gli1/2/3) (Bai and A. L. Joyner 2001, Varjosalo et al., 2006, 
Svard et al., 2006, Hsu et al., 2011, Zhang et al., 2013). Since Gli1 does not contain the 
repressor domain, its primary function is to activate transcription  (Dai et al., 1999, 
Sasaki et al., 1999, Kaesler et al., 2000). Gli3 mainly functions as a repressor of 
transcription, while Gli2 as an activator, however evidence suggests it can also have 
minor role as a transcriptional repressor  (Vortkamp et al., 1991, Sasaki et al., 1999, 
Wang et al., 2000, Bai et al., 2002, Hui and S. Angers 2011, Li et al., 2011). Fu kinase 
phosphorylates SuFu releasing the Gli proteins that translocate to the nucleus and induce 
transcriptional activation of downstream genes such as PTCH1 and GLI1. In absence of 
Shh, CK1, GSK3β, and protein kinase A (PKA) phosphorylate Gli1/2/3 for E3 ubiquitin 
ligase recruitment and subsequent proteosomal degradation. Phosphorylation of Gli3 and 
partial degradation results in the generation of the repressor form of Gli3  (Wang et al., 
2000, Pan et al., 2006, Wang and Y. Li 2006, Zhu and H. W. Lo 2010). It is unclear if a 
similar mechanism underlies regulation of Gli2. A model suggests that in presence of 
Shh, Gli2 N-terminal repressor domain is degraded liberating the Gli2 activator  (Wong 
and J. F. Reiter 2008). It is typical to monitor Ptch1 and Gli1 protein and/or mRNA to 
assess Shh signaling activity. While canonical Shh signaling requires primary cilia for 
proper signal transduction, it is unclear if noncanonical signaling also requires this 
structure (Figure 1-3)  (Huangfu et al., 2003, Milenkovic et al., 2009, Rohatgi et al., 
2007, Goetz and K. V. Anderson 2010). 
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NONCANONICAL HEDGEHOG SIGNALING PATHWAYS 
 Canonical Hh signaling has been investigated for several decades while recent 
literature describes Gli-independent Hh signaling. This type of Hh signaling is referred to 
as “noncanonical”. Researchers identified novel Smo and Gli independent effects of 
Ptch1 activation, known as Type I noncanonical Hh signaling. Additionally, Type II 
noncanonical Hh signaling involves activation of Ptch1 and Smo, but is Gli-independent 
(Figure 1-4) (Brennan et al., 2012, Robbins et al., 2012). 
 Type I noncanonical Hh signaling revealed that Ptch1 can regulate apoptosis and 
cell cycle progression. Similar to other receptors involved in regulated cell death, Ptch1 
has a dependence-associated receptor C-terminal domain routinely cleaved by pro-
apoptotic caspases. In absence of Dhh, Ihh, or Shh, Ptch1 C-terminal domain is hidden 
and is therefore unavailable for caspase cleavage thus liberating cells from cell death. In 
contract, in the presence of the ligand, Ptch1 C-terminal domain is cleaved and associates 
with a proapoptotic complex subsequently leading to programmed cell death. Effects are 
not dependent on Gli activity and cannot be rescued with Smo activation. These findings 
suggest Type I Hh signaling does not require Smo or downstream Gli transcriptional 
function  (Thibert et al., 2003, Mille et al., 2009, Kagawa et al., 2011, Chinchilla et al., 
2010). An additional Type I noncanonical role for Ptch1 signaling involves the direct 
interaction with Cyclin B1. This interaction is regulated at G2/M checkpoint and thus 
controls cell proliferation. Exposure to Shh or genetic removal of Ptch1 disrupts the 
Cyclin B1 interaction and allows for cell cycle completion. More evidence comes from 
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patients with basal cell carcinoma, some of which express truncated C-terminal Ptch1 
required for Cyclin B1 interaction  (Barnes et al., 2001, Barnes et al., 2005). 
 In contrast to Type I noncanonical Hh signaling, Type II is Smo-dependent. Like 
other GPCRs, recent studies show that Smo leads to downstream G protein signaling 
(Ogden et al., 2008). In fact in 2013, Cherezov and Stevens group were able to confirm 
this by resolving the crystal structure of human Smo. Although the crystal structure was 
resolved, the authors describe that Smo extracellular heptahelical loops are long and more 
complex than those of classical GPCRs suggesting Smo can be a novel subset or family 
of GPCRs and may bind small molecules at distinct sites  (Wang et al., 2013, Wang et al., 
2014). Classical GPCRs interact with small G proteins and are first phosphorylated by 
kinases that immediately lead to desensitization via β-Arrestin1/2 cytosolic accessory 
proteins. Desensitization of GPCRs results in clathrin-mediated endocytosis and 
precludes further binding to extracellular ligand and subsequent signaling to small G-
proteins. Several GPCRs such as β2 adrenergic receptor (β2-AR) and GPR3 are 
documented to modulate APP metabolism and Aβ generation by directly altering γ-
secretase subcellular localization  (Thathiah and B. De Strooper 2011). In particular in 
2013 Bart De Strooper’s group described the mechanism by which β-Arrestins and G 
protein-coupled receptor kinases (GRKs) regulate endocytosis of APP, γ-secretase 
cleavage and Aβ production (Thathiah et al., 2013). Not surprisingly, since Smo is a 
GPCR, it is also regulated by GRKs and β-Arrestin2 in human HEK293 cells  (Chen et 
al., 2004). Together these findings and identifying Shh signaling components in our 
genetic screen lead us to hypothesize that Smo can also regulate APP metabolism. 
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 Moreover, many GPCRs are coupled to small G proteins, activators and 
repressors are two types of GTPases. This gave rise to further studies monitoring small 
GTPase activity during Hh signaling  (Ayers and P. P. Therond 2010, Ogden et al., 
2008). Reports established Smo coupling to small inhibitory G proteins (Gαi) and induce 
down-regulation of adenylate cyclase signaling and cell migration  (Riobo et al., 2006, 
Polizio et al., 2011, Polizio et al., 2011). Active adenylate cyclase catalyzes cAMP and 
leads to a variety of effects including cytoskeletal re-organization at the plasma 
membrane and increased CREB transcriptional activity  (Polizio et al., 2011, Brennan et 
al., 2012, Shen et al., 2013, Riobo et al., 2006, Meloni et al., 2006). Interestingly previous 
reports document adenylate cyclase and cAMP can modulate APP cleavage at the level of 
γ-secretase. More importantly however, it was demonstrated that increased cAMP and 
CREB activation can ameliorate memory deficits in mouse model of AD and increase 
long term potentiation, synaptic plastic and memory formation  (Gong et al., 2004, Yiu et 
al., 2011, Sierksma et al., 2013). Therefore, one can speculate that decreasing Smo 
activity will decrease Gαi protein activity thereby allowing accumulation of active cAMP 
and CREB transcriptional activation. Perhaps this can ameliorate the memory deficits 
observed in Alzheimer’s disease. 
 Upon activation, many GPCRs induce changes in Ca2+ levels. Recent studies 
demonstrated a direct relationship between Shh peptide exposure and Ca2+ signaling  
(Belgacem and L. N. Borodinsky 2011). The authors reportedly observed a Ca2+ spike in 
developing neurons upon Shh treatment in vitro. This effect was recapitulated using 
SAG, a potent Smo agonist. In support, cyclopamine (Smo antagonist) treatment 
abolished the Ca2+ spike suggesting these effects are Smo-dependent. Finally the authors 
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were able to show that these Ca2+ changes were dependent on Gαi proteins. They 
proposed that Shh activating Smo and Gαis mediate the Ca2+ spike by activation of PLCγ 
and IP3 signaling which is known to open voltage gated channels and induce Ca2+ spike 
neuronal activity  (Belgacem and L. N. Borodinsky 2011). Intriguingly, vertebrate Shh 
signaling is dependent on primary cilia, which are thought to be Ca2+ sensors  (DeCaen et 
al., 2013, Delling et al., 2013). In support of this notion, the authors detected IP3 and Ca2+ 
changes in primary cilia upon activating Smo with SAG. These finding and the observed 
Ca2+ dyshomeostasis in late stages of Alzheimer’s disease, prompted us to investigate the 
possible role of primary cilia and AD. 
 
PRIMARY CILIA 
 Cilia are small microtubule projections at the apical side of post-mitotic cells. 
Two types of cilia are characterized: motile and primary (immotile) cilia. The cylindrical 
nine doublet arrangement of microtubules is conserved between both types of cilia. 
However, immotile cilia lack a pair of central microtubules (9+0), dynein arms and radial 
spokes that motile cilia require for the “stroking” motion (9+2) (Figure 1-5)  (Satir et al., 
2010, Mike Adams 2010). Motile cilia line the apical surface of epithelial layers like 
trachea and brain ventricles. Primary immotile cilia are found on most, but not all cells 
throughout the body. Nonetheless, both motile and primary cilia are located at the 
embryonic node during development and are critical for left-right symmetry, Ca2+ and 
morphogen sensing, respectively (McGrath et al., 2003).  
 Cellular entry into G0, allows commencement of ciliogenesis. First, the mother 
centriole docks at the apical side of the cell membrane and attaches to a Golgi-derived 
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vesicle. This vesicle contains all of the necessary components for ciliogenesis  
(SOROKIN 1962). Primary cilium base complex is called the basal body and is required 
for ciliogenesis and cilia maintenance. From the basal body, a microtubule axoneme 
grows forcing the plasma membrane to extend. As the microtubules polymerize at the 
growing distal tip, intraflagellar transport (IFT) particles deliver necessary materials via 
kinesin 2 motor proteins in the anterograde direction  (Pedersen et al., 2008, Pedersen and 
J. L. Rosenbaum 2008, Cole and W. J. Snell 2009). Finally, the vesicle is exocytosed and 
the primary cilium continues to polymerize for several micrometers more. This is the last 
time a vesicle will be found in cilia. It is well-established that vesicles do not fuse nor 
enter the primary cilia, thus any entry or exit of materials relies on the highly conserved 
IFT and “ciliary pore complex” also known as the cilia diffusion barrier. Instead cargo-
containing vesicles fuse with the plasma membrane adjacent to cilia and await sorting at 
the basal body transition zone  (Leroux 2007, Nachury et al., 2007, Hsiao et al., 2012). 
The diffusion barrier mains the ciliary membrane and molecular environment that is 
distinct from the cytoplasm  (Hu et al., 2010, Chih et al., 2011, Hu and W. J. Nelson 
2011). A growing body of evidence indicates cilia are enriched with receptor proteins 
hence, proteins destined for cilia localization contain a “cilia targeting sequence” without 
which delivery is ablated. These findings lead to the growing “ciliome” database which 
includes proteins demonstrated to specifically localize to primary cilia  (Andersen et al., 
2003, Inglis et al., 2006, Berbari et al., 2008, Berbari et al., 2008).  
 Primary cilia were described a century ago however, this structure was ignored 
and assumed to be a vestigial organelle  (K. W. Zimmermann 1898). Only recent reports 
of cilia related diseases shed light on the importance of proper cilia structure and 
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function. Diseases associated with abnormal cilia structure and signaling are known as 
“ciliopathies” that can affect a wide rage of organ systems and result in a range of 
phenotypes and symptoms (Figure 1-6, Table 1-1)  (Badano et al., 2006, Hildebrandt et 
al., 2011, Sattar and J. G. Gleeson 2011). Since Shh signaling depends on primary cilia, it 
is not surprising that disruption of cilia structure leads ciliopathies that are detrimental to 
normal development. Interestingly, a common symptom to all ciliopathies is cognitive 
impairment (Gitten et al., 1998). Researchers speculated cilia play a role in cognition and 
must be present somewhere in the brain. Microscopy and cilia specific antibodies 
revealed neural tissue and cultured cells all express primary cilia  (Del Cerro and R. S. 
Snider 1969, Mandl and R. Megele 1989, Handel et al., 1999, Whitfield 2003, Fuchs and 
H. D. Schwark 2004, Bishop et al., 2007, Berbari et al., 2007, Arellano et al., 2012). 
Since, researchers developed genetically modified mouse models of conditionally 
disrupted cilia and are now beginning to address fundamental questions of neuronal cilia 
functions and behavior. To this end, studies demonstrate neuronal primary cilia are 
critical for neurodevelopment and maintenance of neurogenesis in the adult hippocampal 
and cortical structures  (Breunig et al., 2008, Town et al., 2008, Kumamoto et al., 2012, 
Willaredt et al., 2013). However, these studies illustrate that disrupting cilia structure 
subsequently leads to ablation of critical signaling pathways that are required for 
mechanisms such as neurogenesis. It would be interesting to see if the observed effects 
are due to interrupted signaling pathways or the cilia structure itself.  
 Recent reports suggest cilia and type 3 adenylyl cyclase are involved in cognitive 
functions like learning and memory (Wang et al., 2011). Progressive decline in memory 
is observed in Alzheimer’s disease which lead us to hypothesize cilia may be affected in 
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AD brains. In support of our hypothesis, Chakravarthy and colleagues recently reported 
diminished cilia length of hippocampal dentate granule cells in an AD mouse model  
(Chakravarthy et al., 2012). In addition, we detected a putative cilia targeting sequence in 
APP C-terminal domain (discussed in later chapters). A recent report revealed that APP 
homodimerizes upon binding extracellular Aβ resulting in subsequent synaptic activation 
(Fogel et al., 2014). Together we speculate that APP localizes to the primary cilia and 
functions as a sensing receptor for extracellular Aβ levels. Therefore, overwhelming 
levels of neurotoxic Aβ could be disruptive to neuronal cilia and perhaps be an 
underlying mechanism of neuronal loss and cognitive decline observed in AD. 
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DISSERTATION RESEARCH SUMMARY 
Using the APP-Gal4 UAS-Luciferase assay system we identified Shh signaling 
components as putative regulators of APP metabolism  (Cao and T. C. Sudhof 2001, 
Zhang et al., 2007). From this we hypothesized that pharmacological modulation of Shh 
will alter APP metabolism. The best characterized antagonist and agonist of Shh 
signaling is cyclopamine and SAG, respectively  (Stanton et al., 2009, Stanton and L. F. 
Peng 2010). Treatment of cells with SAG did not alter APP metabolism. However, an 
obvious APP-CTF accumulation was observed upon in vitro cyclopamine treatment. 
Cyclopamine is a plant equivalent of cholesterol, and other plant sterols were recently 
shown to alter APP metabolism (Burg et al., 2013). Together, this prompted us to 
investigate how cyclopamine alters APP metabolism.  
 We determined cyclopamine decreases γ-secretase mediated cleavage of APP and 
Aβ generation. These effects were due to alterations to the retrograde trafficking of APP-
CTFs to the trans-Golgi network (TGN). Interestingly these results were not due to direct 
inhibition of γ-secretase. Instead we observed cyclopamine induces APP-CTF 
accumulation in lysosomes in a specific manner. We determined that increased APP-CTF 
trafficking to lysosomes is the underlying mechanism by which we observed decreased γ-
secretase mediated cleavage of APP and Aβ generation. Importantly, we were able to 
recapitulate similar results using an in vivo γ-secretase reporter Drosophila model (Guo et 
al., 2003). 
 Cyclopamine’s target is the Smo 7-TM GPCR, therefore we hypothesized 
ablation of Smo expression in cells would result in similar effects as cyclopamine. In 
support of our hypothesis, we observed accumulation of APP-CTFs to a similar extent as 
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cyclopamine treatment. We were able to recapitulate these effects in vivo using a γ-
secretase reporter Drosophila model. These findings encouraged us to investigate other 
Shh signaling components in APP metabolism. Comparable to Smo knockdown and 
cyclopamine treatment, sequestering Shh peptide lead to accumulation of APP-CTF 
levels. In contrast, inhibition of Gli1 and Gli2 and knockdown of Gli3 using shRNA did 
not alter APP proteolysis. Together these data suggest that Shh signaling modulates APP 
metabolism in a Gli-independent manner. Finally we tested other known Smo 
antagonists. Unlike cyclopamine, we did not observe changes in APP-CTF levels upon 
treatment with other Smo antagonists. Together these finding implicate the Shh peptide, 
Smo and possibly Ptch1 in regulating APP metabolism. Because these effects we 
describe are Gli-independent, suggests this may be through a noncanonical Shh signaling 
mechanism. 
 Shh requires primary cilia for signal transduction and several components, 
including Smo, are localized to cilia upon activation. With our previous findings that 
Smo regulates APP metabolism, we hypothesized APP may also localize to the primary 
cilia. In support of our hypothesis, immunostaining revealed both APP and Smo co-
localize at the primary cilia in cells. Cilia are thought to be antenna structures enriched 
with receptors used for sampling the extracellular matrix. In support of this notion and 
our findings, recent experiments demonstrate APP functions as a receptor for Aβ (Fogel 
et al., 2014). From this, one may speculate that APP at the primary cilium senses levels of 
extracellular Aβ and the binding of which may lead to downstream signaling via AICD.  
 Growing literature describes proteins required for cilia structure, disruption of 
which leads to interrupted ciliogenesis. However, the latter are implicated in ciliopathies 
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due to impaired embryogenesis and development. Ciliopathies have not been described 
previously in neurodegenerative diseases until Chakravarthy and colleagues investigated 
cilia in an AD mouse model  (Chakravarthy et al., 2012). The authors describe decreased 
hippocampal cilia immunostaining in an AD mouse mode. Since AD neuropathologies 
accumulate with age, the authors determined cilia length is diminished in an age-
dependent manner. These finding and other literature implicate cilia in cognitive 
functions, thus it is not surprising that these microscopic structures are affected in an AD 
mouse model. In agreement with the amyloid hypothesis; that elevated Aβ load is the 
underlying cause of AD neuropathology, we postulated that Aβ peptide may be the 
underlying cause of decreased cilia length. Treating ciliated cells with Aβ conditioned 
media decreased cilia skeletal length as well as the number of cells bearing cilia. We 
observed similar upon treatment with synthetic Aβ. 
 To our knowledge our studies are first to implicate Shh signaling in APP 
metabolism. Our data suggests the observed effects are via noncanonical Shh signaling. 
Importantly, we discovered a previously unknown function of Smo GPCR. Canonical 
Shh signaling requires primary cilia. Since we observed APP localizing to cilia, it would 
be interesting to determine whether the effects we observed on APP metabolism are 
dependent on this structure. Together with our finding that Aβ is “ciliotoxic”, we propose 
a novel neuropathological hallmark of Alzheimer’s disease that opens nocvel avenues for 
disease therapeutics. In addition, these findings will lead to further investigation of Smo 
as a putative target for AD treatment.  
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FIGURES & LEGENDS 
 
Figure 1-1: Model of Amyloid precursor protein (APP) Proteolysis. In the first cleavage 
step, APP is processed by α- or β-secretase. This cleavage liberates a soluble N-terminal 
sAPP fragment and a membrane-tethered C-terminal domain (C83 or C99, collectively 
known as APP-CTFs). In the non-amyloidogenic proteolysis, α-secretase cleaves APP 
within the Aβ sequence thereby precluding its generation. In the second proteolytic 
cleavage step, APP-CTFs are processed by γ-secretase producing p3 and AICD or Aβ 
and AICD peptides. 
 
Figure 1-2: Model of Amyloid precursor protein (APP) trafficking and cleavage. Full 
length (FL-APP) is trafficked from the trans-Golgi network (TGN) to the plasma 
membrane. Majority of FL-APP is cleaved by α-secretase at the plasma membrane. This 
liberated soluble APP (sAPP) into the extracellular matrix and APP C-terminal fragments 
(APP-CTFs) are endocytosed. Endocytosed FL-APP from the plasma membrane is either 
recycled back or trafficked to the early endosome for β-secretase cleavage. After the first 
proteolytic cleavage, APP-CTFs are trafficked to late endosomes/multivesicular bodies 
that fuse with lysosomes for subsequent degradation. Alternatively, APP-CTFs are 
retrogradely trafficked to the TGN for γ-secretase mediated proteolysis and Aβ 
generation. 
 
Figure 1-3: (Adopted from Goetz & Andersen, 2010) Model of vertebrate Sonic 
hedgehog signaling. In presence of Shh peptide, Ptch1 relieves its inhibitory effects on 
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Smo. Upon activation, Smo translocates to the tip of the primary cilium and allows Gli 
proteins to dissociate from repressor complex. Glis are transported down the ciliary shaft 
and enter the nucleus to induce transcriptional activation of downstream genes. 
 
Figure 1-4: (Adapted from Adams, M. The Primary Cilium: An Orphan Organelle Finds 
a Home. Nature Education. 2010. 3(9):54). Diagram of primary and motile cilia. While 
immotile primary cilia have a 9+0 microtubule doublet arrangement, motile cilia bear a 
9+2 arrangement. Motile cilia also have radial spokes and dynein inner and outer arms 
required for the characteristic “beating” or “stroking” motion. 
 
Figure 1-5: (Adapted from Brenna et al., 2012). Cartoon representation of noncanonical 
Sonic Hedgehog signaling Type I (left) and Type II (right). While both Type I and II are 
Gli-independent, Type I is also Smo-independent. Type II Shh noncanonical signaling is 
dependent on Shh binging to Ptch1 and subsequently activating Smo. In addition, while 
Type I is cyclopamine-insensitive, Type II noncanonical Shh signaling is cyclopamine-
sensitive.  
 
Figure 1-6: (Adapted from Goetz & Andersen, 2010) Representation of the organ 
systems effected by ciliopathies and the underlying molecular defects. 
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TABLES 
Table 1-1: (Adapted from Jeong Lee & Joseph Gleeson, 2009) Table representation of 
several major ciliopathies and the characteristic neurological deficits. Note that cognitive 
impairment is a common symptom observed across several ciliopathies. 
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CHAPTER 2: CYCLOPAMINE MODULATES GAMMA-SECRETASE 
MEDIATED CLEAVAGE OF AMYLOID PRECURSOR PROTEIN BY 
ALTERING ITS SUBCELLULAR TRAFFICKING AND LYSOSOMAL 
DEGRADATION 
 
 
 
 
ABSTRACT 
 Alzheimer's disease (AD) is a progressive neurodegenerative disease leading to 
memory loss. Numerous lines of evidence suggest that Aβ, a neurotoxic peptide, initiates 
a cascade that results in synaptic dysfunction, neuronal death and eventually cognitive 
deficits. Aβ is generated by the proteolytic processing of the amyloid precursor protein 
(APP) and alterations to this processing can result in AD. Using in vitro and in vivo 
models we identified cyclopamine as a novel regulator of γ-secretase mediated cleavage 
of APP. We demonstrate that cyclopamine decreases Aβ generation by altering APP 
retrograde trafficking. Specifically, cyclopamine treatment reduced APP-CTF delivery to 
the trans-Golgi network where γ-secretase cleavage occurs. Instead cyclopamine 
redirects APP-CTFs to the lysosome. These data demonstrate that cyclopamine treatment 
decreases γ-secretase mediated cleavage of APP. In addition, cyclopamine treatment 
decreases the rate of APP-CTF degradation. Together, our data demonstrate that 
cyclopamine alters APP processing and Aβ generation by inducing changes in APP 
subcellular trafficking and APP-CTF degradation.  
 
INTRODUCTION 
 Alzheimer’s disease (AD) is the most common form of dementia. It is an 
irreversible neurodegenerative disease characterized by gradual cognitive decline  (Tanzi 
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and L. Bertram 2005, Serrano-Pozo et al., 2011). AD is neuropathologically characterized 
by senile plaques, composed of amyloid-β (Aβ), and neurofibrillary tangles (NFTs), 
composed of hyperphosphorylated tau. The amyloid cascade hypothesis suggests 
neurotoxic Aβ initiates a series of events that result in synaptic dysfunction leading to 
neuronal loss  (Hardy and D. Allsop 1991, Tanzi 2012, Tanzi 2005, Hardy and D. J. 
Selkoe 2002, Selkoe 2003, Selkoe 1991, Herrup 2010). The Aβ peptide is produced by 
proteolysis of amyloid precursor protein (APP)  (Haass et al., 2012, Haass and B. De 
Strooper 1999, Gandy et al., 1994, Gandy and P. Greengard 1994, Gandy and P. 
Greengard 1994, Golde et al., 1993).   
 APP is a type I transmembrane protein containing an intracellular C-terminal 
domain and a larger external N-terminal domain  (Palmert et al., 1989, Palmert et al., 
1990). APP is proteolytically processed via non-amyloidogenic or amyloidogenic 
pathways. After translation, N- and O-glycosylated APP (mature APP) is trafficked to the 
plasma membrane where α-secretase (non-amyloidogenic) can cleave full-length APP 
(FL-APP) liberating a soluble N-terminal fragment (sAPPα) and a membrane tethered C-
terminal (APP-CTFα) fragment. Alternatively, FL-APP can be endocytosed and either 
recycled back to plasma membrane or localized to the early endosome where β-secretase 
cleavage of FL-APP initiates amyloidogenic cleavage. This β-secretase cleavage liberates 
a soluble N-terminal fragment (sAPPβ) and a membrane tethered C-terminal fragment 
(APP-CTFβ) (Vassar et al., 1999). Following this initial cleavage by either α- or β-
secretase, retrograde trafficking mechanisms deliver APP-CTFs to the trans-Golgi 
network (TGN). Recent literature demonstrates that the majority of γ-secretase cleavage 
of APP occurs at the TGN (Choy et al., 2012). Here, APP-CTFs are cleaved by 
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γ−secretase to generate the APP intracellular domain (AICD) and p3 or AICD and 
Aβ depending on whether the APP-CTF was derived from α- or β-secretase, respectively.  
 APP proteolysis is intimately associated with its subcellular localization, therefore 
APP trafficking plays a critical role in amyloidogenesis. Cholesterol can alter cellular 
membrane fluidity and therefore can alter trafficking of transmembrane proteins like APP  
(Runz et al., 2002, Bodovitz and W. L. Klein 1996). Cholesterol has been shown to play 
an important role in AD risk and pathogenesis  (Kalman and Z. Janka 2005, Wolozin et 
al., 2000, Jick et al., 2000). High cholesterol levels have been implicated as an AD risk 
factor  (Pappolla et al., 2003, Levin-Allerhand et al., 2002, Levin-Allerhand et al., 2002). 
Clinically, patients treated with statins, inhibitors of cholesterol synthesis, have reduced 
risk for AD  (Yao and V. Papadopoulos 2002, Jick et al., 2000, Wolozin et al., 2000). 
Increasing cholesterol levels in in vitro and in vivo AD models exacerbates 
Aβ production  (Pappolla et al., 2003, Ghribi et al., 2006, Frears et al., 1999). 
Conversely, inhibiting cholesterol synthesis in vitro or in vivo reduces Aβ generation 
(Fassbender et al., 2001).  
 Recently, phytosterols were also demonstrated to modulate Aβ generation. 
Stigmasterol treatment decreased Aβ generation by modulating γ-secretase activity and β-
secretase trafficking (Burg et al., 2013). Cyclopamine is a naturally occurring plant 
phytosterol from the corn lily (Veratrum californicum) plant  (Keeler 1978). 
Cyclopamine and its analogs have been used to treat cancer, specifically, in combination 
with lovastatin to treat medulloblastoma  (Lee et al., 2014, Bar and D. Stearns 2008).  
 Here we demonstrate that cyclopamine modulates APP metabolism. Specifically, 
cyclopamine prevents Aβ generation by decreasing γ-secretase mediated cleavage of 
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APP-CTFs. This occurs due to alteration in subcellular trafficking of APP-CTFs. Upon 
cyclopamine treatment APP-CTFs accumulate in lysosomes rather than being trafficked 
to the TGN. Once in the lysosomes, APP-CTF degradation is decreased leading to its 
accumulation. Together our data demonstrate a novel use of cyclopamine and may open 
new avenues to treat Alzheimer’s disease. 
 
EXPERIMENTAL PROCEDURES 
Antibodies, Plasmids and Reagents- Antibodies were obtained from the following: mouse 
C-terminus APP clone c1/6.1 (a kind gift from P. Mathews, Nathan Kline Institute, NY, 
USA), mouse APP N-terminus 4A 22C11 (Millipore), rabbit APP C-terminus A8717, 
mouse anti-Myc clone 9E10, rabbit LC3IIB and mouse β-Actin (Sigma), mouse cleaved 
Notch1 clone D3B8 and rabbit PSEN1 CTF clone D39D1 (Cell Signaling), mouse 
LAMP1, TGN38 and mouse EEA1 (BD Biosciences), rat LAMP1 clone 1D4B and 
mouse MP6R clone 22d4 (DSHB), rabbit TGN46 (AbD Serotech) and rabbit cathepsin D 
(kind gift from Dr. Stefan Höning). Fluorescent secondary antibodies (Alexa Fluor 488, 
594) were from Jackson Immunoresearch Laboratories and IR-conjugated secondary 
antibodies (IRDye680, IRDye800) were from Li-Cor Biosciences. Peroxidase-conjugated 
secondary antibodies were from Cell Signaling. Cyclopamine (0.5-10 µM) was purchased 
from LC Laboratories, GW4869 (15 µM) from EMD Millipore, Wortmannin (200 nM) 
from Calbiochem, L-685,458 (2 µM), cycloheximide (50 µg/ml) and DMSO  from 
Sigma. pCS2-Myc-ΔENotch was used for overexpression studies. pMst-APP-Gal4 
originally developed by Cao & Südhof  (Cao and T. C. Sudhof 2001). Human Chmp2a-
GFP construct was a gift from Dr. Elias Spiliotis. 
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Cell Culture and Transfection- HeLa cells were maintained at 37°C, 5%CO2 in complete 
DMEM (Corning) supplemented with 10% FBS (Altanta Biologicals), 100 units/ml 
penicillin and 100 mg/ml streptomycin (Corning), 2 mM L-glutamine (Corning). Cells 
were grown to 80% confluence and serum starved (0.5%FBS DMEM) for 24 hours prior 
to pharmacological or genetic manipulation. For pharmacological manipulation, drugs 
were diluted in 0.5%FBS DMEM. For genetic overexpression experiments, cells were 
grown to 80% confluence then transfected using with TurboFect Transfection Reagent 
(Thermo Scientific) according to manufacturer’s protocol. Culture media was removed 
24 hours post transfection and cells were collected or further treated with 
pharmacological agents (0.5% FBS DMEM) for an additional 24 hours.  
 
Primary Neuron Culture- Primary cortical neuron cultures were isolated from postnatal 
day 1 (P1) Sprague-Dawley rat pups. Briefly, cortices were dissected out, minced, treated 
with papain (100 Units; Worthington Biochemicals) for 15 minutes at 37°C. Following, 
tissue was treated with Type II-O trypsin inhibitor from chicken egg white (Sigma) for 15 
minutes at 37°C. Tissue was washed with fresh Neurobasal medium (Invitrogen) 
supplemented with B-27 (Invitrogen), 2 mM L-glutamine, 100 Units/ml penicillin, and 
100 mg/ml streptomycin. Tissue was triturated, centrifuged at 1000 rpm for 10 minutes 
then resuspended in the fresh, complete Neurobasal medium. 2 X 106 cells per 35mm 
well were plated onto poly-DL-lysine (50 µg/ml; Sigma) coated tissue culture plates. 
Cortical neurons were treated with pharmacological agents on DIV6 (days in vitro) for 24 
hours and lysates collected for further biochemical analysis. All animals were used in 
accordance with animal protocols approved by the Institutional Animal Care and Use 
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Committee (IACUC Protocol # 19787). Animals were delivered to and maintained at the 
Calhoun Animal Facility (Drexel University, PA, USA). Animal procedures were 
performed strictly in accordance with the National Institute of Health Guide for the care 
and use of Laboratory Animals approved by the Drexel University Animal Care and Use 
Committee.  
 
Drosophila stocks and genetics- Drosophila husbandry was performed as previously 
described  (Chakraborty et al., 2011). For experiments utilizing the γ-secretase reporter 
GMR-APP-Gal4; UAS-Grim/Cyo model  (Guo et al., 2003), flies were crossed on 
standard cornmeal agar food supplemented with cyclopamine (100 nM) or DMSO 
vehicle control (0.1%), flies were collected 24 hours post eclosion and their compound 
eye inspected. Assessment of penetrance and severity of the rough-eye phenotype, was 
accomplished by photographing the compound eye using a Canon PowerShot S70 digital 
camera mounted to a Leica Mz 125 stereomicroscope. Severity of rough-eye phenotype 
was scored + (mild) to +++ (severe). One “+” refers to where less than ½ of the eye was 
apoptotic and therefore appears “rough”. A score of “++” (moderate) defined increased 
penetrance, where apoptosis affected approximately ½ of the eye. Severe “+++” rough-
eye phenotype described when more than ½ of the eye appeared “rough” and eye size 
significantly reduced. For objective quantification, five blinded lab personnel analyzed all 
experiments. 
 
Immunoblotting- Lysates were collected in complete RIPA buffer (50 mM Tris-HCL, pH 
8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40) supplemented 
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with Halt Protease and Phosphatase Inhibitor and EDTA (ThermoFisher). Lysates were 
briefly cleared at 20,000 x g at 4°C, and stored at -20°C. Protein concentrations were 
determined using the BCA assay kit according to manufacturer’s protocol (Pierce). 40 µg 
of lysate was supplemented with NuPAGE LDS Sample Buffer (Invitrogen) and heated 
to 75°C for 10 minutes. Protein was separated on 4-12% NuPAGE BisTris gels 
(Invitrogen) using MES running buffer (Invitrogen) then transferred onto Immobilon 
PVDF membrane (Millipore). Odyssey blocking buffer (Li-Cor Biosciences) was used 
for blocking and resuspending primary and secondary antibodies. Membranes were 
scanned using Li-Cor Odyssey infrared scanning instrument.  
 
Aβ ELISA- HeLa cells and primary rat cortical neurons were treated with 
pharmacological agents for 24 hours and conditioned supernatants collected and cleared 
at 20,000 x g for 20 minutes at 4°C. Fresh cleared supernatants were used for Aβ40 
ELISA kit (Wako, Japan) according to the manufacturer’s protocol. Briefly, samples 
were diluted 1:1 using kit diluent and incubated over night at 4°C. Samples were 
compared to the ELISA kit positive control and negative control (diluent alone). Samples 
were incubated and analyzed using a luminescence plate reader. 
 
In vitro γ-secretase assay- We utilized a well-established cell-free γ-secretase activity 
assay that utilizes a fluorogenic peptide substrate corresponding to the APP γ-secrease 
cleavage site  (Farmery et al., 2003, Sarajarvi et al., 2011). HeLa cells grown to 100% 
confluence in 150 mm culture dishes were collected in ice cold PBS and pelleted at 5,000 
rpm for 5 minutes. The pellet was homogenized in 500 µl Buffer B (20 mM HEPES pH 
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7.5, 150 mM KCl, 2 mM EGTA, Protease & Phosphatase inhibitors) using a 27 gauge 
needle. The resulting homogenate was cleared at 45,000 rpm at 4°C for 1 hour. 
Supernatant was stored at -80°C while pellet was washed with 500 µl Buffer B and 
passed through 27 gauge needle on ice. The suspension was cleared again at 45,000 rpm 
for 1 hour at 4°C. Supernatant was discarded and pellet resuspended in 75 µl Buffer B + 
1% CHAPSO and passed through 27 gauge needle on ice. The resulting membrane 
samples were solubilized on a rotator at 4°C for 2 hours. Solubilized samples were 
cleared at 45,000 rpm for 1 hour at 4°C, supernatant (total cell membrane) was collected 
and pellet discarded. Total protein was determined using BCA assay (Pierce) and 200 µg 
of protein were used for in vitro γ-secretase activity assay. Briefly, membranes were 
resuspended in γ-secretase assay buffer (100 mM Tris-HCl pH 6.8, 4 mM EDTA, 0.5% 
CHAPSO), and pre-treated with vehicle control, L-685,458 or cyclopamine. Since the 
membrane prep enriches total γ-secretase in sample, amount of pharmacological agent 
was increased accordingly. Therefore, 20 µM of drug in total vehicle volume of 1 ml per 
was used. 150 µl total volume per well of 96-well plate was used. Membranes were pre-
treated for 3 hours at 37°C 5% CO2 then fluorogenic γ-secretase substrate (Calbiochem, 
EMD Millipore) was added to membranes and further incubated at 37°C, 5% CO2 for the 
indicated time points at which time membranes were removed and fluorescence was 
measured using plate reader (Promega). BSA was used as negative control in place of 
membranes.  
 
Subcellular Fractionation- HeLa cells grown to 80% confluence in 100 mm culture 
dishes were treated with 5 µM cyclopamine or DMSO for 24 hours, rinsed and collected 
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in PBS then, cleared at 1000 rpms for 7 minutes. The cell pellet was resuspended in 
homogenization buffer (250 mM Sucrose, 150 mM NaCl, 25 mM Tris, 1 mM EDTA, 
Protease & Phosphatase inhibitor cocktail) and homogenized using ball-bearing 12 mm-
clearance cell buster. Homogenates were cleared at 1000 x g for 15 minutes at 4°C and 
post-nuclear supernatant was loaded into discontinuous density gradient (50%, 30%, 
10%) medium (OptiPrep, Sigma) in Opti-Seal centrifuge tubes (Beckman). Homogenates 
were spun at 30,000 rpms for 19 hours at 4°C and 300 µl fractions collected. 
 
Immunofluorescence- Cells were fixed using 4% PFA, 0.1% Triton-X-100, blocked in 
2% BSA for 30 minutes and incubated with primary antibodies over night at 4°C. Cells 
were rinsed with PBS and stained with secondary antibodies at room temperature for 1 
hour, washed with PBS and mounted. Cells were imaged using Olympus Fluoview 1000 
inverted confocal microscope. Quantification of 3D confocal image stacks was 
accomplished using Slidebook 5.0 or Volocity Image analysis software (PerkinElmer).  
 
Surface Biotinylation- HeLa cells were treated with 5 µM cyclopamine or DMSO for 24 
hours. Cells were placed on ice to halt membrane dynamics, rinsed with ice cold PBS and 
incubated with Sulfo-NHS-SS-biotin (1 mg/ml in PBS; Thermo Scientific) for 40 minutes 
on ice with gentle rocking. Biotin was quenched with 100 mM glycine in PBS for 15 
minutes. Cells were collected in PBS and pelleted at 500 x g for 5 minutes at 4°C. The 
pellet was lysed in 200 µl standard RIPA lysis buffer containing protease and 
phosphatase inhibitors. Lysate was sheared using a 27 gauge needle on ice and 
solubilized for 2 hours at 4°C on rotator. Lysate was cleared by centrifugation at 10,000 x 
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g for 5 minutes and 50 µl from each sample was set aside for “total” protein analysis. The 
rest of the supernatant was loaded into a capped spin column (Pierce; 69725) with 
NeutrAvidin-coated agarose resin (Thermo Scientific) at a 1:1 ratio and incubated over 
night at 4°C on rotator. Columns were centrifuged at 10,000 rpm for 1 minute and 
flowthrough (“unbound” control) was collected and saved. Resin was washed several 
times with complete RIPA. Then 50 µl of NuPAGE LDS Sample Buffer (Invitrogen) 
with 5% β-mercaptoethanol was loaded into each column and incubated for 30 minutes at 
room temperature on shaker. To collect the surface biotinylated protein, columns were 
centrifuged at maximum speed for 2 minutes. Biotinylated protein was separated on 4-
12% NuPAGE BisTris gels (Invitrogen) then transferred and membrane probed for 
surface APP. Non-biotinylated lysates were collected as control samples. Biotinylated 
“surface” samples were compared to “total” lysate samples.  
 
Statistical Analysis- All graphs and diagrams represent mean values ± standard error of 
all triplicates from at least three independent experiments. Either two-tailed or one-tailed 
Student’s t-test was used to compare two treatment groups and calculate significance 
from at least three independent experiments (* p<0.05, ** p<0.01, *** p<0.005). For in 
vivo Drosophila melanogaster experiments, G-test (goodness of fit) was used to 
determine significance of phenotypic penetrance in experimental populations. Degree of 
significance and corresponding p value criteria for G-test were identical to previously 
mentioned Student’s t-test. 
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RESULTS 
Cyclopamine treatment results in APP C-terminal fragment accumulation- To test 
whether cyclopamine modulates APP metabolism, we treated primary rat cortical neurons 
with cyclopamine  (Dahmane et al., 2001, Palma and A. Ruiz i Altaba 2004). We did not 
observe an appreciable change in the full-length APP (FL-APP) holoprotein after 24 
hours of 5 µM cyclopamine treatment (Figure 2-1 A, B). However, the 8-12 kDa APP 
products of α- and β-secretase (α- and β- CTFs; collectively known as APP-CTFs) 
significantly increased when compared to vehicle control treated neurons (p=0.0190) 
(Figure 2-1 A, C). To determine if these effects can be observed in other models, we 
utilized HeLa cells because they are easily manipulated and have been previously utilized 
to study APP processing and trafficking  (Chyung et al., 2005, Choy et al., 2012). Using 
naïve HeLa cells, we performed cyclopamine time and dose dependence experiments. 
Cells were treated for 24 hours with increasing concentrations of cyclopamine from 0.5 to 
10 µM (Figure 2-1 D). Compared to vehicle control (Figure 2-1 E, dotted line), we 
observed a significant increase in APP-CTF levels with as little as 0.5 µM cyclopamine 
(p=0.000615) (Figure 2-1 E). No change in FL-APP was observed in cells exposed to 5, 
1 or 0.5 µM of drug (Figure 2-1 E). A small, yet significant, increase in FL-APP was 
observed upon 10 µM cyclopamine treatment. To address time dependence of 
cyclopamine’s effects on APP-CTF accumulation, we performed a time course 
experiment. Since we observed robust increases in APP-CTFs after 24 hours with as little 
as 0.5 µM of drug, we hypothesized that using 5 µM of cyclopamine would significantly 
increase APP-CTF levels within a shorter exposure time. Accumulation of APP-CTFs 
was evident by 3 hours of exposure (p=0.000488) and further accumulation continued for 
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the remainder of the time course (by 24 hours p=9.50x10-6) (Figure 2-1 F, G). The lack 
of significant changes in FL-APP levels upon 5 µM cyclopamine exposure suggests APP 
gene transcription is not altered. In fact, using qPCR we analyzed APP mRNA in naïve 
HeLa cells upon cycopamine treatment and did not observe changes in APP transcript 
levels as compared to vehicle control (data not shown).  
 APP proteolysis is initiated by α- or β-secretase. This cleavage liberates soluble 
N-terminal APP ectodomains (sAPP). Treatment of naïve HeLa cells with cyclopamine 
did not alter sAPP levels (Figure 2-1 H, I). This suggests the increase in APP-CTFs is 
not due to modulation of α- or β-secretase cleavage of APP by cyclopamine. The 
observed increase in APP-CTFs and the lack of change in FL-APP levels resembles the 
effects of γ-secretase inhibitors, but to a diminished degree (Figure 2-1 J, K, L)  (Barthet 
et al., 2011, Shearman et al., 2000).  
 
Cyclopamine decreases γ-secretase mediated cleavage of APP in vitro and in vivo- 
Since cyclopamine treatment increased levels of APP-CTFs, analogously to γ-secretase 
inhibitor treatment, we hypothesized that cyclopamine would decrease levels of γ-
secretase cleavage products; namely Aβ and the APP intracellular domain (AICD). Both 
Aβ and AICD are produced upon γ-secretase cleavage of APP-CTFs. To test this 
hypothesis we exposed naïve HeLa and primary rat cortical neuron cells to cyclopamine 
for 24 hours. Cyclopamine treated cells secreted significantly less Aβ compared to 
vehicle control in primary cortical neurons and HeLa cells (p=0.00567, p=0.000914; 
respectively) (Figure 2-2 A). The other product of γ-secretase cleavage, AICD, is 
difficult to detect. Therefore we used a previously described APP-Gal4 construct to aid in 
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detection  (Zhang et al., 2007, Cao and T. C. Sudhof 2001). We exposed HeLa cells 
transiently overexpressing APP-Gal4 to cyclopamine for 24 hours and detected AICD-
Gal4 levels using Western blot analysis. The γ-secretase inhibitor L-685,458 served as a 
positive control since it prevents AICD generation. As predicted, in comparison to 
vehicle control cyclopamine significantly decreased AICD-Gal4 levels (p=0.000228) 
(Figure 2-2 B, C). However, these effects were much more modest than those observed 
upon γ-secretase inhibition with L-685,458. 
 To determine if the observed effects were specific to APP, we monitored γ-
secretase cleavage of Notch in response to cyclopamine treatment. Similar to AICD, 
endogenous NICD is also difficult to detect. To overcome this difficulty, we transiently 
overexpressed Myc-ΔENotch in HeLa cells and treated with cyclopamine for 24 hours  
(De Strooper et al., 1999, Kopan et al., 1996). Cyclopamine significantly decreased 
NICD levels (p=8.87x10-5) to a similar extent as observed in Aβ and AICD levels 
(Figure 2-2 D, E). These effects on AICD and NICD were much more modest than those 
observed upon γ-secretase inhibition. Similar to endogenous APP-CTFs, cyclopamine 
increased APP-CTF-Gal4 levels (Figure 2-2 F). Interestingly, no change in ΔENotch 
levels was observed suggesting that the effects are specific (Figure 2-2 F).  
Given these results and the availability of an in vivo γ-secretase reporter, we 
tested the ability of cyclopamine to modulate γ-secretase cleavage of APP in vivo. 
Briefly, in 2003 Guo and colleagues developed and characterized a Drosophila 
melanogaster γ-secretase reporter (Guo et al., 2003). These transgenic flies express the 
APP γ-secretase substrate, APP-C99-Gal4, specifically in the fly eye ommatidia. These 
flies also carry a UAS element upstream of GRIM, a cell death activator. Upon γ-
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secretase cleavage of APP-C99-Gal4, the resulting AICD-Gal4 can bind to the UAS 
element and induce GRIM expression. GRIM expression leads to death of ommatidia and 
results in a rough-eye phenotype  (Guo et al., 2003, Takasugi et al., 2002, Fossgreen et 
al., 1998). To test whether cyclopamine decreases γ-secretase mediated cleavage of APP-
C99-Gal4, we raised APP-C99-Gal4; UAS-GRIM flies on normal, vehicle or 
cyclopamine supplemented food. Flies were collected one day post eclosion and their 
eyes were scored for rough-eye phenotype. Flies raised on cyclopamine displayed 
decreased severity of the rough-eye phenotype (p=2.40x10-34) (Figure 2-2 G, H, I, J, K). 
More specifically, 10% of the flies raised on cyclopamine displayed “severe” rough-eye 
phenotype compared to the 47% raised on vehicle food.  While only 10% of the vehicle 
treated flies displayed “mild” rough-eye phenotype, 53% of cyclopamine treated flies 
displayed this phenotype (Figure 2-2 K). Together, these data demonstrate that 
cyclopamine treatment decreases γ-secretase mediated cleavage of APP-CTFs in vitro 
and in vivo.  
 
Cyclopamine does not alter γ-secretase activity- Since in vivo and in vitro cyclopamine 
treatment leads to decreased γ-secretase cleavage of APP-CTFs we investigated whether 
cyclopamine inhibits γ-secretase activity. One major step in γ-secretase complex 
maturation is the autoproteolysis of Presenilin1 (PSEN1) to form the active N- and C-
terminal fragments. Therefore detection of the PSEN1-CTF is an indicator of an active γ-
secretase complex  (Haass and B. De Strooper 1999). To this end, we exposed naïve 
HeLa cells to cyclopamine for 24 hours and observed an increase in APP-CTFs levels 
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however, PSEN1-CTF levels did not change in response to cyclopamine treatment 
(Figure 2-3 A, B).  
 To assess overall γ-secretase activity we utilized an in vitro, fluorescence based 
activity assay (Sarajarvi et al., 2011). We isolated total cellular membranes from naïve 
HeLa cells and treated these membranes with vehicle, L-685,458 or cyclopamine  
(Fraering et al., 2004, LaVoie et al., 2003, Wang et al., 2009, Esler et al., 2002). As 
expected, treatment with L-685,458 decreased cleavage of the fluorogenic γ-secretase 
peptide substrate resulting in decreased fluorescence intensity over time. Surprisingly, 
treatment with cyclopamine did not alter γ-secretase activity (Figure 2-3 C). These 
results suggest that cyclopamine decreases γ-secretase mediated cleavage of APP without 
directly affecting γ-secretase activity. One mechanism that could explain these results is 
that cyclopamine mediates a change in the subcellular localization of APP and/or γ-
secretase. 
 
Cyclopamine alters APP-CTF subcellular localization- Proteolytic processing of APP is 
dependent on its subcellular localization. To investigate if cyclopamine alters APP 
subcellular localization, naïve HeLa cells were exposed to cyclopamine for 0, 6, or 24 
hours and APP subcellular distribution was visualized using immunofluorescence. 
Analogous to the time course experiment in which we observed increased APP-CTFs by 
Western blot (Figure 2-1 G), here cyclopamine treatment induced significant 
accumulation of APP positive puncta detected with an antibody raised to the APP C-
terminus (p=0.00120) (Figure 2-4 A, B, C). Visualization of APP distribution using an 
antibody specific to the N-terminal portion of APP did not reveal similar cyclopamine-
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induced APP puncta. In fact a lack of colocalization was observed between the N- and C-
terminal APP antibodies in the cyclopamine-induced APP puncta (Figure 2-4 D, E). This 
suggests that the cyclopamine-induced puncta are APP-CTFs and not FL-APP nor sAPP. 
FL-APP is not a suitable substrate for γ-secretase cleavage. The  increase in APP-CTF 
subcellular puncta and the lack of change in FL-APP and sAPP protein levels suggests 
that cyclopamine does not alter APP biosynthetic pathway. Further it also suggests that 
cyclopamine may induce alterations in APP-CTF endocytosis.  
 To further investigate this latter possibility we measured surface APP levels using 
cell surface biotinylation and Western blot analysis. We treated naïve HeLa cells with 
cyclopamine for 24 hours, and observed a significant decrease in surface FL-APP 
(p=0.00446) (Figure 2-4 F, G). Therefore, the observed accumulations of APP-CTF 
positive puncta coupled with decreased surface FL-APP suggests that cyclopamine alters 
internalization and possibly retrograde trafficking that is required for γ-secretase 
mediated cleavage of APP-CTFs.  
 
Cyclopamine alters retrograde trafficking and promotes APP-CTFs localization to 
lysosomes- Previous reports indicate that upon endocytosis, FL-APP and APP-CTFs are 
localized to early endosomes then sorted to either one of three possible trafficking 
pathways. One route is for FL-APP to be recycled back to the plasma membrane. For 
α− or β− secretease cleaved APP fragments, APP-CTFs, a second route is available 
which allows these fragments to be retrogradely trafficked to the trans-Golgi network 
(TGN) for γ-secretase cleavage (Choy et al., 2012). Finally, APP-CTFs can be trafficked 
to the lysosome for degradation. To gain insight into these possibilities, we investigated 
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the subcellular localization of APP-CTFs using immunofluorescence and subcellular 
fractionation.  
 To initially investigate where cyclopamine-induced APP-CTFs accumulate, we 
utilized co-immunofluorescence to identify the subcellular compartment(s) to which 
these APP-CTF puncta are localized to (Figures 2-5 A-E, 2-6 A-E). Specifically, we 
assessed markers of early endosomes (EEA1), late endosomes (MP6R), trans-Golgi 
network (TGN46), autophagosomes (LC3), and lysosomes (LAMP1) for accumulation of 
APP-CTFs. We initially noticed that upon cyclopamine treatment the total intensity of 
EEA1, MP6R, LC3 and LAMP1 significantly increased (p=1.18x10-11, p=2.52x10-6, p= 
3.91 x 10-42, and p=2.69x10-22, respectively), while no change was observed in TGN46 
total intensity (Figure 2-7 A-E). These data suggest that cyclopamine alters subcellular 
trafficking. In agreement with our findings, Jimenez-Sanchez et al recently showed that 
cyclopamine increases autophagosome formation (Jimenez-Sanchez et al., 2012).  
 To determine which subcellular compartment APP-CTFs localize to, we 
quantified colocalization of APP-CTFs with these markers. While the overall co-
localization is low, we noticed that upon cyclopamine treatment there was a significant 
increase in APP colocalization with EEA1, MP6R and LAMP1 positive puncta 
(p=1.17x10-6, p=1.12x10-14, and p=4.39x10-33; respectively) (Figure 2-7 F, G, H). While 
a significant reduction in colocalization with TGN46 (p=3.21x10-5) was observed 
(Figure 2-7 I). No change in colocalization of APP-CTFs with LC3 was observed 
(Figure 2-7 J). In addition, we detected APP-CTF positive puncta in close association 
with the ESCRT multivesicular body (MVB) markers, Tsg101 and Chmp2a (Figure 2-8 
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A, B). These data suggest that cyclopamine decreases retrograde trafficking of APP-
CTFs to the TGN while increasing trafficking to lysosomes.   
 To independently verify that APP-CTF localization is altered upon cyclopamine 
treatment, we utilized subcellular fractionation of vehicle and cyclopamine treated HeLa 
cells (Figure 2-9 A, B). Very modest changes in the distribution of subcellular markers 
such as EEA1 and LAMP1 were observed upon cyclopamine treatment.. With respect to 
APP-CTF distribution, in vehicle treated cells 69% of APP-CTFs are found in fractions 5, 
6 and 7, which correspond to the TGN (TGN46) (Figure 2-9 C, H). However, in 
cyclopamine treated cells we observed a shift in APP-CTF distribution; APP-CTFs in 
fractions 5, 6, and 7 decreased to 37% while an increase was observed in fractions 9 and 
10. These latter fractions are enriched for the lysosomal marker LAMP1 (Figure 2-9 C, 
G). In contrast to APP-CTFs, we did not detect an observable change in FL-APP 
distribution upon cyclopamine treatment (Figure 2-9 D). Thus cyclopamine decreases 
trafficking of APP-CTFs to the TGN where γ-secretase mediated Aβ generation occurs, 
and increases APP-CTF transport to the lysosome. Since we did not observe a change in 
the distribution of PSEN1-CTF and FL-APP upon cyclopamine treatment this suggests 
the effects are specific to APP-CTFs. 
 Increased localization to lysosomes would suggest increased degradation of APP-
CTFs. Surprisingly we observed cyclopamine treatment increased APP-CTF levels. One 
way to rationalize our observations is that cyclopamine may attenuate lysosomal 
degradation of APP-CTFs.  
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Cyclopamine decreases APP-CTF lysosomal degradation- To investigate if cyclopamine 
affects APP-CTF degradation, we pre-treated HeLa cells with cyclopamine for 24 hours 
then added cycloheximide to inhibit protein synthesis for an additional 0-4 hours. At the 
end of this additional 4 hours, APP-CTFs decreased by 76%. in vehicle treated cells 
while only a 38% decrease was observed in cyclopamine treated cells (p=0.00218) 
(Figure 2-10 A, B). Cyclopamine treatment nearly doubled APP-CTFs’ half-life from 2 
hours to 3.6 hours  (Figure 2-10 B). Similar to our previous findings, cyclopamine did 
not alter FL-APP rate of degradation (p= 0.0645) (Figure 2-10 C). 
 To validate cyclopamine’s specificity to APP-CTFs, we repeated this experiment 
on cells over-expressing ΔENotch (Figure 2-10 A). No change in ΔENotch rate of 
degradation was observed in cells pre-treated with cyclopamine (p=0.297) (Figure 2-10 
D). These data further validate that the cyclopamine-induced effects are specific to APP-
CTFs. Importantly these results imply that cyclopamine specifically attenuates APP-CTF 
degradation which explains the substantial APP-CTF accumulation.  
To test if these changes are due to decreased lysosomal maturation we monitored 
cathepsin D levels, a reliable marker of lysosomal maturation  (Xiang et al., 2013, Karaca 
et al., 2014). We detected a modest but significant (p=0.030) decrease in the ratio of 
mature (31 kDa) to immature (53 kDa) cathepsin D levels (Figure 2-10 E, F). Together 
our results implicate that cyclopamine leads to increased preferential retrograde 
trafficking of APP-CTFs to lysosomes and decreased lysosomal degradation of these 
APP-CTFs.  
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Cyclopamine-induced APP-CTF accumulation is not mediated by PI3P or nSMase- 
Morel and colleagues identified low levels of phosphatidylinositol-3-phosphate (PI3P) in 
human and mouse AD brains and demonstrated PI3P is critical for APP sorting to MVBs 
destined for lysosomal degradation (Morel et al., 2013). Because PI3P is produced by PI 
3-kinase, we tested if PI 3-kinase and PI3P levels mediate APP-CTF accumulation. Cells 
were pretreated with pre-treated with PI 3-kinase inhibitor, wortmannin, then exposed to 
5 µM cyclopamine for 24 hours. Wortmannin pre-treatment significantly reduced 
cyclopamine’s APP-CTF accumulation by 22% (p=0.01009) (Figure 2-11 A, B). 
Wortmannin treatment without additional cyclopamine also decreased APP-CTF 
accumulation by a mere 6%. These results suggest PI3P may play a modest role in the 
observed changes in APP-CTF metabolism. 
 Sphingolipids also play an important role in APP proteolysis and lysosomal 
maturation (Cutler et al., 2004, Lee et al., 2014). Sphingolipids are metabolized by 
sphingomyelinases into sphingomyelin and ceramide. There are two classes of 
sphingomyelinases, acid sphingomyelinase (aSMase) and neutral sphingomyelinase 
(nSMase). Previously, cyclopamine was shown to modulate nSMase activity resulting in 
an increase in ceramide levels, however, the cyclopamine concentrations used in this 
study were more than four times (Meyers-Needham et al., 2012). Despite this, we treated 
cells with cyclopamine in the presence and absence of an nSMase inhibitor, GW4869. In 
the absence of cyclopamine, GW4896 treatment decreased APP-CTF levels by 20%. 
When combined with cyclopamine treatment, GW4896 treatment reduced the 
cycolpamine-induced APP-CTF increase also by approximately 20% (Figure 2-11 A, C). 
No changes in FL-APP were detected using these drugs. These results suggest PI3P, but 
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nor nSMASE, may play a role mediating cyclopamine’s effect on APP-CTF 
accumulation. 
 
DISCUSSION 
 Here we have discovered novel effects on APP trafficking and lysosomal 
maturation induced by treatment with cyclopamine. Specifically we demonstrate an 
accumulation of APP-CTFs in lysosomes and a decrease in Aβ and AICD generation.  
 After translation APP is trafficked to the plasma membrane via the secretory 
pathway. APP can then be cleaved by α- or β-secretase at the plasma membrane or early 
endosome after endocytosis, respectively. These APP-CTFs are then retrogradely 
trafficked to the trans-Golgi network (TGN) for γ-secretase cleavage and Aβ generation 
(Choy et al., 2012). APP retrograde trafficking is highly regulated because APP 
proteolysis is dynamic and can lead to rapid changes in Aβ production (Jiang et al., 
2014). A consequence of decreased APP-CTF trafficking to the TGN is the decrease in γ-
secretase mediated cleavage of APP-CTFs and the concomitant decrease in Aβ and AICD 
generation. Hence, modulating APP retrograde trafficking independent of secretase 
activity can have novel implications for therapeutic avenues to treat AD. 
 Cyclopamine is a naturally occurring phytosterol isolated from the corn lily plant. 
The animal sterol, cholesterol, promotes amyloidogenic processing and increases Aβ 
generation, while cyclopamine exhibits the opposite effects on Aβ generation  (Frears et 
al., 1999, Ghribi et al., 2006). Phytosterols were recently shown to modify APP 
metabolism. Some phytosterols increased amyloidogenic processing and Aβ levels while 
others decreased Aβ levels (Burg et al., 2013). In fact, stigmasterol demonstrated anti-
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amyloidogenic properties; decreased β-secretase cleavage of APP and decreased 
Aβ generation.  Moreover, mice fed stigmasterol-enriched diets showed decreased γ-
secretase complex protein expression but, lacked direct inhibition of γ-secretase activity 
in isolated mouse brain tissue (Burg et al., 2013). We also observed that cyclopamine 
treatment decreases γ-secretase mediated proteolysis of APP without inhibiting γ-
secretase activity directly. However, we observed cyclopamine treatment leads to the 
accumulation of APP-CTFs derived from α- and β-secretase equally. This is because the 
observed cyclopamine effects were downstream of APP-CTF generation at the plasma 
membrane (α-secretase) or early endosome (β-secretase).   
 Cyclopamine decreased APP-CTF retrograde trafficking to the TGN. Choy and 
colleagues demonstrated that γ-secretase cleavage of endocytic APP-CTFs and Aβ 
generation occurs at the TGN (Choy et al., 2012). Since cyclopamine does not inhibit γ-
secretase activity, it is clear that the changes in APP-CTF levels are not due to changes in 
activity. Instead these changes could be due to APP-CTF retrograde trafficking and 
thereby preventing colocalization with γ-secretase. Because we observed decrease 
localization of APP-CTFs at the TGN we rationalize that altered trafficking is the 
mechanism by which cyclopamine decreases Aβ generation (Figure 2-12). Alternatively, 
after APP-CTF endocytosis, these fragments can be trafficked to the late endosome/MVB 
and then to the lysosome for degradation. Here we demonstrate cyclopamine increases 
APP-CTF trafficking to lysosomes. This increased trafficking to lysosomes could result 
in increased protein degradation and decreased APP-CTF levels. Surprisingly though we 
observed increased APP-CTF levels, and attenuated lysosomal degradation of APP-CTFs 
upon cyclopamine treatment. These effects seem to be specific to APP-CTFs. Unlike the 
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increased APP-CTF half-life, analysis of ΔENotch degradation revealed no change in 
half-life upon cyclopamine exposure. Interestingly, the accumulation of APP-CTFs was 
completely reversible upon washout of cyclopamine (data not shown). Therefore, it will 
be interesting to determine if the APP-CTF accumulations are completely degraded after 
removal of drug and whether this acute drug exposure will still result in decreased Aβ 
levels. 
Upon reaching the plasma membrane, FL-APP immediately sheds the sAPP 
ectodomain. Lack of change in FL-APP and sAPP levels indicates cyclopamine does not 
alter the APP biosynthetic pathway. Decreased surface FL-APP suggests enhanced 
endocytosis after shedding,, which can explain the increase in early endosome 
immunofluorescence intensity. The change in Aβ, AICD, and APP-CTF levels in the 
absence of changes in FL-APP and sAPP levels imply the effects of cyclopamine on APP 
metabolism are specific. The lack of change in FL-APP and sAPP levels upon 
cyclopamine treatment may also suggest it is a good candidate for possible AD therapy as 
it induces APP-CTF sequestration in lysosomes resulting in modest decreases in Aβ 
levels while not affecting FL-APP levels and sAPP generation. However, the chronic 
accumulation of APP-CTFs in the lysosome may be detrimental to protein homeostasis.  
 Interestingly, cyclopamine’s effects seem to be specific to APP-CTFs since we 
did not see the exact same changes in exogenous ΔENotch processing. We did observe 
decreased NICD levels similar to the decrease in AICD levels. However, we did not 
observe the increased ΔENotch levels like we did for exogeneous APP-CTF-Gal4 and 
endogeneous APP-CTFs. Therefore, it appears cyclopamine leads to an accumulation of 
APP-CTFs while sparing	   the equivalent γ-secretase substrate in the Notch signaling 
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pathway. Notch proteolysis is analogous to APP in that both are cleaved by α- and γ-
secretases (De Strooper et al., 1999). Both APP and Notch require primary cleavage at 
the plasma membrane for downstream endocytosis and retrograde trafficking to the TGN 
for γ-secretase and AICD/NICD generation  (Lane et al., 2013, Brou et al., 2000, Fortini 
2002, Kopan et al., 1996). One way to explain this specificity is that cyclopamine 
modulates the highly conserved retromer complex of proteins which mediates retrograde 
trafficking of transmembrane proteins, APP included, from endosomes to the TGN  
(Fjorback et al., 2012, Fjorback and O. M. Andersen 2012, Rojas et al., 2008). 
Alternatively the specificity of cyclopamine’s effect may lie in lipid rafts. Approximately 
10% of FL-APP localizes to lipid rafts, however upon shedding of the sAPP fragment the 
resulting APP-CTFs predominantly associate within these microdomains  (Vetrivel and 
G. Thinakaran 2010, Ehehalt et al., 2003). In fact recent studies suggest the APP 
cytosolic tail mediates these effects (Vetrivel et al., 2009). Therefore it will be interesting 
to determine if the effects we observe upon cyclopamine exposure are due to disrupted 
lipid rafts. Interestingly, Vetrivel and colleagues demonstrated that unlike APP-CTFs, 
other γ-secretase substrates such as Notch1, Jagged2, N-cadherin and DCC do not 
localize to lipid rafts (Vetrivel et al., 2005). The latter observation could explain the 
specificity of our results that demonstrate cyclopamine’s effects on APP-CTFs while 
sparring ΔENotch. 
 In addition, we addressed three mechanisms by which cyclopamine could alter 
APP metabolism and subcellular localization. Marginal but significant rescue effects 
were detected using the PI3P inhibitor Wortmannin suggest PI3P may play a role in 
mediating the observed effects induced by cyclopamine treatment. We tested nSMase, a 
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previously identified cyclopamine target and did not detect rescue of APP-CTF 
accumulation upon nSMase inhibiton. Nonetheless we cannot exclude the possibility that 
our reported observations could be mediated through an alternative sphingomyelinase, 
aSMase. In fact, aSMase is primarily localized to lysosomal lumen and is required for 
efficient lysosomal maturation. Studies show disrupted aSMase activity can lead to 
lysosomal storage disorders (Schramm et al., 2008, Meyers-Needham et al., 2012). Our 
observations indicate APP-CTFs are localized to lysosomes and their turnover is 
attenuated upon cyclopamine treatment, thus one can speculate cyclopamine could alter 
lysosomal function through an aSMase mediated effect. Interestingly, aSMase produces 
ceramide, which binds cathepsin D and induces proteolysis to generate the mature 
cathepsin D lysosomal protease (Heinrich et al., 2000). In agreement with the previous 
notion, we detected a marginal but significant reduction in the ratio of mature to 
immature cathepsin D. The latter suggests lysosomal maturation is somehow attenuated 
by cyclopamine exposure which could explain the decreased APP-CTF rate of 
degradation. Therefore it will be interesting to measure ceramide levels and aSMase 
activity upon cyclopamine treatment. 
 Cyclopamine is known to bind to and inhibit Smoothened (Smo)  (Chen et al., 
2002). Smo is a GPCR that is a component of the Sonic hedgehog (Shh) signaling 
pathway  (Alcedo et al., 1996, van den Heuvel and P. W. Ingham 1996, van den Heuvel 
and P. W. Ingham 1996). It will be interesting to determine what role, if any, Smo and 
Shh play in APP trafficking and proteolysis.  
 A balance between retrograde and lysosomal degradation trafficking pathways 
ensures proper distribution of APP and Notch holoproteins and their metabolites. Since 
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these metabolites have been shown to be involved in regulating cell death/survival and 
synaptic plasticity, completely ablating the production of these metabolites would be 
detrimental  (Dahlhaus et al., 2008, Muller et al., 2008, Puzzo et al., 2008, Costa et al., 
2005, Laird et al., 2005, Wang et al., 2004, Wang et al., 2004, Costa et al., 2003, Dawson 
et al., 1999). The modest but significant decrease observed in Aβ, AICD, and NICD 
levels, suggests cyclopamine may not have the negative consequences that γ-secretase 
inhibition displays in some AD patients  (Imbimbo and G. A. Giardina 2011, Fleisher et 
al., 2008).  
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  FIGURES & LEGENDS 
Figure 2-1. Cyclopamine treatment alters APP metabolism. A, Primary rat cortical 
neurons treated with 5 µM cyclopamine for 24 hrs. Endogenous FL-APP and APP-CTFs 
were detected using Western immunoblotting and a C-terminus APP antibody (c1/6.1). B, 
C, FL-APP protein levels and APP-CTFs were normalized to β-Actin and FL-APP, 
respectively. D, HeLa cells treated with indicated concentrations of cyclopamine for 24 
hrs followed by FL-APP and APP-CTF detection in cell lysates via Western 
immunoblotting. E, Quantification of dose dependent accumulation of APP-CTFs 
normalized to FL-APP. Relative protein changes compared to vehicle (DMSO) control 
(E. dotted line). F, Western blot time course analysis of endogenous FL-APP and APP-
CTFs in HeLa cells treated with 5 µM cyclopamine. G, Normalized APP-CTFs increase 
in a time dependent manner as compared to vehicle (DMSO) control (G. dotted line). H, 
Using Western blot analysis and N-terminus APP antibody (22C11), endogenous sAPP 
levels were monitored in supernatants of HeLa cells treated with 5 µM cyclopamine for 
24 hrs. I, sAPP levels were normalized to protein concentrations in lysates; determined 
using BCA assay. Lack of change in sAPP protein levels are illustrated in comparison to 
vehicle control (DMSO). J, Endogenous FL-APP and APP-CTFs from naïve HeLa cells 
treated with 5 µM cyclopamine were compared to cells treated with 2 µM L-685,458 
using Western immunoblot analysis and C-terminus APP antibody (c1/6.1). Lower panel 
represent increased exposure of APP-CTFs. K,L, Cyclopamine increased APP-CTF levels 
(not FL-APP) compared to vehicle (DMSO) control. Values denote mean ± standard 
errors of the means. Student’s t-test was used for statistical analysis: ***p<0.005, 
**p<0.01, *p<0.05. 
66
	   
Figure 2-2. Cyclopamine decreases γ-secretase cleavage of APP in vitro and in vivo. 
A, Secreted Aβ40 levels from HeLa cells and primary cortical neurons (DIV6) treated 
with 5 µM cyclopamine for 24 hrs were measured using an ELISA and compared to 
vehicle (DMSO) control. Secreted Aβ40 levels were normalized to total protein in 
respective cell lysates.. B, HeLa cells transiently overexpressing FL-APP-Gal4 treated 
with vehicle (DMSO) control, 2 µM L-685,458 or 5 µM cyclopamine for 24 hrs. APP-
CTF-Gal4 and AICD-Gal4 levels analyzed using Western immunoblotting and a C-
terminus APP antibody (c1/6.1). C, APP-AICD-Gal4 levels normalized to APP-CTF-
Gal4 levels. D, HeLa cells transiently overexpressing ΔENotch-Myc treated with vehicle 
(DMSO) control, 2 µM L-685,458 or 5 µM cyclopamine for 24 hrs. NICD and ΔENotch 
levels analyzed using Western immunoblotting, a anti-Myc and anti-NICD (Val1744) 
antibody. E, NICD levels normalized to ΔENotch levels. F, APP-CTF-Gal4 and ΔENotch 
levels normalized to β-Actin. G-J, representative images of rough-eye phenotype from 
GMR-APP-Gal4; uas-grim (γ-secretase reporter) flies raised on normal food, 100 nM 
cyclopamine or vehicle control (DMSO). Flies were scored one day after eclosion: mild 
(+), moderate (++), severe (+++). K, Relative changes in penetrance of rough-eye 
phenotype in flies raised on normal food (n=168), vehicle containing food (n=72), or 
cyclopamine containing food (n=112). Population of flies with mild, moderate or severe 
rough-eye phenotype is illustrated as percent of total population per experimental group. 
Statistical analysis in vivo experiments; a G-test: ***p<0.005, **p<0.01, *p<0.05, was 
performed. Student’s t-test was used for statistical analysis of cell based in vitro studies: 
***p<0.005, **p<0.01, *p<0.05. Values denote mean ± standard errors of the means. 
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Figure 2-3. γ-secretase activity is not altered by cyclopamine treatment. A, HeLa 
cells treated with 5 µM cyclopamine or vehicle control (DMSO) for 24 hrs. PSEN1-CTF 
levels from respective lysates analyzed via Western immunoblotting. B, PSEN1-CTFs 
levels normalized to β-Actin. C, Fluorometric γ-secretase activity assay. Fluorescence 
intensity over time using total membranes isolated from naive HeLa cells treated with 
cyclopamine (20 µM), L-685,458 (20 µM) or vehicle control (DMSO). Graph represents 
relative changes in fluorescence as percent activity of control (membranes treated with 
DMSO) over time. Values denote mean ± standard errors of the means. Student’s t-test 
was used for statistical analysis: ***p<0.005, **p<0.01, *p<0.05. 
 
Figure 2-4. Cyclopamine induces subcellular accumulation of APP-CTF. Confocal 3-
D analysis of HeLa cells treated with vehicle control (DMSO) A, or 5 µM cyclopamine B, 
for 0, 6, or 24 hours. APP was detected  using an antibody against the C-terminus of APP 
(A8717). Scale bar, 10 µm. C, Number of APP puncta normalized to ROIs. ROI=10x10 
mm, 20-30 ROIs per treatment analyzed. Puncta were defined as 2X the intensity of 
background in cytosolic non-punctate region, and objects were restricted to 0.2-2.0 µm 
skeletal diameter. Confocal 3-D analysis of naïve HeLa cells treated with vehicle control 
(DMSO) D, or 5 µM cyclopamine E, for 24 hrs. Cells were stained using (left panel) C-
terminus APP (A8717) and (middle panel) N-terminus APP (22C11) antibodies. Right 
panel denotes merged channels. Scale bar, 10 µm. E, Cell surface FL-APP levels in HeLa 
cells treated with 5 µM cyclopamine or vehicle (DMSO) for 24 hrs and then biotinylated. 
Biotinylated, surface FL-APP levels were measured by Western blot with a C-terminus 
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  APP antibody (c1/6.1). Top panel is total FL-APP from whole cell lysate, middle panel is 
biotinylated surface FL-APP purified with NeutrAvidin-coated resin. F, Surface FL-APP 
levels normalized to total FL-APP as percent of vehicle (DMSO) control. Values denote 
mean ± standard errors of the means. Student’s t-test was used for statistical analysis: 
***p<0.005, **p<0.01, *p<0.05. 
 
Figure 2-5. Endogenous APP-CTF distribution in vehicle treated HeLa cells. 
Confocal 3-D analysis of HeLa cells treated with vehicle control (DMSO) for 24 hrs. 
Cells were stained for APP-CTFs using an APP C-terminal antibody (A8717) and 
antibodies (A, EEA1; B, MP6R; C, LAMP1; D, TGN46; E, LC3) for subcellular markers 
(middle column). Right-hand columns are the merged images. Scale bar, 10 µm. 
 
Figure 2-6. Cyclopamine alters retrograde trafficking of APP-CTFs. Confocal 3-D 
analysis of HeLa cells treated with 5 µM cyclopamine for 24 hrs. Cells were stained for 
APP-CTFs using an APP C-terminal antibody (A8717) and antibodies (A, EEA1; B, 
MP6R; C, LAMP1; D, TGN46; E, LC3) for subcellular markers (middle column). Right-
hand columns are the merged images. Scale bar, 10 µm. 
 
Figure 2-7. Quantification of APP-CTF subcellular localization and 
immunofluorescence of APP-CTFs and MVBs in HeLa cells . Single cells in each 
image were masked off, background intensities subtracted from each channel and 
Manders’ coefficients calculated for each cell independently, 26-51 cells were analyzed 
per experimental group. A-D, Manders’ coefficients for co-localization. Dot plot 
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  diagrams represent raw data points, while horizontal line represents the means of 
Manders’ coefficients of subcellular marker and APP-CTF colocalization. Student’s t-test 
was used for statistical analysis: ***p<0.005, **p<0.01, *p<0.05 
 
Figure 2-8. Immunofluorescence of APP-CTFs and MVBs in HeLa cells. Confocal 3-
D analysis of HeLa cells treated with vehicle control (DMSO) A, or 5 µM cyclopamine B, 
for 24 hrs. Cells were co-stained using (left panel) C-terminus APP (A8717) and an MVB 
ESCRT-I marker, Tsg101. In middle panel an MVB ESCRT-III marker, Chmp2a-GFP, 
was overexpressed and cells were stained with A8717.  Right panel denotes all merged 
channels. Scale bar, 10 µm. As expected, APP-CTFs are in close association with MVB 
markers, Tsg101 and Chmp2a-GFP upon cyclopamine treatment. 
 
Figure 2-9. Cyclopamine increases APP-CTF levels in lysosome-enriched 
compartments. HeLa cells treated with vehicle (DMSO) A, or 5 µM cyclopamine B, for 
24 hrs then collected, homogenized and post-nuclear fractions were subject OptiPrep step 
gradient fractionation. Fractions 2-13 (50%-10% gradient) were subject to Western blot 
analysis with APP C-terminal (c1/6.1), PSEN1-CTF, EEA1, LAMP1, and TGN46 
antibodies. C-H, Densitometry of each fraction as percent of combined total (fractions 2-
13) densitometry for each respective protein. 
 
Figure 2-10. Cyclopamine leads to moderate decrease in lysosomal maturation and 
significantly attenuates APP-CTF rate of lysosomal degradation. A, Western 
immunoblot analysis of FL-APP and APP-CTFs using a C-terminus APP antibody 
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  (c1/6.1) and ΔENotch using anti-Myc tag antibody. For FL-APP, APP-CTF and ΔENotch 
analysis, naïve HeLa cells were pre-treated with 5 µM cyclopamine of vehicle (DMSO) 
for 24 hours then exposed to 50 µg/ml cycloheximide for indicated times. B-D, FL-APP, 
APP-CTFs, and ΔENotch protein levels were normalized to β-Actin first. Line graphs 
represent protein levels as percent remaining of total protein at time 0 hrs. Line represents 
the linear fit and relative rate of protein degradation. E, Naïve HeLa cells treated with 
vehicle (DMSO) or 5 µM cyclopamine for 24 hrs followed by mature and immature 
cathepsin D detection in cell lysates via Western immunoblotting. F, Bar diagram 
represents ratio of mature to immature cathepsin D protein quantification normalized to 
β-Actin. Values denote mean ± standard errors of the means. Student’s t-test was used for 
statistical analysis: ***p<0.005, **p<0.01, *p<0.05. 
 
Figure 2-11. PI 3-K and nSMase inhibiton does not fully rescue cyclopamine-
induced APP-CTF accumulation.  HeLa cells pretreated with 200 nM Wortmannin or 
15 µM GW4869 for 1 hour then media was supplemented with 15 µM cyclopamine or 
vehicle control (DMSO) for the remaining 24 hr treatment. A, Western blot analysis of 
FL-APP and APP-CTFs using C-terminal APP antibody c1/6.1. B, Quantification 
representing relative changes in FL-APP and APP-CTFs upon cyclopamine and 
wortmannin treatment. C, Quantification representing relative changes in FL-APP and 
APP-CTFs upon cyclopamine and GW4869 treatment. Values denote mean ± standard 
errors of the means. Student’s t-test was used for statistical analysis: ***p<0.005, 
**p<0.01, *p<0.05. 
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  Figure 2-12. Model representation of APP-CTF retrograde trafficking and 
lysosomal localization upon cyclopamine exposure. Trafficking and cleavage of FL-
APP and APP-CTFs in normal conditions A, compared to cyclopamine treatment B, FL-
APP proteolysis and production of APP-CTFs occurs at the plasma membrane (α-
secretase) and early endosomes (β-secretase). APP-CTFs are then trafficked, via the 
retrograde pathway, to trans-Golgi network (TGN) for subsequent γ-secretase cleavage 
and Aβ generation  (Choy et al., 2012). Alternatively, APP-CTFs are trafficked to late 
endosomes/multivesicular bodies thus destined for lysosomal degradation. B, 
Cyclopamine treatment favors the lysosomal degradation trafficking pathway (bold 
arrows) of APP-CTFs thereby preventing γ-secretase proteolysis of APP-CTFs and Aβ 
generation. 
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CHAPTER 3: CHARACTERIZATION OF SONIC HEDGEHOG SIGNALING 
PATHWAY IN AMYLOID PRECURSOR PROTEIN METABOLISM 
 
 
ABSTRACT 
 Strong evidence suggests increased Amyloid-β (Αβ) accumulation in the brain 
initiates Alzheimer’s disease (AD) neuropathology resulting in neuronal death and 
memory loss. Αβ peptide is produced by sequential proteolytic cleavage of Amyloid 
precursor protein (APP). Besides Αβ, another byproduct is the APP intracellular domain 
(AICD). Both fragments play a role in AD pathogenesis, thus alterations to APP quantity 
and/or proteolysis can results in AD. Regulators of APP metabolism have been described, 
however a successful therapeutic intervention is yet to be designed. Using in vitro and in 
vivo models, we identified Sonic hedgehog (Shh) signaling pathway components as novel 
regulators of APP metabolism. We demonstrate that APP proteolysis is altered by genetic 
and pharmacologic modulation of Shh signaling. Inhibition of various components of Shh 
signaling cascade revealed that noncanonical, Gli-independent, Shh signaling is 
responsible for the observed changes in APP metabolism. Specifically, reducing Gli 
transcription factor activtity did not alter APP proteolysis while inhibiting upstream Shh 
components did. We were able to confirm these results using the in vivo γ-secretase 
reporter Drosophila model. Our study is the first to report that Shh signaling modulates 
APP proteolysis and may be a novel target for AD therapeutic intervention. 
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INTRODUCTION 
 Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder 
characterized by neurofibrillary tangles and senile plaques. Neurofibrillary tangles 
(NTFs) are composed of hyperphosphorylated microtubule-stabilizing tau protein while 
senile plaques are composed of neurotoxic Amyloid-β (Aβ) peptides  (Tanzi and L. 
Bertram 2005, Serrano-Pozo et al., 2011). Compelling evidence strongly supports the 
amyloid hypothesis, which implicates increased neurotoxic Aβ as the underlying cause 
for synaptic dysfunction, neuronal loss and cognitive decline  (Hardy and D. Allsop 1991, 
Selkoe 1991, Hardy and D. J. Selkoe 2002). Aβ is produced after sequential proteolytic 
processing of Amyloid precursor protein (APP).  
 Two proteolytic pathways can cleave full-length APP (FL-APP); the non-
amyloidogenic or the amyloidogenic pathways. During amyloidogenic processing, β-
secretase cleaves full-length APP releasing a soluble N-terminal ectodomain (sAPPβ) 
while a membrane-tethered C-terminal fragment (APP-CTFβ) remains. Subsequently, γ-
secretase cleaves APP-CTFβ downstream of the Aβ sequence thus liberating a soluble 
Aβ peptide and a cytosolic APP intracellular C-terminal domain (AICD). Alternatively, 
in the non-amyloidogenic pathway α-secretase cleaves full-length APP within the Aβ 
sequence thereby precluding its generation. This cleavage produces a soluble N-terminal 
ectodomain (sAPPα) and a membrane-tethered C-terminal domain (APP-CTFα). 
Subsequently, γ-secretase cleaves APP-CTFα, producing AICD and a small p3 fragment 
of unknown function  (Gandy et al., 1994, Gandy and P. Greengard 1994, Gandy and P. 
Greengard 1994, Vassar et al., 1999). Alterations to APP proteolysis or increased APP 
protein levels can have severe consequences such as amyloidosis and plaque formation. 
92
For example, APP is located on chromosome 21 therefore Down Syndrome (DS) 
(trisomy 21) patients have three copies of APP and develop AD early in life due to 
increased gene dosage and Aβ generation  (Delabar et al., 1987, Robakis et al., 1987). DS 
patients with partial trisomy 21, not including the APP gene, do not develop AD further 
supporting the amyloid hypothesis (Prasher et al., 1998). In lieu of this, identification of 
an Aβ-decreasing therapeutic intervention has been of heightened interest. We recently 
reported that cyclopamine, a well-characterized Sonic hedgehog (Shh) signaling 
antagonist, decreases γ-secretase mediated cleavage of APP in vitro and in vivo, and 
reduces Aβ generation  (Vorobyeva, A.G., Lee, R., Miller, S., Longen, C., Kandelwal, 
P.J., Kim, F.J., Marenda, D.R., Saunders, A.J. 2014). This prompted us to investigate if 
Shh signaling plays a role in APP metabolism.  
 Hedgehog signaling was described in the 1980’s during Drosophila embryo 
segmentation studies (Nusslein-Volhard and E. Wieschaus 1980). Shh is best 
characterized for its role in development, organogenesis, neurogenesis and patterning of 
tissues such as the central nervous system (CNS)  (Lee et al., 1992, Echelard et al., 1993, 
Varjosalo and J. Taipale 2008). Disrupting Shh signaling results in severe developmental 
abnormalities; alobar holoprosencephaly, failure of forebrain division, is most severe  
(Villavicencio et al., 2000, Zhu and H. W. Lo 2010, Hui and S. Angers 2011). Shh is a 
morphogen released from cells and binds the Patched receptor (Ptch1). Ptch1, a 12-
transmembrane domain receptor, is a negative regulator of Shh signaling. Upon binding 
Shh, Ptch1 alleviates its inhibitory effects on Smoothened (Smo). Active Smo, a 7-
transmembrane domain G protein-coupled receptor (GPCR), translocates to the plasma 
membrane and signals downstream to Gli zinc finger effector transcription factors. Gli1 
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is primarily an activator of transcription, Gli3 a repressor, while Gli2 can function as both 
but is primarily an activator  (Vortkamp et al., 1991, Sasaki et al., 1999, Kaesler et al., 
2000, Bai and A. L. Joyner 2001, Bai et al., 2002, Pan et al., 2006, Li et al., 2011). In 
presence of Shh peptide, Gli effectors translocate to the nucleus and induce 
transcriptional activation of downstream genes such as GLI1 and PTCH1. In contrast, 
absence of peptide leads to Gli processing into repressor form or proteosomal degradation  
(Wang and Y. Li 2006). 
 Recent studies shed light on Shh signaling function in neurogenesis and synaptic 
plasticity in the adult brain  (Petralia et al., 2011, Petralia et al., 2011, Gulino and M. 
Gulisano 2012, Petralia et al., 2012, Das et al., 2013). Shh, Ptch1 and Smo are present in 
pre- and postsynaptic terminals of adult hippocampal neurons, also the brain area heavily 
affected by AD  (Petralia et al., 2011, Mitchell et al., 2012). In addition these components 
were identified in dendrites and axons of mossy fibers of the adult hippocampus 
suggesting this region is Shh responsive  (Traiffort et al., 2001, Charytoniuk et al., 2002, 
Alvarez-Buylla and R. A. Ihrie 2014). 
 The results of our study demonstrate that Shh signaling alters APP metabolism in 
vitro and in vivo. Specifically, we show that inhibiting noncanonical Ptch1 and Smo 
signaling decreases γ-secretase mediated cleavage of APP resulting in APP-CTF 
accumulation. The present study elucidates these effects are Shh-dependent and Gli-
independent. Together our data suggests a novel regulatory function for noncanonical 
Shh signaling in APP metabolism. This report suggests Shh signaling may be a novel 
target for AD therapeutics.  
 
94
 EXPERIMENTAL PROCEDURES 
Antibodies, Plasmids and Reagents- Antibodies were obtained from the following: mouse 
C-terminus APP clone c1/6.1 (a kind gift from P. Mathews, Nathan Kline Institute, NY, 
USA), mouse APP N-terminus 4A 22C11 (Millipore), mouse Shh peptide clone 5E1 
(DSHB), rabbit APP C-terminus A8717, mouse anti-Myc clone 9E10 and mouse β-Actin 
(Sigma). IR-conjugated secondary antibodies (IRDye680, IRDye800) were from Li-Cor 
Biosciences. Cyclopamine (5 µM) was purchased from LC Laboratories, GDC0449 (50 
nM) from Selleckhem, SAG (100-250 nM) from Calbiochem, GANT61 (20 µM) from 
Cayman Chemicals, L-685,458 (2 µM)  and DMSO  from Sigma. TRCN human 
Smoothened shRNA construct was a kind gift from D. Schultz (The Wistar Institute, PA, 
USA). Mouse embryonic cells (MEFs) kind gift from Pao-Tien Chuang (University of 
California, San Francisco, USA). 
 
Cell Culture and Transfection- HeLa cells were maintained at 37° C, 5% CO2 in 
complete DMEM (Corning) supplemented with 10% FBS (Altanta Biologicals), 100 
units/ml penicillin and 100 mg/ml streptomycin (Corning), 2 mM L-glutamine (Corning). 
Cells were grown to 80% confluence and serum starved (0.5% FBS DMEM) for 24 hours 
prior to pharmacological or genetic manipulation. For pharmacological manipulation, 
drugs were diluted in 0.5%FBS DMEM. For genetic overexpression experiments, cells 
were grown to 80% confluence then transfected using with TurboFect Transfection 
Reagent (Thermo Scientific) according to manufacturer’s protocol. Culture media was 
removed 24 hours post transfection and cells were collected or further treated with 
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pharmacological agents (0.5% FBS DMEM) for an additional 24 hours. Wild type, Smo-/- 
and Ptch1-/- MEFs were grown in DMEM supplemented with 15% FBS, 100 units/ml 
penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, and 200 µg/ml G418.  
 
Luciferase Assay- Stable NIH3T3 Shh-Light2 (kind gift from N. Dahmane University of 
Pennsylvania, PA, USA) cells were grown to 90% confluence in 96-well plate then, 
serum starved for 24 hours and exposed to indicated pharmacological agents for an 
additional 24 hours.  
Lysates were collected using 1XGLB Lysis Buffer (Promega). Lysates were subject to 
Bright-Glo Luciferase assay (Promega) according to manufacturer’s protocol and 
samples were analyzed using Promega Luminescent plate reader. Firefly Luciferase 
luminescence values were normalized to cell number determined by SYBR (Molecular 
probes) green assay.  
 
Drosophila stocks and genetics- Drosophila husbandry was performed as previously 
described (Chakraborty et al., 2011). For experiments utilizing the γ-secretase reporter 
GMR-APP-Gal4; UAS-Grim/Cyo model (Guo et al., 2003), flies were crossed to 
Smoothened dominant negative (SmoDN) mutants w[*]; P{w[+mC]=UAS-smo.5A}2 
(BL23943; Bloomington Stock Center, http://flybase.bio.indiana.edu/), or Patched loss of 
function (Ptclof) mutants y1 w67c23; P{lacW}ptck02507/CyO (BL10514; Bloomington Stock 
Center, http://flybase.bio.indiana.edu/), or Hedgehog loss of function (Hhlof) mutants 
P{ftz/lacC}4; hh21/TM3, Sb1 (BL5338; Bloomington Stock Center, 
http://flybase.bio.indiana.edu/) on standard cornmeal food. For controls GMR-APP-Gal4; 
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UAS-Grim/Cyo flies were outcrossed to w1118 (w-) (BL3605; Bloomington Stock Center, 
http://flybase.bio.indiana.edu/). Flies were collected 24 hours post eclosion and their 
compound eye inspected. Assessment of penetrance and severity of the rough-eye 
phenotype, was accomplished by photographing the compound eye using a Canon 
PowerShot S70 digital camera mounted to a Leica Mz 125 stereomicroscope. Severity of 
rough-eye phenotype was scored + (mild) to +++ (severe). One “+” refers to where less 
than ½ of the eye was apoptotic and therefore appears “rough”. A score of “++” 
(moderate) defined increased penetrance, where apoptosis affected approximately ½ of 
the eye. Severe “+++” rough-eye phenotype described when more than ½ of the eye 
appeared “rough” and eye size significantly reduced. For objective quantification, five 
blinded lab personnel analyzed all experiments. 
 
Immunoblotting- Lysates were collected in complete RIPA buffer (50 mM Tris-HCL, pH 
8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40) supplemented 
with Halt Protease and Phosphatase Inhibitor and EDTA (ThermoFisher). Lysates were 
briefly cleared at 20,000 x g at 4°C, and stored at -20°C. Protein concentrations were 
determined using the BCA assay kit according to manufacturer’s protocol (Pierce). 40 µg 
of lysate was supplemented with NuPAGE LDS Sample Buffer (Invitrogen) and heated 
to 75°C for 10 minutes. Protein was separated on 4-12% NuPAGE BisTris gels 
(Invitrogen) using MES running buffer (Invitrogen) then transferred onto Immobilon 
PVDF membrane (Millipore). Odyssey blocking buffer (Li-Cor Biosciences) was used 
for blocking and resuspending primary and secondary antibodies. Membranes were 
scanned using Li-Cor Odyssey infrared scanning instrument.  
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 shRNA Knockdown- To generate stable human Smo shRNA knockdown cells, using 
TurboFect according to manufacturer’s protocol, HeLa cells were transfected with five 
shRNA constructs (Sigma-Aldrich mission TRC library; TRCN0000014363, 
TRCN0000014364, TRCN0000014365, TRCN0000014366, TRCN0000014367) 
designed to target human Smo. An additional non-specific shRNA (Addgene, Plasmid# 
1884) was used as negative control. After 48 hours, media was replaced with fresh media 
supplemented with 1 mg/ml puromycin (Sigma). After three weeks of selection, cells 
were used for western blot analysis. An alternative method; naïve HeLa cells were grown 
to 40% confluency, transfected with scrambled or Smo TRCN shRNA using TurboFect 
according to manufacturer’s protocol. Cells were incubated for 24 hours then complete 
media changed and transfection of shRNA constructs was repeated a second time. Cells 
were left to incubate for an additional 24 hours then either collected for immunoblot or 
RNA isolation. To validate knockdown, cells were transiently transfected, with human 
Smo plasmid (a kind gift from M. Bijlsma, U Amsterdam, Amsterdam, The Netherlands) 
to which we genetically introduced a Myc tag. Cells were incubated for 24 hours then 
lysed for detection of Smo expression using Myc antibody. Endogenous Smo transcript 
was determined in transient Smo knockdown cells by isolating RNA (Qiagen) and 
performing a standard PCR on cDNA.  Relative Smo mRNA levels were normalized to 
mRNA levels of actin and compared to scrambled shRNA. Human β-Actin F’ primer: 
AGAAAATCTGGCACCACACC, β -Actin R’ primer: 
GGGGTGTTGAAGGTCTCAAA, human Smo F’ primer: 
GTTCTCCATCAAGAGCAACCAC, human Smo R’ primer: 
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CGATTCTTGATCTCACAGTCAGG, human Ptch1 F’ primer: 
GCTTCCCGTGCTTTTGTCTT, human Ptch1 R’ primer: CTGCAGCTCAATGACTTC, 
human Gli1 F’ primer: GGGATGATCCCACATCTCAGTC, human Gli1 R’ primer: 
CTGGAGCAGCCCCCCCAGT  (Kurita et al., 2010, Jimenez-Sanchez et al., 2012). 
For Gli3 knockdown studies, we utilized identical double transfection experimental 
procedures previously used for Smo knockdown. Five shRNA constructs (Sigma-Aldrich 
mission TRC library; TRCN0000020504, TRCN0000020554, TRCN0000020506, 
TRCN0000020507, TRCN0000020508) designed to target human Gli3. An additional 
non-specific shRNA (Addgene, Plasmid# 1884) was used as negative control. 
 
Statistical Analysis- All graphs and diagrams represent mean values ± standard error of 
all triplicates from at least three independent experiments. Either two-tailed or one-tailed 
Student’s t-test was used to compare two treatment groups and calculate significance 
from at least three independent experiments (* p<0.05, ** p<0.01, *** p<0.005). For in 
vivo Drosophila melanogaster experiments, G-test (goodness of fit) was used to 
determine significance of phenotypic penetrance in experimental populations. Degree of 
significance and corresponding p value criteria for G-test were same as Student’s t-test. 
 
RESULTS 
Pharmacological rescue of canonical Shh signaling does not ameliorate APP-CTF 
accumulation- We previously reported that cyclopamine decreases γ-secretase mediated 
cleavage of APP  (Vorobyeva, A.G., Lee, R., Miller, S., Longen, C., Kandelwal, P.J., 
Kim, F.J., Marenda, D.R., Saunders, A.J. 2014). Since cyclopamine is a Smoothened 
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(Smo) antagonist, this prompted us to investigate Sonic hedgehog (Shh) signaling 
pathway in APP metabolism. Several small molecule regulators of Shh signaling have 
been described. Specifically SAG, Smo agonist, at high concentrations is shown to 
displace cyclopamine and rescue Shh signal transduction (Chen et al., 2002). Monitoring 
Gli1 is a reliable Shh activity marker. To determine the sufficient SAG concentration to 
rescue cyclopamine’s inhibitory effects, we utilized the Gli1-Luciferase reporter cell line 
(NIH3T3 Shh-Light2 cells) (Taipale et al., 2000, Chen et al., 2002). Gli1-Luciferase 
Activity was restored when cells were exposed to 5 µM cyclopamine in combination with 
200 and 250 nM of SAG (Figure 3-1 A). We also confirmed 100 nM SAG treatment 
increased endogenous Gli1 mRNA in HeLa cells (Figure 3-1 B). Similarly, upon Shh 
peptide binding its cell-surface receptor Ptch1, downstream signaling results in increased 
PTCH1 expression. We confirmed this by treating naïve HeLa cells with conditioned 
media with or without Shh peptide (Figure 3-1 B).   
 Full length APP (FL-APP) proteolysis begins with primary cleavage by α- or β-
secretase, which produces two main fragments collectively known as APP C-terminal 
fragments (APP-CTFs). APP-CTFs are subsequently processed by γ-secretase complex to 
generate APP intracellular C-terminal domain (AICD) and Amyloid-β (Aβ) or p3 
fragment. Therefore, monitoring changes in FL-APP and APP-CTF levels are a reliable 
indicator for alteration to APP metabolism.  
 We hypothesized that increased SAG concentrations might also ameliorate our 
previously described cyclopamine effects on APP-CTF accumulation. To test our 
hypothesis, we exposed HeLa cells to similar pharmacological conditions as those 
described for Figure 3-1 A and monitored FL-APP and APP-CTF levels via Western blot 
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analysis (Figure 3-1 C). Concentrations deemed sufficient to rescue canonical Shh 
signaling did not attenuate APP-CTF accumulation (Figure 3-1 C, D). The significant 
accumulation of APP-CTFs (p=0.000507, p=0.000896, p=0.00244, p=0.00454) and the 
lack of change in FL-APP are both consistent with our previous report  (Vorobyeva, 
A.G., Lee, R., Miller, S., Longen, C., Kandelwal, P.J., Kim, F.J., Marenda, D.R., 
Saunders, A.J. 2014). Smo contains extracellular heptahelical bundles that bind small 
molecule modulators of Smo activity. These extracellular binding domains are poorly 
characterized and were previously shown to interact with small molecule modulateors in 
an allosteric fashion (Chen et al., 2002, Carroll et al., 2012, Wang et al., 2013, Wang et 
al., 2014). Therefore, our finding that 250 nM SAG treatment did not ameliorate APP-
CTF accumulation may be due to the incomplete understanding of Smo structure and 
function. To address our uncertainty of Smo involvement in APP metabolism, we tests 
GDC0449 an alternative Smo antagonist previously used for cancer treatment (Italiano et 
al., 2013). We first validated that 50 nM of GDC0449 is sufficient to significantly reduce 
canonical Shh signaling by monitoring Gli-mediated luciferase activity (Figure 3-1 E). 
Unlike cyclopamine, HeLa cells exposed to 50 nM GDC0449 did not alter APP 
metabolism, and APP-CTFs were not altered upon treatment (p=0.256) (Figure 3-1 F, 
G). These data suggest the previously described cyclopamine effects are cyclopamine-
specific and may not be mediated through canonical Shh signaling pathway.  
 
Knockdown of human Smoothened increases APP-CTFs accumulation- Another way 
to test if Smo affects APP metabolism is via genetic knock down of Smo.  We 
knockdown human Smo by transiently transfecting HeLa cells with five different Smo 
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shRNAs or control shRNA. We validated knockdown of endogenous Smo by analyzing 
relative Smo mRNA levels (Figure 3-2 A, B). Since a suitable antibody against Smo is 
unavailable, Smo protein levels were examined by transiently overexpressing human 
Myc-Smo in cells overexpressing Smo shRNAs (Figure 3-2 C). Interestingly transient 
overexpression of Smo shRNAs significantly increased endogenous APP-CTFs (p 
=0.0111, p=0.0207, p=0.0263, p=0.0464, p=0.0235) while no change was detected in 
FL-APP (Figure 3-2 C, D). These effects were exacerbated in our stable Smo 
knockdown HeLa cells (Figure 3-2 E-G). Interestingly, a marginal but significant 
increase in FL-APP levels was observed in stable Smo knockdown cells. This could be 
due to the stable overexpression nature of these cells since we did not detect changes in 
FL-APP in our transient Smo shRNA transfected cells. Nevertheless a substantially more 
significant increase was observed in APP-CTFs when normalized to FL-APP levels, 
which resembles the effects observed upon cyclopamine treatment (Figure 3-2 G). These 
data suggest that Smo could regulate APP metabolism through a previously unknown 
function, which may or may not be dependent on Shh signal transduction. Therefore we 
wanted to address whether these effects are dependent on canonical Shh signaling and 
whether the observed results are up- or downstream of Smo in the Shh signaling cascade. 
  
APP-CTF accumulation upon Shh signaling inhibition is Gli-independent- To test 
whether components upstream of Smo regulate APP metabolism, we used the 5E1 
antibody. Since there is no commercially available antagonist for Ptch1, researchers rely 
on the Shh peptide quenching mouse 5E1 antibody to abolish Shh signaling upstream of 
Smo  (Pepinsky et al., 2000, Beckers et al., 2007, Maun et al., 2010). Similar to Smo 
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knockdown and cyclopamine treatment, 5E1 treatment significantly increased APP-CTFs 
by approximately 140% (p=0.018004) (Figure 3-3 A, B). No change in FL-APP levels 
was observed. This implies that quenching Shh peptide or disrupting Ptch1 and/or Smo 
signaling is required to induce alterations to APP proteolysis and APP-CTF 
accumulation.  
 Canonical Shh signaling downstream of Smo activates Gli transcription factors 
(Gli1, Gli2, Gli3). Upon activation, the Gli’s translocate to the nucleus and induce 
transcriptional activation of downstream genes (i.e. GLI1 and PTCH1) (Zhu and H. W. 
Lo 2010, Hui and S. Angers 2011). To investigate if the observed effects on APP 
proteolysis can be recapitulated by inhibiting Shh signaling components downstream of 
Smo, we HeLa cells with GANT61, a Gli1/2 inhibitor  (Stanton and L. F. Peng 2010). 
We used 20 µM of GANT61 because we determined this concentration was adequate to 
significantly reduce canonical Shh signaling by monitoring Gli-mediate luciferase 
activity (Figure 3-3 C). Upon GANT61 exposure, we did not detect changes in APP 
metabolism like those previously observed with 5E1 and Smo knockdown (Figure 3-3 D, 
E). This indicates that the Gli1 and Gli2 are not required for altering APP proteolysis and 
therefore the effects we observed upon Smo knockdown are a result of Gli-independent 
Shh signaling.  
 The observed APP-CTF accumulation and lack of change to FL-APP, closely 
resemble γ-secretase mediated alterations to APP metabolism. This could mean that Shh 
peptide and/or Ptch1, and Smo could modify APP metabolism by affecting γ-secretase 
proteolysis of APP. 
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Disrupted Hh signaling in vivo decreases γ-secretase mediated cleavage of APP- Given 
our previous results and the availability of an in vivo γ-secretase Drosophila 
melanogaster reporter model, we tested the hypothesis that Hh, Ptch1, and/or Smo 
modulate γ-secretase cleavage of APP in vivo. The γ-secretase reporter Drosophila model 
was developed and characterized by Guo and colleagues in 2003 (Guo et al., 2003). 
Briefly, these flies carry an APP-C99-Gal4 construct controlled by the GMR promoter 
specific to the compound eye ommatidia. These flies also carry a Gal4-UAS element 
upstream of GRIM. Upon APP-C99-Gal4 cleavage by endogenous γ-secretase, the 
released AICD-Gal4 binds to UAS element and induces expression of the pro-apoptotic 
GRIM. Increased GRIM expression leads to ommatidia apoptosis and results in the rough 
eye phenotype (Guo et al., 2003). Therefore, if disrupting Hh, Ptc and/or Smo decreases 
γ-secretase cleavage of APP-C99-Gal4, these flies should have decreased severity of the 
rough eye phenotype. To recapitulate our in vitro effects in this model, we crossed GMR-
APP-C99-Gal4; UAS-GRIM flies to Hh, Ptch1, and Smo loss of function (lof) alleles and 
inspected the F1 generation eyes one day post eclosion. Flies crossed to Smolof allele 
displayed decreased severity of the rough eye phenotype (p=2.17x10-26) while those 
crossed to Ptclof allele displayed exacerbated severity of the rough eye phenotype 
(p=0.0217) (Figure 3-4 C, D, E). Specifically, while 55% of the control flies displayed 
“severe” rough eye phenotype, this population was substantially reduced to 35% and 
inversely increased to 64% in Smolof and Ptclof flies, respectively (Figure 3-4 E). In 
addition flies crossed to Hhlof also displayed significantly less severe rough eye 
phenotype than the control w− flies (p=2.007x10-24). While 28% of the Hhlof flies 
displayed “mild” rough eye phenotype, only 5% of the control w- flies displayed “mild” 
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rough eye phenotype (Figure 3-4 E). Since Hh peptide and Smo are positive Hh 
signaling regulators, Ptch1 is a negative regulator. Therefore detection of Ptclof flies with 
“severe” rough eye phenotype is logical since the loss of Ptch1 would lead to 
exacerbation of Hh signal transduction. Together these results strongly suggest ablating 
Hh signaling decreases γ-secretase mediated cleavage of APP-C99-Gal4 and could 
explain the accumulation of APP-CTFs observed in HeLa cells. Importability, this 
validates that our in vitro results can be recapitulated in vivo using the γ-secretase 
reporter model. 
 
Cell type specific effects of Sonic hedgehog on APP metabolism- Our in vivo results 
suggest Ptch1 plays a role in γ-secretase mediated cleavage of APP, thus we further 
investigated Ptch1 in APP metabolism in vitro. Due to commercial unavailability of 
Ptch1 antagonist, we utilized the well-characterized MEF knockout cell line, which is 
readily used for Shh signaling pathway studies  (Chen et al., 2009, Humke et al., 2010). 
We used wild type, Smo-/- and Ptch1-/- MEFs and compared APP proteolysis in these 
cells. Analogous to our in vitro and in vivo results, we predicted to observe an increase in 
APP-CTFs in Smo-/-, and a decrease in Ptch1-/- MEFs, respectively. Surprisingly, we did 
not observe APP-CTF accumulation in MEF Smo-/- cells as compared to wild type MEFs. 
Instead we detected an 18% decrease in FL-APP and a 44% decrease in APP-CTF 
normalized to FL-APP. In contrast, compared to wild type cells, Ptch1-/- MEFs exhibited 
substantially more FL-APP and APP-CTF levels (Figure 3-5 A, B). These results suggest 
the mechanism by which Shh regulates APP metabolism may be markedly different in 
MEFs as compared to HeLa cells and Drosophila melanogaster. One way to explain 
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these results is that the difference may lie within γ-secretase complex-specific 
differences. We inspected levels of active γ-secretase complex by measuring PSEN1-CTF 
levels. In addition we monitored canonical γ-secretase cleavage by measuring degree of 
“responsiveness” to a known γ-secretase inhibitor L-685,458 and quantified the extent of 
APP-CTF accumulation. While the typical 2 fold increase in APP-CTFs was observed in 
HeLa cells, of the three MEF cell types tested, Ptch1-/- MEFs displayed the most robust 
increase in APP-CTFs upon L-685,458 exposure. We observed an enormous 446% 
increase in APP-CTFs normalized to FL-APP in Ptch1-/- cells treated with the γ-secretase 
inhibitor (Figure 3-5 A, C). Although other changes in FL-APP and APP-CTFs were 
also observed in Smo-/- MEFs, these alterations were more modest and similar to wild 
type MEFs and naïve HeLa cells (Figure 3-5 A, C). Interestingly, a 2 fold increase in 
FL-APP levels upon L-685,458 exposure was also detected in Smo-/- MEFs. While a 
negligible increase in FL-APP is typical with L-685,458 treatment, a 2 fold increase is 
atypical for this drug. Together these data suggest γ-secretase mediated APP proteolysis 
in mouse MEF cells may be distinct from human HeLa cells. One way to measure levels 
of γ-secretase activity is by inspecting PSEN1-CTFs, which are an indicator of active γ-
secretase complex. Measuring PSEN1-CTFs revealed that MEFs of all genotypes 
expressed 3 fold more active γ-secretase complex than HeLa cells (Figure 3-5 A, D). 
Since our previous report implicates cyclopamine decreases γ-secretase mediated 
cleavage of APP, we tested whether cyclopamine treatment will also lead to APP-CTF 
accumulation in wild type MEFs. 5 µM cyclopamine treatment increased APP-CTF 
levels by approximately 28% while no change was observed in FL-APP levels (Figure 3-
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5 E). Further suggesting cyclopamine and Shh signaling have cell-type specific 
mechanisms in APP metabolism, which could be due to species-specific differences.  
 To assess Shh signaling via cyclopamine-mediated regulation of APP proteolysis 
in other cell types, we investigated human HEK293 and SH-SY5Y cell lines as well as 
the mouse NIH3T3 cells in response to cyclopamine. We treated these cells with vehicle 
control and 5 µM cyclopamine for 24 hours. L-685,458 exposure served as a positive 
control for APP-CTF identification. While HEK293s responded to the positive control, 
no change in FL-APP nor APP-CTFs was observed upon cyclopamine treatment (Figure 
3-6 A). Human neuroblastoma SH-SY5Y cell line also demonstrated an accumulation of 
APP-CTFs in response to L-685,458 however, no change was observed in APP-CTFs 
upon cyclopamine exposure (Figure 3-6 A). Mouse NIH3T3s also responded to the 
positive control, L-685,458, as seen by APP-CTF accumulation. Interestingly, a 
significant decrease of 55% (p=0.0305) in NIH3T3 APP-CTFs was detected upon 
cyclopamine exposure (Figure 3-6 A, B). These results suggest the underlying cause for 
the observed differences is cell-type and possibly species-type specificity. Together these 
data implicate Shh signaling in regulating APP metabolism. And evidenced by our 
experiments using the in vivo γ-secretase reporter model, these regulatory alterations 
could be facilitated through γ-secretase mediated cleavage of APP.  
 
DISCUSSION 
 To our knowledge, we are first to report that Sonic hedgehog signaling alters APP 
metabolism. Specifically we provide in vitro and in vivo evidence this regulatory effect 
may be arbitrated via a γ-secretase mediates effect on APP proteolysis. 
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 While we were able to regulate the canonical Shh signaling cascade in HeLa cells, 
interestingly not always did these effects corroborate with expected APP metabolism. 
Specifically, the predicted APP-CTF accumulation in HeLa cells was not detected when 
cells were exposed to an alternate Smo antagonist, GDC0449. And APP-CTF 
accumulation was not rescued with increasing SAG concentrations, determined sufficient 
for Shh signaling rescue. These results suggest that either cyclopamine alters APP 
metabolism via a Shh signaling-independent mechanism or that GDC0449 inactivates 
Smo activity distinctly from cyclopamine. However, our discovery that Smo knockdown 
also increased APP-CTFs suggests Smo regulates APP metabolism though a previously 
unknown function. Smo is a distant member of the seven-transmembrane (7-TM) G 
protein-coupled receptor (GPCR) (Ogden et al., 2008, Wang et al., 2013). In fact, Smo’s 
GPCR function was illustrated by activating inhibitory small G proteins (Gαi) (Riobo et 
al., 2006, Low et al., 2008, Polizio et al., 2011, Polizio et al., 2011, Shen et al., 2013). In 
aggreement with our results, vast literature demonstrates other GPCRs modulate APP 
metabolism via γ-secretase mediated effects. Therefore, we speculate that in addition to 
Smo functioning as a Shh signaling transduction component, it could also regulate γ-
secretase mediated APP proteolysis like other GPCRs. Future studies will be necessary to 
understand the mechanism by which Smo GPCR regulates APP proteolysis and Aβ 
generation in diseased and healthy brains. 
 Besides canonical Shh signaling cascade, two noncanonical Shh signaling 
pathways have been characterized; Type I and Type II. Both noncanonical pathways are 
dependent on the morphogenic Shh peptide. These pathways are Gli-independent since 
the Gli effectors are not required for the downstream noncanonical effects. Type II is Shh 
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peptide and Ptch1 dependent, and Smo independent. Alternatively, Type I signaling 
requires Smo in addition to Shh peptide and Ptch1  (Thibert et al., 2003, Mille et al., 
2009, Chinchilla et al., 2010, Kagawa et al., 2011, Brennan et al., 2012). We observed 
similar changes in APP proteolysis when quenching Shh peptide as those with Smo 
knockdown and cyclopamine. In contrast we did not detect changes upon exposure to 
Gli1/2 inhibitor, GANT61 nor Gli3 knockdown using Gli3 shRNA. Together these data 
indicate that the APP changes we report are mediated through a noncanonical Shh 
signaling cascade. More specifically, since the effects seem to be Shh peptide and Smo-
dependent we hypothesize the alterations are due to Type II noncanonical Shh signaling. 
Although we were able to decrease Ptch1 expression in Drosophila and monitor γ-
secretase cleavage of APP-C99-Gal4, further investigation of Ptch1 in cells is required to 
determine its obligation for the observed APP-CTF accumulation. We attempted this in 
MEF Ptch1-/- cells and learned that there are cell-type and species-type specific effects of 
Shh signaling on APP metabolism. 
 MEF knockout cells did not recapitulate similar results as HeLa cells and 
Drosophila. However, we discovered that disrupted Shh signaling in MEFs altered APP 
metabolism. These data demonstrate Shh regulates APP metabolism via a unique and 
dissimilar mechanism than HeLa cells and Drosophila. Perhaps the strikingly higher 
expression of PSEN1-CTFs in MEFs may explain the unique APP proteolysis profile and 
L-685,458 “responsiveness” these cells exhibit.  
 Other cell types failed to respond to cyclopamine similarly to our previous report 
using HeLa cells, primary rat cortical neurons and Drosophila, several reasons could 
account for these differences  (Vorobyeva, A.G., Lee, R., Miller, S., Longen, C., 
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Kandelwal, P.J., Kim, F.J., Marenda, D.R., Saunders, A.J. 2014). Both HEK293 and SH-
SY5Y cells are readily used for APP studies while NIH3T3 cells are not. Instead 
NIH3T3s are more often used for Shh studies. Interestingly, it was reported that 
HEK293s do not express endogenous Smo, which could explain the lack of APP-CTF 
response to cyclopamine treatment (Meloni et al., 2006). SH-SY5Y cells are not used to 
investigate Shh signaling which could also mean these cells do not express all Shh 
signaling pathway components, which is yet to be reported. This would be the most likely 
reason for the lack of APP-CTF accumulation upon cyclopamine exposure. Besides 
MEFs, NIH3T3 are the most readily used cell line for studying canonical Shh signaling 
(Bidet et al., 2011).  However, NIH3T3s are not a typical model for APP metabolism 
studies. Perhaps these cells lack the proper distribution of APP and other machinery 
required for classical APP proteolysis by the amyloidogenic and non-amyloidogenic 
pathways. Interestingly, in NIH3T3s we observed decreased APP-CTFs upon 
cyclopamine treatment, which is analogous to results we observed in mouse MEF Smo-/- 
cells. This could suggest species-specific differences in Shh signaling cascade and the 
mechanism by which it regulates APP metabolism. 
 Future studies will be required for characterizing the mechanism by which Shh 
signaling regulates APP metabolism. Both Shh signaling and APP metabolism are 
required for synaptic activity since their disruption leads to impaired synaptic plasticity. 
Precise balance of activity in each pathway is required. Exacerbated Shh signaling leads 
to uncontrolled cell division and glioblastoma while disrupted signaling most often leads 
to developmental disorders and ciliopathies  (Remke et al., 2013, Kieran 2014, Metin and 
M. Pedraza 2014) As for APP, increased proteolysis is most notably attributed to Aβ 
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deposition and synaptic dysfunction resulting in cognitive decline  (Tanzi 2005)Therefore 
it is necessary to better understand Shh signaling as a novel putative therapeutic target for 
Alzheimer’s disease treatment. 
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 FIGURES & LEGENDS 
Figure 3-1. SAG treatment rescues canonical Shh signaling but not APP-CTF 
accumulation. A, NIH3T3 Shh-Light2 cells exposed to indicated pharmacological agents 
for 24 hours. Gli-mediated luciferase activity was measured using Promega Luciferase 
Assay kit and Promega plate reader. B, Naïve HeLa cells exposed to vehicle (DMSO), 
100 nM SAG, 100 nM SAG + 5 µM Cyclopamine, or conditioned media with or without 
ShhN peptide for 24 hours followed by RNA isolation and cDNA synthesis. 
Conventional PCR detected relative changes in GLI1, PTCH1, and β-Actin mRNA 
levels. PCR reactions were run on 3% Agarose gel. C, HeLa cells exposed to identical 
pharmacological conditions as previously described in Figure 3-1 A. FL-APP and APP-
CTF protein levels were analyzed using Western blot and APP C-terminal (c1/6.1) 
antibody. D, Diagram representation of FL-APP levels normalized to β-Actin and APP-
CTFs to FL-APP. E, NIH3T3 Shh-Light2 cells treated with 50 nM GDC0449 or vehicle 
(DMSO) for 24 hours. Gli-mediated luciferase activity was measured using Promega 
Luciferase Assay kit and Promega plate reader. F, HeLa cells exposed to 50 nM 
GDC0449 or vehicle control (DMSO) for 24 hours. Endogenous FL-APP and APP-CTFs 
detected using APP C-terminal (c1/6.1) antibody via immunoblotting. G, Quantification 
of FL-APP and APP-CTF levels normalized to β-Actin and FL-APP, respectively. Values 
denote mean ± standard errors of the means. Student’s t-test was used for statistical 
analysis: ***p<0.005, **p<0.01, *p<0.05. 
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Figure 3-2. Transient and stable overexpression of Smo shRNA alters APP 
metabolism. A, PCR analysis of endogenous Smo mRNA levels in HeLa cells transiently 
transfected with TRCN shRNA against human Smo or control nonspecific shRNA. 
Human Smo and Actin plasmid DNA served as positive controls. B, Diagram 
representation of relative Smo mRNA levels and illustrates degree of Smo knockdown. 
C, HeLa cells were double transfected using similar conditions to A, and additionally 
transfected with human Myc-Smo construct. FL-APP, APP-CTFs, and Myc-Smo protein 
levels analyzed via Western blot, APP C-terminal antibody (c1/6.1) and mouse anti-Myc 
(9E10). D, Histogram representation of FL-APP and APP-CTFs normalized to β-Actin 
and FL-APP, respectively. E, Western blot analysis of stable Smo shRNA HeLa cells 
transiently transfected with human Myc-Smo. FL-APP and APP-CTFs detected with APP 
C-terminal antibody (c1/6.1) and Myc-Smo using mouse anti-Myc tag (9E10) antibody. 
F, Diagram illustrates decreased Myc-Smo, normalized to β-Actin, in Smo shRNA stable 
HeLa cells. G, Quantification of FL-APP and APP-CTF protein levels normalized to β-
Actin and FL-APP respectively. Bar Diagram represents mean ± standard errors of the 
means. Student’s t-test was used for statistical analysis: ***p<0.005, **p<0.01, *p<0.05. 
 
Figure 3-3. Gli-independent Sonic hedgehog signaling alters APP metabolism. A, 
Western blot analysis of HeLa cells treated with 10 µg/ml of anti-ShhN peptide 
quenching antibody (5E1) for 24 hours. 10 µg/ml of mouse IgG served as negative 
control. FL-APP and APP-CTFs were detected using APP C-terminal antibody (c1/6.1). 
B, Bar diagram represents FL-APP and APP-CTFs normalized to β-Actin and FL-APP, 
respectively. C, NIH3T3 Shh-Light2 cells exposed to 20 µM GANT61 or vehicle 
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(DMSO) for 24 hours. Gli-mediated luciferase activity was measured using Promega 
Luciferase Assay kit and Promega plate reader. D, Western blot analysis of HeLa cells 
treated with vehicle (DMSO) or 20 µM GANT61 for 24 hours. FL-APP and APP-CTFs 
were detected using APP C-terminal antibody (c1/6.1). E, Histogram representing levels 
FL-APP and APP-CTF protein levels normalized to β-Actin and FL-APP, respectively. 
F, HeLa cells transiently transfected with Gli3 shRNAs or control shRNA on two 
consecutive days. Cell lysates were collected and FL-APP and APP-CTFs were analyzed 
using Western blot analysis with (c1/6.1) C-terminal antibody. G, Histogram 
representation of FL-APP and APP-CTFs normalized to β-Actin levels. Bar diagrams 
represent mean ± standard errors of the means. Student’s t-test was used for statistical 
analysis: ***p<0.005, **p<0.01, *p<0.05. 
 
Figure 3-4. Hedgehog signaling modulates γ-secretase mediated cleavage of APP in 
vivo. A,wild type compound eye. B,C,D, Representative images of rough eye phenotype 
from GMR-APP-C99-Gal4; UAS-Grim (γ-secretase reporter)  flies crossed to Smolof 
(n=206), Ptclof (n=77), Hhlof (n=178) alleles or outcrossed to control w- flies (n=168). 
Flies were crossed and raised on normal cornmeal food. Compound eyes inspected one 
day after eclosion and scored based on severity of apoptosis (rough eye phenotype): mild 
(+), moderate (++), severe (+++). E, Relative changes in % penetrance is illustrated as 
percent of total population per experimental group. G-test was used for statistical 
analysis: ***p<0.005, **p<0.01, *p<0.05. 
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Figure 3-5. MEFs reveal the reverse effect on APP metabolism. A, Western blot 
analysis of Ptch1 and Smo knockout MEFs compared to wild type (WT) MEFs and HeLa 
cells treated with vehicle (DMSO) or 2 µM L-685,458 for 24 hours. Equal protein 
amount from each cell type was loaded. FL-APP and APP-CTFs detected using APP C-
terminal antibody (c1/6.1) and PSEN1-CTFs detected using rabbit anti-presenilin CTF 
antibody (D39D1). B, Histogram represents FL-APP and APP-CTF levels normalized to 
β-Actin and FL-APP of WT MEFs treated with vehicle control. C, represents the 
quantification of cells treated with L-685,458. Protein levels were normalized to 
respective vehicle treated cell type. D, Bar graph representation of presenilin-CTFs 
normalized to β-Actin in each cell type. Diagram represents values as % of HeLa 
PSEN1-CTF expression (control). E, Quantification of Western blot analysis of wild type 
MEFs exposed to vehicle (DMSO) or 5 µM cyclopamine for 24 hours. FL-APP and APP-
CTF analyzed via Western blot using c1/6.1 C-terminal APP antibody. FL-APP and APP-
CTFs were normalized to β-Actin and FL-APP, respectively. Bar Diagram represents 
mean ± standard errors of the means. Student’s t-test was used for statistical analysis: 
***p<0.005, **p<0.01, *p<0.05. 
 
Figure 3-6. Analysis of APP metabolism in response to cyclopamine in various cell 
types. A, Western blot analysis of FL-APP and APP-CTFs with APP C-terminal antibody 
(c1/6.1) in naïve HEK293, NIH3T3, and SH-SY5Y cells upon 24 hour exposure to 
vehicle control (DMSO), positive control 2 µM L-685,458 or 5 µM cyclopamine. B, Bar 
diagram illustrates increase and decrease of normalized APP-CTFs in NIH3T3 cells 
treated with L-685,458 and cyclopamine, respectively. APP-CTFs normalized to FL-APP 
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while FL-APP to β-Actin levels. Bar Diagram represents mean ±  standard errors of the 
means. Student’s t-test was used for statistical analysis: ***p<0.005, **p<0.01, *p<0.05. 
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CHAPTER 4: AMYLOID-β  DISRUPTS PRIMARY CILIA STRUCTURE: 
INSIGHT INTO AMYLOID PRECURSOR PROTEIN TRAFFICKING AND 
FUNCTION AT THE PRIMARY CILIUM 
 
 
 
 
ABSTRACT 
 Primary cilia are small cell membrane protrusions that act as sensory antennae 
sampling the extracellular environment. Disruption of cilia structure and/or function 
results in a spectrum of diseases collectively known as ‘ciliopathies’. More recent reports 
validate that cortical and hippocampal neurons bear a primary cilium. A common 
phenotype of brain ‘ciliopathies’ is neurocognitive impairment, a symptom also observed 
in Alzheimer’s disease (AD). AD is a neurodegenerative disease, one hallmark of which 
is accumulation of senile plaques composed of neurotoxic Amyloid-β (Aβ) peptide. 
Aβ peptide is produced from proteolysis of Amyloid Precursor Protein (APP). Here we 
report that APP localizes to primary cilia and that cilia structure is disrupted in response 
to neurotoxic Aβ treatment. Since vertebrate Sonic hedgehog (Shh) signaling requires 
primary cilia, we demonstrate that Aβ treatment interrupts canonical Shh signal 
transduction. 
 
INTRODUCTION 
 Elevated levels of Amyloid-β peptide is the leading cause of Alzheimer’s disease 
(AD) and has gained extensive support since the amyloid hypothesis was proposed  
(Hardy and D. Allsop 1991, Selkoe 1991, Hardy and D. J. Selkoe 2002). Amyloid-β (Aβ) 
is a small (4kDa) neurotoxic peptide having a tendency to oligomerize into higher order 
structures. In AD these structures are referred to as senile plaques. In Alzheimer’s 
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disease, senile plaques interrupt neuronal activity and result in synaptic dysfunction, 
neuronal death and eventually cognitive decline  (Hsia et al., 1999, Stern et al., 2004, 
Berezov et al., 2005, Kelly and A. Ferreira 2007, Spires-Jones et al., 2007, Potter et al., 
2011). Amyloid-β is produced by sequential β- and γ-secretase proteolytic cleavage of 
Amyloid precursor protein (APP) (Scheuner et al., 1996, Kim and R. E. Tanzi 1997, De 
Strooper et al., 1998, De Strooper et al., 1999, Haass and B. De Strooper 1999, Vassar et 
al., 1999, Wolfe et al., 1999). APP function is still elusive, however recent studies shed 
light on the physiological role of Aβ in non-diseased brains  (Seubert et al., 1992, 
Pearson and C. Peers 2006). Specifically, studies show Aβ plays a role in synaptic 
transmission and is involved in learning and memory formation  (Saura et al., 2004, 
Puzzo et al., 2008). For this reason, it is critical to maintain adequate soluble Aβ levels 
that support synaptic plasticity and do not exceed pro-amyloidosis threshold. In our 
recent reports we discovered Sonic hedgehog (Shh) signaling pathway decreases γ-
secretase cleavage of APP and Aβ generation  (Vorobyeva, A.G. et al., 2014a, 
Vorobyeva, A.G. et al., 2014b)  
 Sonic hedgehog (Shh) signaling pathway is best known for its pivotal role in 
development and neurogenesis  (Lee et al., 1992, Echelard et al., 1993, Varjosalo and J. 
Taipale 2008). More recent reports identified active Shh signaling in the adult brain, 
specifically in dentate gyrus of the hippocampus, one of the brain regions plagued by 
Alzheimer’s disease. Briefly, Shh peptide binds receptor Patched1 (Ptch1), which 
alleviates its inhibitory effects on G protein-coupled receptor (GPCR) Smoothened 
(Smo). Upon activation Smo signals downstream to the Gli1/2/3 effectors that induce 
transcriptional activation of downstream genes (Sasaki et al., 1999, Bai et al., 2002, 
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Taipale et al., 2002, Wang et al., 2013). Clinical evidence shows deficient Shh signaling 
results in similar phenotypes as those observed in patients with disrupted cilia structures 
(Attanasio et al., 2007, Hildebrandt et al., 2009, Hildebrandt et al., 2011).  Later 
experimental evidence confirmed that vertebrate canonical Shh signaling requires 
primary cilia for signal transduction (Huangfu et al., 2003, Corbit et al., 2005, Huangfu 
and K. V. Anderson 2005, Rohatgi and M. P. Scott 2007, Rohatgi et al., 2007, 
Milenkovic et al., 2009). The aforementioned discoveries and our previous finding that 
Shh signaling alters APP metabolism and Aβ levels, prompted us to investigate a possible 
molecular relationship between Shh signaling, Aβ and primary cilia. 
 Primary cilia are microscopic membrane enclosed protrusions from post-mitotic 
cells (Mandl and R. Megele 1989, Fuchs and H. D. Schwark 2004, Whitfield 2004, 
Berbari et al., 2007, Wheatley 2008, Satir et al., 2010). Non-motile, primary cilia, bear a 
9+0 microtubule doublet arrangement and range from 0.5 – 10 µm in length and have an 
approximately 0.2 µm diameter. For an extended period, these organelles were though to 
be vestigial however, recent literature suggests they are sensory organelles decorated with 
GPCRs and other receptor proteins for sampling the extracellular environment. The 
identification of neuronal cilia lead to addressing fundamental questions of cilia function 
in the adult brain (Handel et al., 1999, Brailov et al., 2000, Whitfield 2004). Since 
virtually all vertebrate cells bear a primary cilium, abnormal cilia structure results in 
dysfunctions of a variety of organ systems referred to as ‘ciliopathies’ (Badano et al., 
2006, Sharma et al., 2008, Duldulao et al., 2010, Hildebrandt et al., 2011, Lee and J. G. 
Gleeson 2011, Sattar and J. G. Gleeson 2011, Waters and P. L. Beales 2011). 
Interestingly, similar to one AD hallmark, a common symptom among ciliopathies is 
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cognitive impairment. The latter suggests neuronal cilia may house signaling cascades 
critical for learning and memory formation, which may be compromised in AD 
pathogenesis (Wang et al., 2011).  
 In the current study we evaluated whether increased Aβ levels disrupt primary 
cilia structure. Using immunofluorescence microscopy we detected changes in structural 
morphology of primary cilia upon exposure to Aβ peptide. We also provide evidence that 
Aβ treatment abolishes Shh signaling in NIH3T3 cells, which was especially apparent 
upon pharmacological Shh activation. Further, we identified APP and Smo colocalization 
at the primary cilium of NIH3T3s. The latter indicates a putative functional role of APP 
at the primary cilium and the possibility that distorted cilia structure and impaired Shh 
signaling could be contributing factors to AD neuropathology. 
 
EXPERIMENTAL PROCEDURES 
Antibodies, Plasmids and Reagents- Antibodies were obtained from the following: rabbit 
APP C-terminus A8717, mouse anti-acetylated tubulin (Sigma). Fluorescent secondary 
antibodies (Alexa Fluor 488, 594, 649) were from Jackson Immunoresearch Laboratories. 
Cyclopamine (5 µM) was purchased from LC Laboratories, L-685,458 (2 µM)  and 
DMSO  from Sigma, SAG (100 nM) from Calbiochem, and human Aβ42 peptide (0.1-5 
µM) from Tocris R&D Systems. EGFP-Smo and Cherry-APP695 were used for 
overexpression studies.  
 
Cell Culture - HeLa and NIH3T3 cells were maintained at 37° C, 5 % CO2 in complete 
DMEM (Corning) supplemented with 10% FBS (Altanta Biologicals), 100 units/ml 
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penicillin and 100 mg/ml streptomycin (Corning), 2 mM L-glutamine (Corning). Cells 
were grown to 80% confluence and serum starved (0.5% FBS DMEM) for 24 hours prior 
to pharmacological or genetic manipulation. For pharmacological manipulation, drugs 
were diluted in 0.5 % FBS DMEM. For genetic overexpression experiments, cells were 
grown to 80% confluence then transfected using with TurboFect Transfection Reagent 
(Thermo Scientific) according to manufacturer’s protocol. For Aβ culture media, stable 
HEK293 APP695swd or naïve HEK293 cells were grown to 100% confluence and culture 
media was replaced with just enough 0.5 % FBS DMEM to cover the cells. Cells were 
cultured with or without supplemental L-685,458 for an additional 48 hours then 
collected and cleared by a brief 1000 x g centrifugation. For NIH3T3 treatment with 
biological Aβ, indicated conditioned media was diluted 1:2 in fresh 0.5 % FBS DMEM 
prior to addition to confluent NIH3T3s. 
 
LDH Cytotoxicity Assay- Levels of LDH were analysed according to manufacturer’s 
protocol (Roche). Briefly, supernatants were collected from treated cells, 1:1 ratio of 
supernatant to the LDH master mix was incubated at ambient temperature for 30 minutes. 
Samples were analyzed using spectrophotometer. 
 
Luciferase Assay- Stable NIH3T3 Shh-Light2 (kind gift from N. Dahmane University of 
Pennsylvania, PA, USA) cells were grown to 90% confluence in 96-well plate then, 
serum starved for 24 hours and exposed to indicated pharmacological agents for an 
additional 24 hours.  
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Lysates were collected using 1XGLB Lysis Buffer (Promega) and subject to Bright-Glo 
Luciferase assay (Promega) according to manufacturer’s protocol and samples were 
analyzed using Promega Luminescent plate reader. Firefly Luciferase luminescence 
values were normalized to cell number determined by SYBR (Molecular probes) green 
assay.  
 
Immunofluorescence- Cells were fixed using 4% PFA, 0.1% Triton-X-100, blocked in 
2% BSA for 30 minutes and incubated with primary antibodies over night at 4°C. Cells 
were rinsed with PBS and stained with secondary antibodies at room temperature for 1 
hour, washed with PBS and mounted. Cells were imaged using Olympus Fluoview 1000 
inverted confocal microscope. Quantification of 3D confocal image stacks was 
accomplished using Volocity Image analysis software (PerkinElmer).  
 
RESULTS 
Amyloid-β  decreases primary cilia length and frequency in NIH3T3 cells- To 
determine whether Amyloid-β (Aβ) affects primary cilia structure, we exposed cells to 
extracellular Aβ and examined cilia structure and frequency using an anti-acetylated 
tubulin antibody as a marker for primary cilia. We utilized the mouse fibroblast NIH3T3 
cell line, which is readily used for cilia studies and one primary cilium per cell is typical 
in these cells. To generate media containing biological Aβ, we cultured APP695swd stably 
overexpressing HEK293 cells to 100 % confluence and collected the culture media 
(Figure 4-1 A). APP695swd cells bear the Swedish mutation within APP (K670N/M671L), 
which favors β-secretase cleavage of APP thereby elevating Aβ generation to above 
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physiological levels (Citron et al., 1992). We used conditioned media from naïve HEK 
cells as a negative control. NIH3T3 cells exposed to Aβ-containing media for 24 hours, 
displayed a significant (p=1.22x10-10, p=1.06x10-6) decrease of 57 and 43% in cilia 
volume and length, respectively (Figure 4-1 B-D). Additionally, in cells treated with Aβ-
conditioned media we detected a significant decrease of 48% (p=4.095x10-6) in the ration 
of cilia to nuclei (Figure 4-1 E). Because these cells were serum-starved, a typical 
ciliogenesis protocol, prior to Aβ exposure our results suggests increasing extracellular 
levels of biological Aβ leads to cilia degeneration. Remarkably, these effects were 
rescued in NIH3T3s exposed to conditioned media collected from APP695swd cells treated 
with 2 µM L-685,458 (Figure 4-1 A-E). L-685,458 is a commonly used γ-secretase 
transition-state inhibitor which precludes Aβ generation. The latter further suggests our 
detected changes in cilia structure are Aβ-dependent. Exposing NIH3T3s to synthetic 
human Aβ42 further confirmed our previous findings as cilia structure was also disrupted 
in these cells (Figure 4-2 A-C). Upon 0.5 µM Aβ42 treatment, cilia length decreased 
from nearly 7 µm to 4 µm. Interestingly we did not observe a change in cilia diameter 
(Figure 4-2 D). Since cilia gains length at the tip, site of tubulin polymerization; a lack of 
change in diameter suggests Aβ could lead to tubulin depolymerization at the tip of the 
axoneme. Disrupted cilia structure and maintenance abolishes cilia-dependent cell 
signaling pathways such as the canonical vertebrate Sonic hedgehog (Shh) signaling 
pathway (Haycraft et al., 2005, May et al., 2005, Ocbina and K. V. Anderson 2008). 
 
Amyloid-β  disrupts canonical Sonic hedgehog signaling- Vertebrate canonical Shh 
signaling requires primary cilia, thus we predicted Aβ interrupts canonical Shh signaling. 
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To test this, we utilized stable NIH3T3 Shh-Light2 cells that carry a Gli-responsive 
luciferase construct. Upon Shh activation, endogenous Gli transcription factors enhance 
luciferase expression. Upon Aβ42 exposure, we measured luciferase activity and detected 
a dose dependent decrease in Shh signaling. Specifically, Gli-mediated luciferase activity 
significantly decreased by 42 and 30%  (p=0.000113, p=0.00354) in cells treated with 2 
µM and 1 µM Aβ42, respectively (Figure 4-3 A, B). These effects were not due to 
cytotoxicity as confirmed by an LDH cytotoxicity assay (Figure 4-3 C). To further 
validate these results, we exacerbated Shh signaling in these cells by treating them with a 
potent Shh signaling antagonist, SAG. 100 nM SAG treatment increased Gli-mediated 
luciferase activity by approximately 2,000% (p=0.00395) (Figure 4-3 D). We detected 
significant decreases in Shh activity upon addition of various concentrations of synthetic 
Aβ42. Specifically, we observed a 56 % decrease in cells treated with 2 µM Aβ42 and an 
11% decrease in cells treated with as little as 100 nM Aβ42 (Figure 4-3 E). These results 
validate our hypothesis that Aβ antagonizes Shh signaling which could be due to our 
previous observation that Aβ disrupts cilia structure.  We previously reported that Shh 
signaling modulates APP metabolism and Aβ generation, since Shh signaling is linked to 
primary cilia we explored the possibility that APP and Shh signaling component Smo 
localize to this organelle (Han et al., 2008, Vorobyeva, A.G. et al., 2014b). 
 
APP localizes to primary cilia- Given the lack of a reliable commercially available Smo 
antibody and the ubiquitous expression of APP throughout the cell, we overexpressed 
Cherry-APP and GFP-Smo in NIH3T3 cells. We co-stained these cells with acetylated 
tubulin, a cilia marker, and observed that both Smo and APP colocalize at the primary 
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cilium in NIH3T3 cells (Figure 4-4 A-D). To confirm these observations, we examined 
endogenous APP localization at primary cilia in human HeLa cells and also detected 
APP-positive primary cilia (Figure 4-4 E, F). Since APP function is still largely 
unknown, the aforementioned results suggest APP may have a functional role at the 
primary cilium. 
 
DISCUSSION 
 At the base of all primary cilia is a protein complex responsible for maintaining a 
distinct lipid and protein environment from the cytoplasm (Hu and W. J. Nelson 2011). 
Therefore, only those proteins destined for the primary cilia are trafficked to cilia. 
Specified cilia targeting sequences mediate exclusive trafficking of proteins from the 
Golgi to the base of primary cilia and a growing ‘ciliome’ database was recently created 
(Li et al., 2004, Blacque et al., 2005, Stolc et al., 2005, Inglis et al., 2006). Examples of 
cilia targeting sequences include VxPx, RVxP, AxxxQ(Berbari et al., 2008, Dishinger et 
al., 2010). Interestingly human APP695, the predominant brain isoform, bears two types 
of these cilia targeting sequences for a total of 8 putative sequences (Figure 4-5 A). We 
found that all putative targeting sequences, except for one (#8), are located in the N-
terminal ectodomain of APP (Figure 4-5 B). Biosynthetic APP is trafficked from the 
trans-Golgi network to its destination via vesicular trafficking. Adaptor and motor 
proteins that recognize sequences at the cytoplasmic C-terminus of APP mediate 
trafficking to its final destination  (Haass et al., 2012). Thus, one may speculate that 
putative sequence #8 may be responsible for APP localization to primary cilia.  
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 Latest report by Fogel and colleagues demonstrates that APP dimerizes at the 
plasma membrane and binds Aβ in a receptor-to-ligand mechanism (Fogel et al., 2014). 
This report suggests APP may function as a receptor for its own liberated peptide, Aβ. 
Consistent with their results, our report may also implicate a receptor function for APP. 
Cilia are sensory organelles decorated with an assortment of receptor proteins such as G 
protein-coupled and growth factor receptors (Handel et al., 1999, Bishop et al., 2007, 
Berbari et al., 2008). Therefore it is likely that if APP is localized to the primary cilia it 
may function as a receptor for Aβ. Our observation of Aβ affecting cilia structure further 
supports the aforementioned hypothesis. 
 Sonic hedgehog (Shh) signaling requires proper cilia structure. Evidence 
demonstrates that Shh activity fails in cells with disrupted cilia structure. The latter was 
confirmed when researchers observed unsuccessful Shh activation upon agonist exposure 
in cells with defective cilia (Breunig et al., 2008, Han et al., 2008, Town et al., 2008). We 
provide two lines of evidence suggesting Shh signaling and cilia are novel targets for 
Alzheimer’s disease (AD) therapeutics. First line of evidence is our previous report 
describing Shh signaling in APP metabolism  (Vorobyeva, A.G. et al., 2014b). Our 
second line of evidence is the current report demonstrating that increased Aβ levels 
disrupt cilia structure, which might have been the underlying cause of the aberrant Shh 
activity.  Shh has not been previously identified in neurodegenerative diseases. Instead, 
vast amounts of literature demonstrate its role in development, neurogenesis and cell 
survival (Machold et al., 2003, Palma et al., 2005, Breunig et al., 2008). One may 
speculate that increased Aβ levels in AD pathogenesis first lead to cilia degeneration, 
which ultimately impairs Shh signaling and precludes Shh-mediated neuronal survival.  
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 Ciliopathies are caused by mutations in genes involved in ciliogenesis and or 
maintenance of the primary cilia structure. However in the last several years, acquired 
ciliopathies have been suggested. For example, disruption of primary cilia structure was 
implicated in obesity, diabetes and hypertension (Mok et al., 2010, Saigusa et al., 2012). 
However it remains to be determined if these diseases are caused by aberrant cilia 
structure or disruption of a particular cilia-dependent signaling pathway such as Shh 
signaling pathway. In addition, it will be interesting to examine histological cilia structure 
in AD and non-AD human postmortem brain tissue at various stages of the disease.  
 
FIGURES & LEGENDS 
Figure 4-1. Biological Amyloid-β  treatment decreases cilia length. A, Representation 
of experimental approach. Naïve and stable HEK293APPswd cells cultured and 48 hour 
conditioned media collected for NIH3T3 treatment. Conditioned media (CM) collected 
from stable HEK293APPswd is designated as “High Aβ CM” while stable cells treated with 
2 µM L-685,458 is designated as “Low Aβ CM”. Conditioned treatment media was 
diluted 1:1 with fresh media. B, Confocal 3-D analysis of naïve NIH3T3 cells treated 
with vehicle control CM, High Aβ CM, or Low Aβ CM for 24 hrs. Cells were stained 
with acetylated tubulin and >50 cilia per condition analyzed. Scale bar represents 20 µm. 
C-D, Bar graph representing quantification of cilia volume, length and frequency. Values 
denote mean ± standard errors of the means. Student’s t-test was used for statistical 
analysis: ***p<0.005, **p<0.01, *p<0.05. 
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Figure 4-2. Synthetic Amyloid-β  decreases cilia length without altering cilia 
diameter. A-D, Quantification of naïve NIH3T3 cells exposed to synthetic human Aβ42 
for 24 hrs. Cilia length, volume, surface area and diameter were analyzed using an anti-
acetylated tubulin antibody and immunofluorescence. At least 30 cells were analyzed 
using Volocity 3-D analysis software. Values denote mean ± standard errors of the 
means. Student’s t-test was used for statistical analysis: ***p<0.005, **p<0.01, *p<0.05. 
 
Figure 4-3. Synthetic Amyloid-β  disrupts Sonic hedgehog signal transduction. A, 
NIH3T3 Shh-Light2 cells treated with vehicle control (DMSO), 100 nM SAG or in 
combination with 5 µM cyclopamine. Quantification represents Gli-mediated luciferase 
activity normalized to vehicle control treated cells. B, Gli-mediated luciferase activity of 
NIH3T3 Shh-Light2 cells treated with indicated concentrations of synthetic human Aβ42 
peptide for 24 hours. C, LDH cytotoxicity analysis of NIH3T3 Shh-Light2 cells treated 
with Aβ42 peptide for 24 hours. D, Gli-mediated luciferase activity of NIH3T3 Shh-
Light2 cells treated with SAG and increasing concentrations of Aβ42 peptide for 24 hours. 
Values denote mean ± standard errors of the means. Student’s t-test was used for 
statistical analysis: ***p<0.005, **p<0.01, *p<0.05. 
 
Figure 4-4. Amyloid precursor protein localizes to primary cilia of NIH3T3 and 
HeLa cells. A, Confocal analysis of overexpressed Cherry-APP and GFP-Smo 
colocalization in NIH3T3 cells stained using anti-acetylated tubulin antibody. Scale bar, 
19 µm. B, Compartmentilization analysis using Volocity 3-D imaging analysis software 
of the previous image in A. C,D, Colocalization analysis of fluorescence intensity of 
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NIH3T3 cells overexpressing Cherry-APP and GFP-Smo constructs. D, Fluorescence 
intensities of nuclei (blue), acetylated tubulin (green), and APP (red). E, Confocal 
immunofluorescence analysis of naïve HeLa cells co-stained with anti-acetylated tubulin 
and C-terminal APP antibody. Scale bar, 7 µm. F, Graph illustrates fluorescence 
intensities though the 2.73 µm cross section depicted in right-most panel of E. 
 
Figure 4-5. Putative cilia targeting sequences in human APP 695 isoform. A, Amino 
acid sequence of human APP 695 isoform. Based in literature, eight putative cilia 
targeting sequences have been emphasized with red, green and magenta  (Berbari et al., 
2008, Dishinger et al., 2010). Cartoon of APP protein bearing putative cilia targeting 
sequences in reference to APP metabolites and secretase cleavage sites.   
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CHAPTER 5: DISCUSSION 
 
 
 
 
 Synaptic dysfunction and neuronal loss are key events in Alzheimer’s disease 
(AD) that lead to the devastating cognitive defects. Two neuropathological hallmarks of 
AD are neurofibrillary tangles and senile plaques consisting largely of 
hyperphosphorylated tau protein and the amyloid-β peptide, respectively. The amyloid 
cascade hypothesis suggests these neuropathologies are due to elevated amyloid-β (Aβ) 
peptide levels (Hardy and D. J. Selkoe 2002). Aβ peptides are produced by sequential 
proteolysis of the amyloid precursor protein (APP) by β- then γ-secretase (De Strooper et 
al., 1999, Haass and B. De Strooper 1999, Vassar et al., 1999). APP function is poorly 
understood however, decreasing APP proteolysis decreases Aβ production and may 
ameliorate AD pathology. Three approaches aimed at reducing Aβ load are heavily 
investigated; 1) to diminish Aβ generation, 2) to increase Aβ clearance, or 3) to decrease 
Aβ oligomerization.  
 AD presents in two forms, familial AD (FAD, also known as early onset AD or 
EOAD) or the late onset sporadic AD (LOAD / SAD). The current view is that both 
LOAD and FAD are due to elevated Aβ levels initiating neuropathological events. 
Therefore, according to the amyloid hypothesis, decreasing Aβ levels prior to 
symptomology might prevent the development of sporadic and familial AD.  While 
genetic mutations in APP and components of the γ-secretase complex result in elevated 
Aβ levels and FAD, no known genetic factors are known to directly cause LOAD. 
Genetic association studies have revealed a number of genetic variants that increase the 
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risk for developing LOAD, however more genetic risk factors have yet to be discovered 
(Bertram et al., 2010, Tanzi 2012). This notion prompted researchers to search for genetic 
factors common among SAD patients (Tanzi and L. Bertram 2005). 
 Our lab identified components of the Sonic hedgehog (Shh) signaling pathway as 
putative regulators of APP metabolism. We used an AICD-mediated γ-secretase reporter 
model to further validate our findings (Zhang et al., 2007). This encouraged us to 
investigate the putative role Shh signaling might play in APP metabolism. Shh is best 
characterized for its role in development, organogenesis, cell cycle homeostasis, survival 
and neurogenesis (Fuccillo et al., 2006, Cohen 2010). Cyclopamine is the first described 
Shh small molecule antagonist (Cooper et al., 1998, Heretsch et al., 2010). Given that 
cyclopamine is readily available and widely studied, we tested its’ affects in vitro and 
discovered it induced profound changes in APP proteolysis (Figure 2-1). Our results 
demonstrate that cyclopamine decreases γ-secretase mediated cleavage of APP thereby 
decreasing Aβ generation. Cyclopamine’s target is the seven-transmembrane (7-TM) 
domain G protein-coupled receptor (GPCR) Smoothened (Smo) (Chen et al., 2002, Wang 
et al., 2013). When we tested other inhibitors that target Smo, we failed to detect changes 
in APP metabolism (Figure 3-1). While this does not rule out that Smo may be involved 
in APP metabolism, we pursued to investigate cyclopamine-induced effects on APP 
metabolism. One way to rationalize our conflicting pharmacological results is that recent 
evidence shows cyclopamine does not bind to the same heptahelical bundle of Smo as 
other Smo inhibitors such as SANT1/2 (Wang et al., 2009, Wang et al., 2014). The 
aforementioned study also demonstrated that while SANT1/2 decreased Smo 
translocation to its active site, the primary cilium, cyclopamine actually promoted its 
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localization to this microscopic structure. These data further suggest that although Smo is 
required for downstream Shh signal transduction, the mechanism by which small 
molecules regulate Smo is largely unknown. Distinct Smo localization in response to 
cyclopamine lead us to speculate Smo may have alternate functions besides Shh signal 
transduction. 
 We discovered that cyclopamine decreases γ-secretase mediated cleavage of APP 
and Aβ generation by promoting the alternative retrograde trafficking of APP C-terminal 
fragments (APP-CTFs). After biosynthesis, full-length APP is trafficked from the trans-
Golgi network (TGN) to the plasma membrane. After primary cleavage by α- and/or β-
secretase, APP-CTFs are quickly endocytosed then sorted in the early endosome for 
recycling, lysosomal degradation or retrograde trafficking back to the TGN for γ-
secretase processing (Figure 1-1 B) (Choy et al., 2012). Cyclopamine treatment 
increased APP-CTFs in lysosomes and decreased APP-CTF retrograde trafficking to the 
TGN (Figure 2-7, 2-9). We observed significant accumulation of lysosomal-positive 
puncta in cells treated with cyclopamine suggesting cyclopamine facilitates lysosomal 
biogenesis or decreases turnover of lysosomal contents. In fact we observed reduced 
lysosomal maturation upon cyclopamine treatment which could explain the substantial 
increase in APP-CTFs we detected (Figure 2-10).  
 A recent report by Morel and colleagues indicates that PI3P lipids, critical for 
APP sorting to lysosomes, are altered in AD brains (Morel et al., 2013). We detected a 
marginal rescue of APP-CTF accumulation in cells exposed to cyclopamine combined 
with PI 3-kinase inhibitor, Wortmannin (Figure 2-11). However, it was not sufficient 
enough to conclude PI3P levels are the sole underlying cause for cyclopamine-dependent 
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lysosomal APP-CTF accumulation. Emerging evidence has revealed a wider range of 
lipid dyshomeostasis in Alzheimer’s disease. Both cholesterol and sphingolipid levels are 
significantly altered in AD brains (Cutler et al., 2004, Di Paolo and T. W. Kim 2011). 
Earlier studies showed cholesterol and sphigolipids play a major role in APP trafficking 
and amyloidogenic processing (Bodovitz and W. L. Klein 1996, Runz et al., 2002, 
Grimm et al., 2005, Lippincott-Schwartz and R. D. Phair 2010). Increases in either 
cholesterol or sphingolipid processing product, ceramide, favor β- and γ-secretase 
cleavage of APP and thereby increase amyloidosis and Aβ production. Conversely, 
studies show Aβ levels decreased in response to statin-mediated cholesterol depletion in 
vitro and in vivo (Simons et al., 1998, Fassbender et al., 2001). Cholesterol and 
sphingolipids are major components of lipid rafts, which are highly dynamic areas of the 
plasma member, and favor γ- and β-secretase localization with APP-CTFs for subsequent 
cleavage (Ehehalt et al., 2003, Vetrivel et al., 2004, Vetrivel et al., 2009, Vetrivel and G. 
Thinakaran 2010). However, this relationship between lipid rafts and APP amyloidogenic 
processing may be cell type specific (Simons et al., 1998, Ehehalt et al., 2003, Yoon et 
al., 2007, Schneider et al., 2008, Vetrivel and G. Thinakaran 2010). This could in part 
explain the lack of change in APP metabolism in HEK293s and SH-SY5Ys upon 
cyclopamine exposure (Figure 3-5). Additionally, we detected cell type specific changes 
in APP metabolism when we exposed mouse embryonic fibroblasts (MEFs) to 
cyclopamine (Figure 3-6). While APP-CTFs are preferably cleaved when located in 
lipid-rich domains, studies indicate other γ- and β-secretase substrates such as Notch1 
and Jagged2, are processed in non-raft membranes (Vetrivel et al., 2005, Vetrivel and G. 
Thinakaran 2010). The latter could also explain why we did not observe significant 
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changes in ΔENotch1 C-terminal fragment, the APP-CTF equivalent (Figure 2-2). 
Perhaps, cyclopamine-induced changes in APP metabolism could be due to alterations in 
lipid rafts, cholesterol and/or sphingolipids. 
 In contrast to mammalian cholesterol, phytosterols exhibit beneficial effects on 
APP metabolism. Phytosterols are plant equivalents of cholesterol; cyclopamine is one 
example. Burg and colleagues recently reported that certain phytosterols decrease 
amyloidogenic processing of APP in vitro and in vivo (Burg et al., 2013). Although our 
findings do not demonstrate similar mechanism of action as the aforementioned study, 
both analyses of phytosterols in APP metabolism open a novel avenue for AD therapeutic 
intervention.  
 Lysosomes contribute to cellular cholesterol trafficking and processing. Since 
amyloidogenic processing is tightly regulated by lipid levels, it will be interesting to 
examine vertebrate cholesterol and lipid rafts upon cyclopamine exposure. Interestingly, 
cyclopamine was previously shown to exacerbate neutral sphingomyelinase (nSMase) 
activity, which increases ceramide levels and plays a role in lysosomal biogenesis 
(Meyers-Needham et al., 2012). Ceramide is produced from sphingolipids processed by 
sphingomyelinases. Ceramide binds to cathepsin D, the major lysosomal aspartic 
protease, and induces cathepsin D maturation (Heinrich et al., 2000). Mature cathepsin D 
is the main facilitator of lysosomal maturation, degradation and protein turnover. 
Impaired cathepsin D decreases Aβ clearance and was recently reported at reduced 
expression levels in cells from AD patients (Hamazaki 1996, Tian et al., 2014). We 
observed increased lysosomes in cyclopamine treated cells (Figure 2-5, 2-6, 2-7). Since 
the majority of APP-CTFs localized to lysosomes, one would predict increased APP-CTF 
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turnover. Instead cyclopamine attenuated lysosomal degradation rate of APP-CTFs. The 
latter might be partially due to the modest but significant disruption to lysosomal 
maturation, determined by mature cathepsin D levels (Figure 2-10). Combination of 
cyclopamine and an nSMase inhibitor did not significantly rescue APP-CTF 
accumulation suggesting the observed effects may not be nSMase-mediated (Figure 2-
11). It will be interesting to examine Acid sphingomyelinase (aSMase), an alternative 
sphingomyelinase. aSMase also processes sphingolipids into ceramide and is critical for 
proper lysosomal function and biogenesis(Schramm et al., 2008, Lee et al., 2014). It will 
be interesting to test if cyclopamine alters APP metabolism and lysosomal function in a 
aSMase-dependent manner. In fact, Grimm and colleagues showed that cholesterol and 
sphingomyelin metabolism is regulated by Aβ and presenilin (Grimm et al., 2005). The 
authors demonstrate that Aβ40 inhibits cholesterol synthesis and the more neurotoxic 
Aβ42 stimulates sphongomyelinase-mediated generation of ceramide. Increased ceramide 
subsequently exacerbates cathepsin D maturation and lysosomal proteolysis. These 
effects were reversed in cells expressing reduced presenilin confirming γ-secretase 
mediates lipid metabolism and lysosomal proteolysis. This could partly explain the 
decreased lysosomal turnover we observed upon cyclopamine exposure and further 
confirms our results are γ-secretase mediated. 
 Another conceivable mechanism is β-Arrestin1/2-mediated alterations to GPCRs 
and downstream small G protein signaling. Previously we mentioned that other Smo 
antagonists did not recapitulate cyclopamine’s effects on APP metabolism. However, we 
discovered that Smo knock down in HeLa cells increased APP-CTFs similar to 
cyclopamine treatment (Figure 3-2). Literature confirms several GPCRs, such as β-
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adrenergic and GPR3, facilitate γ-secretase mediated cleavage of APP and Aβ generation. 
Studies show the underlying mechanism is in part due to β-Arrestin desensitization of 
GPCRs from the plasma membrane into endomembrane vesicles (Thathiah and B. De 
Strooper 2009, Thathiah et al., 2009, Thathiah and B. De Strooper 2011, Thathiah et al., 
2013). In 2004 Chen and colleagues showed that Smo, like other GPCRs, is 
phosphorylated at the C-terminus by G protein-coupled receptor kinase 2 (GRK2) 
required for β-Arrestin2 docking and internalization (Chen et al., 2004). The authors 
detected Smo interaction with β-Arrestin2 was abolished upon cyclopamine treatment. 
To this end, we speculate that since APP is closely regulated by GPCRs and β-Arrestins, 
Smo may also be in close proximity with APP at the plasma membrane and regulate its β-
Arrestin mediated endocytosis (Shi et al., 2013). Perhaps this putative Smo function in 
APP metabolism is distinct from its well-characterized function in the Shh pathway. If so, 
this could explain our inability to recapitulate similar effects on APP metabolism using 
alternative Smo antagonists designed specifically to modulate canonical Shh signaling 
which might not rely on Smo functions.  
 In contrast to the previously described “Smo-GPCR” hypothesis, our studies of 
canonical Shh signaling revealed that sequestering ShhN peptide also exacerbated APP-
CTF accumulation (Figure 3-3). Given the lack of commercially available Ptch1 
inhibitor, we used an in vivo γ-secretase reporter Drosophila model and crossed the flies 
to Ptch1 loss of function allele (lof). Our in vivo studies confirmed Ptclof exacerbates γ-
secretase mediated cleavage of APP-C99-Gal4 while Smolof and Hhlof alleles ameliorate 
amyloidogenic processing (Figure 3-4). Moreover we identified these effects were not 
mediated through downstream canonical Shh signaling pathway components, namely 
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Gli1, Gli2 and Gli3. We speculate noncanonical Shh signaling facilitates changes in APP 
metabolism. Noncanonical Shh signaling pathways are either Smo-dependent (Type II) or 
Smo-independent (Type I) (Brennan et al., 2012, Robbins et al., 2012). Thus far our data 
implies Shh, Smo and/or Ptch1 alters APP proteolysis in a Gli-independent manner, this 
would implicate the Type II noncanonical Shh signal transduction is responsible for the 
observed decrease in γ-secretase mediated cleavage of APP. 
 In our final study we analyzed primary cilia structure in response to the 
amyloidogenic APP metabolite, Aβ. In the adult brain canonical Shh signaling is critical 
for neurogenesis, maintenance of neural stem cells and neuronal survival (Charytoniuk et 
al., 2002, Lai et al., 2003, Ihrie et al., 2011, Gulino and M. Gulisano 2012, Alvarez-
Buylla and R. A. Ihrie 2014). Vertebrate Shh signaling requires proper primary cilia 
structure (Haycraft et al., 2005, Breunig et al., 2008, Ocbina and K. V. Anderson 2008). 
Primary cilia are microscopic sensory organelles whose function is currently of 
significant interest. Besides housing Shh signaling pathway components, primary cilia are 
decorated with other receptors required for a variety of signaling pathways. One example 
is Adenylate Cyclase Type 3 (AC3). In fact, AC3 receptor is enriched in neuronal 
primary cilia and is therefore a well-established marker for primary cilia (Berbari et al., 
2007, Bishop et al., 2007). All post-mitotic cells have the potential to generate primary 
cilia, thus it is to no surprise that polarized post-mitotic neurons bear a primary cilium 
(Mandl and R. Megele 1989, Del Cerro and R. S. Snider 1969, Berbari et al., 2007, Lee 
and J. G. Gleeson 2011). Little is known about the function of neuronal cilia, however 
one common symptom among neuronal ciliopathies (diseases characterized by disrupted 
cilia structure) is cognitive impairment (Badano et al., 2006, Hildebrandt et al., 2011). 
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Therefore, one may speculate that neuronal cilia is central to sustaining signaling 
pathways such as Shh and may also be involved in neurodegenerative disorders 
characterized by cognitive decline, namely AD. Our finding that biological and synthetic 
Aβ disrupts primary cilia structure (Figure 4-1, 4-2) lead us to investigate whether 
elevated Aβ levels alter canonical Shh signaling. We detected a dose-dependent decrease 
in canonical Shh signaling using Aβ concentrations that were not cytotoxic  (Figure 4-3). 
Even the SAG treatment, a potent Smo agonist, failed to induce adequate Shh signaling in 
cells exposed to Aβ peptide.  
 The ciliary axoneme is composed of acetylated tubulin; a posttranslational 
modification denoting a more stable version of tubulin. Acetylated tubulin is an 
established marker for primary cilia. Since we used an acetylated tubulin antibody to 
monitor changes in primary cilia structure, we speculate Aβ disrupts acetylated tubulin 
that makes up the cilia axoneme by a currently unknown mechanism. Disrupted Shh 
signaling upon exposure to similar Aβ concentrations used for cilia structure studies, 
suggests the observed decrease in acetylated tubulin immunostainability is a consequence 
of decreased cilia length. To confirm our results, it will be key to stain NIH3T3s using 
alternative cilia markers, such as AC3 or SSTR3, upon Aβ exposure. One recent study 
demonstrated Aβ affects tubulin stability in cells (Pianu et al., 2014). In aforementioned 
study Aβ treatment surprisingly increased microtubule (MT) stability by increasing 
detyrosynated MTs. The authors suggest this effect is tau-independent because like us, 
the authors utilized NIH3T3 cells, which do not express tau. Of note, the authors did not 
examine either acetylated tubulin or primary cilia.  
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 With this work and that of others suggesting APP is a receptor for Aβ peptide, we 
made an anticipated discovery that exogenous APP localizes to the primary cilia in 
NIH3T3 and endogenous APP localizes to cilia in human HeLa cells (Figure 4-4). 
However not all cilia were APP positive suggesting there is some functional differences 
between pools of cilia. In support of our observations, Berbari and colleagues came 
across similar findings when staining brain tissue and cultures of neurons using a variety 
of cilia markers (Berbari et al., 2007). In particular the authors show that AC3-positive 
neuronal cilia were not always SSTR3-positive. In fact, they report that 21% of cilia-
positive neurons were SSTR3-positive and 62% were AC3-positive. Together with our 
observations, these data suggest functional differences between individual cilia and that 
other markers for cilia are yet to be identified.   Primary cilia sustain a distinct 
microenvironment maintained by the ciliary diffusion barrier (Hu and W. J. Nelson 
2011). Therefore, proteins, lipids and small molecules destined for cilia are localized 
there in a precise trafficking manner. In particular, proteins encoding cilia localization 
sequence(s) are recognized by motor and/or adaptor proteins necessary for trafficking to 
cilia (Hsiao et al., 2012). Several sequences are described and we also identified eight in 
human APP695 amino acid sequence, the brain enriched isoform (Berbari et al., 2008, 
Dishinger et al., 2010) (Figure 4-5). Future studies will identify whether any of these 
cilia targeting sequences mediate APP localization to the primary cilium in cell lines and 
primary neurons alike. Finally our findings provide a significant insight into a possible 
functional role for APP. Fogel and colleagues provide evidence that APP dimerizes upon 
binding Aβ in a receptor-peptide mediated fashion (Fogel et al., 2014). These and our 
observations lead us to speculate that cilia APP may function as a sensory receptor 
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probing the environment for levels of neurotoxic Aβ. And upon increased neurotoxic 
Aβ levels could mediate downstream cellular response via AICD.  
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CONCLUDING REMARKS: 
 Here we report a novel function of cyclopamine and a previously uncharacterized 
function of Sonic hedgehog (Shh) signaling pathway in regulating APP proteolysis. Our 
in vivo and in vitro data demonstrates Smo regulates APP metabolism and Aβ generation. 
Given that vertebrate Shh signaling requires primary cilia, we also report that APP 
localizes with Smo at the primary cilium whose structure is sensitive to increasing levels 
of neurotoxic Aβ.  
 As for Alzheimer’s disease pathogenesis, we propose a hypothesis incorporating 
Shh signaling Aβ and cilia. The hippocampal structure receives major cholinergic 
projections from the basal forebrain. Shh is detected in the axons projecting to the 
hippocampus and the neocortex where cells express the Shh receptor suggesting these 
brain structures are responsive to the peptide (Traiffort et al., 2001, Masdeu et al., 2007, 
Alvarez-Buylla and R. A. Ihrie 2014). The cortex and especially the hippocampus are 
plagued by AD neuropathology, namely tissue atrophy. Could this be due to abolished 
pro-survival Shh signaling from the basal forebrain structure since the cholinergic 
projections undergo cytotoxicity prior to hippocampal and cortical atrophy (Davies and 
A. J. Maloney 1976, Perry et al., 1978)? Alternatively, is it possible that elevated Aβ 
levels first disrupt neuronal primary cilia subsequently resulting in abolished Shh 
signaling thus decreasing release of pro-survival signals to the hippocampus and the 
cortex without which these structures atrophy (Miao et al., 1997) (Figure 5-1)? Similarly, 
diagram representations of AD neuronal dysfunction and pathogenesis depict an Aβ 
positive feedback loop. Here we propose to incorporate Shh signaling and primary cilia.   
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FIGURES & LEGENDS: 
Figure 5-1. Proposed hypothesis: Aβ  and Shh signaling in Alzheimer’s disease 
neuropathology. Brain cartoon illustrates the basal forebrain structure from which 
majority of cholinergic projections arise (green). Shh was localized to the axons of these 
projections reroute to the hippocampus and the neocortex suggesting these structures are 
responsive to Shh peptide. Blow up depicts neuronal cilia affected by increased levels of 
Aβ. Based on our studies, we propose that increased Aβ at the basal forebrain distorts 
neuronal primary cilia subsequently disrupting canonical Shh signaling and secretions of 
survival factors. Due to disrupted cilia and impaired Shh signaling, diminished Shh 
peptide (survival factor) trafficking along the cholinergic projections from the basal 
forebrain to the cortex and hippocampus will be observed. Cortical and hippocampal 
neurons will ultimately atrophy without the necessary survival factors.  
 APP localizes to primary cilia and samples the environment for Aβ peptide levels. 
Increased Aβ levels results in AICD-mediated signaling. AICD is known to induce 
apoptosis and expression of β-secretase subsequently shifting APP towards 
amyloidogenic cleavage and stimulating Aβ generation.  
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CHAPTER 6: FUTURE DIRECTIONS 
 
 
 
 
SPECIFIC AIMS 
 The accepted molecular mechanism underlying Alzheimer’s disease (AD) 
initiation and pathogenesis is the increase in neurotoxic Amyloid-β (Aβ) peptide which 
deposits and initiates plaque formation. Several mechanisms can account for the observed 
increase in cerebral Aβ in AD patients. Aβ peptide is produced by the proteolysis of the 
Amyloid precursor protein (APP), and alterations to APP metabolism is one principal 
mechanism which accounts for increased Aβ generation. This prompted researches to 
investigate mechanisms that modulate APP metabolism and studies are directed at 
decreasing Aβ production and clearance. We too utilized a directed in vitro method to 
identify novel regulators of APP proteolysis and Aβ generation. Our studies resulted in 
identification of the Sonic hedgehog (Shh) signaling pathway as a putative regulator of 
APP metabolism. In particular we detected significant reduction in APP proteolysis and 
Aβ generation upon pharmacological inhibition of Shh signaling using cyclopamine. 
Cyclopamine is a phytosterol derived from the corn lily and is the best known inhibitor of 
Shh signaling. While increased cholesterol levels are considered a risk factor for 
developing AD, plant equivalents of cholesterols have been shown to have positive 
effects on APP proteolysis. This notion also prompted us to investigate the mechanism by 
which cyclopamone ameliorates amyloidogenic processing of APP in vitro and in vivo. 
Upon further investigation of this pathway we learned there are three types of Shh 
signaling; canonical (Gli-mediated), noncanonical Type I and noncanonical Type II. Both 
noncanonical Shh signaling pathways are Gli-independent and growing evidence 
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suggests these pathways have alternate downstream effects distinct from canonical 
signaling. The latter is critical for our studies because canonical Shh signaling is known 
for its major role in CNS development, body patterning and neurogenesis. More recent 
literature points to a role in adult neurogenesis and stem cell maintenance specifically at 
the subventricular zone and the subgranular zone of the hippocampus, a region plagued 
by Alzheimer’s disease. Therefore inhibition of the noncanonical Shh signaling pathway 
while maintaining canonical signaling is critical for our findings. With our central 
hypothesis, modulating noncanonical Shh signaling alters γ-secretase mediated 
proteolysis of APP and decreases Aβ  generation, we seek to continue to investigate the 
molecular mechanism by which Shh signaling and cyclopamine alter APP metabolism. A 
better understanding of the molecular mechanism by which Shh signaling modulates APP 
metabolism and Aβ generation will shed light on AD pathogenesis and result in novel 
targets and strategies for AD treatment. To address our hypothesis we will: 
  
Aim 1: Elucidate the mechanism by which cycloapmine regulates APP metabolism 
 Rationale: Our previous and current ongoing in vitro studies show that 
cyclopamine treatment reduces γ-secretase cleavage of APP thereby decreasing Aβ 
generation. In particular we detected that upon cyclopamine treatment, APP C-terminal 
fragments (CTFs), the immediate substrate of γ-secretase and precursor of Aβ localize to 
lysosomes. Our re-submitted work demonstrates our current findings, however the 
molecular mechanism is still unclear. Thus we plan to: 
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a. Determine if cyclopamine directly inhibits γ-secretase activity or subcellular 
localization. 
b. Determine if cyclopamine alters membrane lipid rafts which are shown to 
modulate APP proteolysis. 
c. Determine if cyclopamine alters the retromer complex required for mediating 
endocytosed APP-CTFs retrograde trafficking.  
 
Aim 2: Elucidate the mechanism by which Sonic Hedgehog signaling modulates 
APP proteolysis 
 Rationale: Our current ongoing in vitro studies indicate that Shh signaling alters 
APP proteolysis, specifically at the γ-secretase cleavage step. We determined that 
inhibition of Shh signaling using genetic knockdown and small pharmacological 
molecules lead to reduced γ-secretase cleavage of APP. Similar to cyclopamine, which 
targets the Smoothened (Smo) GPCR of Shh signaling cascade, knockdown of Smo 
resulted in decreased γ-secretase mediated cleavage of APP. Therefore we seek to 
continue to investigate this pathway as a putative novel target for APP modulators. Thus 
we plan to: 
 
a. Identify the Shh signaling component(s) required for modulating APP 
metabolism. 
b. Establish the underlying mechanism by which Shh signaling component(s) 
regulate APP proteolysis and Aβ generation. 
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c. Determine if primary cilia are required for Shh-dependent regulation of APP 
metabolism. 
 
Aim 3: Investigate the effects of Shh signaling on the biochemical, neuropathological 
and cognitive impairments observed in transgenic AD models 
 Rationale: Our work illustrates the effects cyclopamine and Shh signaling 
components have on the in vivo γ-secretase reporter Dorosophila model. Namely, we 
show that cyclopamine and Shh signaling loss of function alleles decrease γ-secretase 
mediated cleavage of APP-C99-Gal4 in these flies resulting in a rescue of the typical 
rough eye phenotype described in this model. Together with our in vitro work, strongly 
suggests similar drug and knockout experiments will have an effect on the previously 
described AD Drosophila model. Similar to the neuropathology and cognitive defects 
observed in humans upon onset of AD, the AD fly model recapitulates these 
impairments. Therefore we seek to continue to investigate the Shh signaling pathway and 
the currently available pharmacological agents designed to modulate Shh signaling in the 
AD Drosophila model. This work could validate our in vitro results and further specify 
the target to pursue in rodent AD models. 
a. Determine if cyclopamine ameliorates AD-like biochemical pathologies and 
cognitive impairment in the in vivo AD Drosophila model. 
b. Determine if knockdown or overexpression of Hh genes rescues or 
exacerbates AD-like biochemical pathologies and cognitive impairment in the 
in vivo AD Drosophila model. 
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c. Investigate if the Shh component(s) and pharmacological Shh modulator(s) 
affect AD pathology in a transgenic AD mouse model.  
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APPENDIX 1: ADDITIONAL EXPERIMENTS 
 
 
Figure A1. SAG does not rescue cyclopamine-induced autophagy. A,B, Western blot 
analysis of HeLa cells exposed to vehicle control (DMSO), 5µM cyclopamine or 
combination of 5µM cyclopamine  and increasing concentrations of SAG for 24 hours. 
Authophagy was analyzed using rat anti-LC3IIB antibody which recognizes the cytosolic 
LC3I and the autophagosome-incorporated LC3II fragments. Increased LC3II levels 
indicate increased autophagy. B, increasing SAG concentrations (sufficient for displacing 
cylopamine from Smo and inducing Shh signaling) did not diminish cyclopamine-
induced autophagosome formation. Results suggest cyclopamine has an off target effect 
facilitating autophagy independent of canonical Shh signaling. 
(5µM cyclopamine: p=0.00228, Cyc +150nM SAG: p=0.000145, Cyc +200nM SAG: 
p=0.00205, Cyc +250nM SAG: p=0.0005801). Student’s t-test was used for statistical 
analysis: ***p<0.005, **p<0.01, *p<0.05 
 
Figure A2. Cyclopamine-induced APP-CTF accumulation is reversible. A,B, Western 
blot analysis of HeLa cells exposed 5µM cyclopamine for 24 hours and washed out and 
lysates collected at indicated time points. APP C-terminal antibody (c1/6.1) was used to 
monitor changes in FL-APP and APP-CTFs. Western blot analysis indicated APP-CTF 
accumulation decreases upon removal of drug suggesting cyclopamine-induced effects 
can be reversed.  
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Figure A3. Cyclopamine and L-685,458 treatment increases APP-positive puncta. A, 
3-D Confocal analysis of HeLa cells exposed to 100nM SAG, 5µM cyclopamine, 2µM 
L-685,458 or vehicle control (DMSO) for 24 hours. APP was detected using APP C-
terminal antibody (A8717). For each treatment: 4-6 fields/slip, 5 ROIs/field (10x10µm 
ROIs) in cytoplasm, excluding nucleus and extracellular matrix. Total 20-30 ROIs/drug 
treatment were analyzed. Puncta were identified as anything 2X intensity of intracellular 
non-punctate region (background) and population was filtered by gating 0.2-2.0µm 
skeletal diameter. Scale bar = 20µm. B, Bar diagram represents quantification of total 
APP-positive puncta normalized to ROI. Student’s t-test was used for statistical analysis: 
***p<0.005, **p<0.01, *p<0.05 
 
Figure A4. APP puncta are found adjacent to multivesicular bodies. A, 3-D Confocal 
analysis of HeLa cells exposed to 5µM cyclopamine for 24 hours. APP was detected 
using APP C-terminal antibody (A8717) and MVBs were detected by overexpression of 
Chmp-4a-GFP construct. Scale bar = 10µm. APP is in close proximity to MVBs 
suggesting cyclopamine favors APP trafficking to MVBs which are destined for 
subsequent lysosomal degradation. 
 
Figure A5. Cyclopamine does not induce APP-CTF accumulation in mouse primary 
cortical neurons. A, Western blot analysis of primary rat cortical neurons (DIV6) 
exposed to vehicle control (DMSO), 5µM cyclopamine, 2µM L-685,458,  or 50nM  
GDC0449 for 24 hours. Endogenous FL-APP and APP-CTFs were detected using a C-
terminal APP antibody (c1/6.1). B, Diagram represents quantification of FL-APP and 
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APP-CTFs normalized to β-Actin or FL-APP, respectively. L-685,458 served as a 
positive control since it is a well-established γ-secretase inhibitor and leads to significant 
APP-CTF accumulation. These results could imply cyclopamine alters APP metabolism 
in a species-specific manner. Student’s t-test was used for statistical analysis: 
***p<0.005, **p<0.01, *p<0.05 
 
Figure A6. Cyclopamine rescues motor neuron deficits in an in vivo Drosophila 
model of Alzheimer’s disease. In collaboration with Dr. Marenda’s lab and the help of 
an undergraduate student, Sean Miller, we tested if cylopamine could rescue the motor 
neurons deficits observed in the Alzheimer’s disease Drosophila model. A, Elav-Gal4 x 
UAS-APP; UAS-BACE flies were crossed on vehicle (0.1% DMSO) or cyclopamine 
(100nM) containing cornmeal. F1 progeny were raised on drug-supplemented food and 
motor functions (timed geotaxis assay) were tested from day 1 to 21 post eclosion. 
Cyclopamine rescued motor neuron deficits observed in these AD fruit flies. B, 
Represents same data as depicted in A however more detailed daily data. (These 
experiments were performed, data collected and analyzed by Sean Miller) Student’s t-test 
was used for statistical analysis: ***p<0.005, **p<0.01, *p<0.05. 
 
Figure A7. Genetic analysis of Hedgehog signaling pathway in regulation of γ-
secretase mediated cleavage of APP-C99-Gal4. In collaboration with Dr. Marenda’s 
lab we set out to determine the Hh signaling component responsible for altering γ-
secretase mediated proteolysis of APP-C99-Gal4. We purchased several fruit flies 
carrying genetic mutations in several Hh signaling genes. These flies were crossed to 
199
GMR-APP-C99-Gal4; UAS-Grim flies on normal food. F1 progeny flies were scored one 
day after eclosion: mild (+), moderate (++), severe (+++). Graph depicts relative changes 
in penetrance of rough-eye phenotype in flies with various genetic backgrounds. 
Approximately 77 to 206 flies per experimental genetic cross were scored. Population of 
flies with mild, moderate or severe rough-eye phenotype is illustrated as percent of total 
population per experimental group. Statistical analysis in vivo experiments; a G-test: 
***p<0.005, **p<0.01, *p<0.05, was performed.  
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GMR-APP-Gal4;UAS-Grim/w-  
% Rough Eye Phenotype 
G
en
ot
yp
e 
Hh allele x GMR-APP-Gal4;UAS-Grim 
Mild Moderate Severe 
% % % %
Genotype Genotype None Mild Moderate Severe Two-Tail G-Test
5338_x_APP-Gal4;UAS-Grim Hh21(LOF)_x_APP-Gal4;UAS-Grim 0 28.0898876 41.011236 30.8988764 n=178 4.01404E-24
10514_x_APP-Gal4;UAS-Grim Ptck02507(LOF)_x_APP-Gal4;UAS-Grim 0 9.09090909 27.2727273 63.6363636 n=77 0.043441094
23943_x_APP-Gal4;UAS-Grim Smo5A(DomNeg)_x_APP-Gal4;UAS-Grim 0 27.184466 37.8640777 34.9514563 n=206 4.34133E-26
3277_x_APP-Gal4;UAS-Grim SMO3(NULL)_x_APP-Gal4;UAS-Grim 0 5.15463918 44.3298969 50.5154639 n=97 2.25978E-18
21960_x_APP-Gal4;UAS-Grim SUFU(GOF)_x_APP-Gal4;UAS-Grim 0 0 34.2105263 65.7894737 n=152 7.80052E-05
7203_x_APP-Gal4;UAS-Grim FU41(LOF)_x_APP-Gal4;UAS-Grim 0 8.23529412 49.4117647 42.3529412 n=85 0.062692621
7204_x_APP-Gal4;UAS-Grim FU50(LOF)_x_APP-Gal4;UAS-Grim 0 0.72992701 43.0656934 56.2043796 n=137 0.011564129
7205_x_APP-Gal4;UAS-Grim FU52(LOF)_x_APP-Gal4;UAS-Grim 0 3.47826087 24.3478261 72.173913 n=115 0.000524328
21875_x_APP-Gal4;UAS-Grim FUHP10439(GOF)_x_APP-Gal4;UAS-Grim 0 6.72268908 52.1008403 37.8151261 n=119 0.000536495
11156_x_APP-Gal4;UAS-Grim COS2K16101(LOF)_x_APP-Gal4;UAS-Grim 0 5.88235294 38.2352941 55.8823529 n=68 0.946432372
644_x_APP-Gal4;UAS-Grim CI57(LOF)_x_APP-Gal4;UAS-Grim 0 18.4713376 51.5923567 29.9363057 n=157 0.000527733
4229_x_APP-Gal4;UAS-Grim CI1(LOF)_x_APP-Gal4;UAS-Grim 0 77.4566474 20.8092486 1.73410405 n=173 2.17323E-78
642_x_APP-Gal4;UAS-Grim CI1(LOF)_x_APP-Gal4;UAS-Grim 0 32.885906 55.704698 11.409396 n=149 2.59795E-16
646_x_APP-Gal4;UAS-Grim CIW(GOF)_x_APP-Gal4;UAS-Grim 0 63.3928571 29.4642857 7.14285714 n=112 7.77303E-66
6303_x_APP-Gal4;UAS-Grim CIDplac(LOF)_x_APP-Gal4;UAS-Grim 0 10.3896104 42.2077922 47.4025974 n=154 0.021716034
GMR-APP-Gal4;UAS-Grim/w- GMR-APP-Gal4;UAS-Grim/w- 0 5.35714286 39.8809524 54.7619048 n=168
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